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Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial disease with an 
estimated prevalence of 1:500 to 1:200.(1, 2) It is defined by an increased left ventricular wall 
thickness that is not solely explained by abnormal loading conditions(3-5) (Figure 1). HCM is 
frequently caused by mutations in genes that encode proteins of the cardiac sarcomere; the smallest 
contractile unit of the cardiac muscle.(6) Classic microscopic features of HCM are muscle fiber 
disarray, microvascular remodeling, and interstitial fibrosis.(7, 8) The distribution of the hypertrophy 
is typically asymmetrical with a predilection for the septum and the anterior wall, but concentric 
hypertrophy is also observed and the hypertrophy can be located in other parts of the left or right 
ventricle including the papillary muscles.(7, 9, 10) Other abnormalities include systolic anterior 
motion (SAM) of the mitral valve, mitral regurgitation, outflow obstruction, impaired diastolic 
relaxation, and autonomic dysregulation.(4)  
 
 
Figure 1. Parasternal long axis two-dimensional echocardiogram illustrating asymmetrical septal left ventricular 
hypertrophy (*) in a patient with hypertrophic cardiomyopathy. 
 
HCM can present from infancy to the very elderly.(11) Symptoms associated with HCM include chest 
pain, exertional dyspnea, palpitations and syncope which have a range of causes such as microvascular 
ischemia, outflow obstruction, heart failure or arrhythmias.(3) The clinical course ranges from normal 
life expectancy to sudden cardiac death (SCD) at a young age, progressive heart failure, and atrial 
fibrillation with an increased risk of thromboembolism.(11, 12). Although overall the life expectancy 
of patients with HCM is good with many achieving advanced longevity, a proportion of the patients 
follow a distinctive pathway in which there is worsening systolic and diastolic function, increasing 
fibrosis, and elevated risk of ventricular and atrial arrhythmias.(7, 13) (Figure 2) 
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Figure 2. Stages of hypertrophic cardiomyopathy. Percentages in brackets represent prevalence of each stage. 
The prevalence of genotype-positive, phenotype-negative individuals is unknown. Figure adapted from figure 1. 
in reference 13. 
 
 
A brief historical overview of the diagnosis and management 
In the 1950s the first modern descriptions of HCM were published by Donald Teare, a forensic 
pathologist, describing the association of HCM with SCD in young people, the asymmetric 
distribution of the hypertrophy, and the muscle fiber disarray.(8) Russell Brock, Andrew Morrow and 
Eugene Braunwald recognized the presence of functional left ventricular outflow tract obstruction.(14, 
15) In 1961, Morrow introduced the myotomy-myectomy procedure, in which excessive tissue in the 
outflow tract is excised during open heart surgery.(16) In 1995 a trans catheter approach to relieve 
outflow obstruction was introduced, the alcohol septal ablation.(17) Today, both procedures are 
offered to patients with drug-refractory symptoms and have similar effects on functional status and 
similar procedural mortality.(3) Overall, the procedure of choice depends largely on the mechanism of 
the outflow obstruction, the severity of the hypertrophy, the coronary artery anatomy, patient 
preference, and the experience of the referral center.(18) 
The most feared complication of HCM is SCD, although it is relatively infrequent among patients with 
HCM (annual risk 0.5-1%).(12) It occurs most commonly in young asymptomatic patients < 35 
years(4). In fact, a number of studies from the Unites States have reported that HCM is the most 
common cause of SCD in young athletes.(4, 19) Although rare, exercise can induce ventricular 
arrhythmias leading to SCD.(20) And so, current guidelines for patients with HCM advise against 
participation in competitive sports and intense physical activity.(3, 4) Furthermore, in certain countries 
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and major sporting federations it is the rationale for pre-participation cardiovascular screening of 
competitive athletes.(21) The impact, cost-effectiveness and preferred strategies are however 
debatable.(21)  
During the past 50 years extensive research has been performed to identify clinical SCD risk factors. 
SCD risk stratification became especially relevant when in 1980 the implantable cardiac defibrillator 
(ICD) was introduced, a device that can effectively terminate malignant ventricular arrhythmias and 
thus save lives.(22, 23) Currently, there is an ongoing debate between Europe and the United States 
regarding the most appropriate SCD risk stratification and the indication for ICD implantation.(24-28) 
 
 
Genetics and family screening  
In the 1940s Evans had noticed the familial nature of HCM.(29) Family studies subsequently 
elucidated the autosomal dominant mode of inheritance.(30, 31) Pedigree analysis is an important 
aspect of the clinical management of patients with HCM (Figure 3). Since the year 2003 guidelines 
have encouraged family screening by electrocardiography and echocardiography.(3-5) Current 
guidelines recommend cardiac evaluation from age 10-12 years until 18-21 years of age, and every 2-5 
years thereafter until advanced age.(3, 4, 32) Younger children can be screened in case of a severe 
family history, competitive sports participation, or when cardiac symptoms are present.(3)  
 
Figure 3. Example of pedigree analysis by using a family tree. Black filling of the squares (males) and circles 
(females) indicate a diagnosis of HCM. ICD, implantable cardiac defibrillator; SCD, sudden cardiac death. 
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In 1989 the genetic substrate of HCM was demonstrated by Seidman et al. and located on 
chromosome 14q1(6). Since then, more than 1500 mutations in at least 11 genes have been identified 
to cause HCM.(12) Most of these genes encode proteins of the myofilaments or Z-disc of the 
sarcomeres.(33) Mutations in the myosin-binding protein C (MYBPC3) gene and the ß-myosin heavy 
chain (MYH7) gene represent >70% of the mutations.(33) In the Netherlands, MYBPC3 mutations are 
exceptionally frequent, due to the presence of three Dutch MYBPC3 founder mutations. Roughly 35% 
of HCM is caused by one of these three Dutch MYBPC3 founder mutations.(34, 35) These mutations 
cause C-terminally truncated protein leading to haplo-insufficiency.(36) Pathophysiologic studies have 
demonstrated that these mutations are associated with a reduced force generating capacity of 
cardiomyocytes, cardiomyocyte hypertrophy and reduced myofibril density.(37, 38) 
 
The extreme genetic and clinical heterogeneity of HCM makes it challenging to assess genotype-
phenotype associations.(39) Currently, asides from its use in the differentiation between HCM and 
phenocopies, genetic testing is mainly used for the evaluation of family members.(3, 32, 40) A 
pathogenic mutation is identified in 50-60% of patients with HCM.(41) Determining the pathogenicity 
of DNA variants involves several steps including the assessment of public databases, published data, 
co-segregation in families, and predicted effects on slicing and the protein.(42) Variants are then 
classified into 5 categories: (I) benign; (II) likely benign; (III) uncertain significance; (IV) likely 
pathogenic; and (V) pathogenic (Figure 4).(42) During the past decade, advances in DNA sequencing 
methodology has enabled us to offer multigene testing to all patients with HCM, but it also generates 
many variants with uncertain significance, which complicate the interpretation of the results.(33) 
Therefore, a multidisciplinary team composed of cardiologists, molecular biologists, bio-
informaticians, clinical geneticists and genetic counsellors is crucial.(33, 43) Counselling is essential 
before and after genetic testing, due to the potential psychosocial, emotional and financial 
consequences of genetic testing.(32, 44) 
 
Figure 4. Classification of variants according to the American College of Medical Genetics and Genomics 
recommendations(42). VUS, variant with uncertain significance. 
Introduction 
14 
 
In case a pathogenic mutation is identified, relatives can undergo pre symptomatic genetic testing.(32) 
Relatives who have not inherited the mutation can be reassured and discharged from follow-up and 
there is no increased risk of transmitting the disease to offspring.(32) Relatives who have inherited the 
mutation but have no clinical expression of HCM are advised to undergo repeated clinical evaluation, 
because HCM can develop later in life i.e. there is age-related penetrance.(32) HCM mutation carriers 
without clinical expression of HCM are of tremendous interest to researchers, because it helps us 
understand the pathophysiological processes which occur before the expression of disease.(45) 
Subsequently, gene-therapy and other novel therapeutics might in the future be able to prevent the 
development of HCM instead of treating the symptoms after HCM has developed as is the case 
presently.(40, 46) 
 
Outline of the thesis 
An overview of the chapters and its content is presented in table 1. During the past 60 years the 
diagnosis and clinical management of HCM has undergone significant changes.(2, 33, 47-49) Septal 
reduction therapies, ICD implantations, heart transplantation, and catheter-based procedures have 
significantly improved the clinical outcome of patients with HCM to the point where it is now a 
treatable disease with many patients reaching extended longevity.(12) However, the impact of adverse 
outcomes associated with HCM (SCD, progressive heart failure, stroke) is huge for individual cases 
and families. Also, due to advances in diagnostic imaging, family screening, and an unexpected high 
prevalence of pathogenic sarcomere mutations in the general population, HCM is more prevalent than 
previously estimated.(2) With the discovery of the genetic substrate of HCM 20 years ago, we have 
entered a new era in which a more preventive approach is aspired.(40) Although we know that 
genotype influences the phenotype and the prognosis in HCM, its prognostic value is currently limited 
due to extreme clinical and genetic heterogeneity.(39) Since roughly 50-60% of the patients with 
HCM have a positive genotype, investigating the impact of a genotype-positive status might gain 
insight into the prognostic value of genetic test results. Therefore, in chapter 1 we compare HCM 
patients with and without sarcomere mutations and investigate the association between a genotype-
positive status and long-term clinical outcome. We continue to investigate genotype-phenotype 
associations in chapter 2, where we analyze the clinical characteristics and long-term outcome of 
HCM caused by Dutch MYBPC3 founder mutations. In chapter 3, we investigate the results of HCM 
family screening including genetic testing. With the introduction of pre symptomatic genetic testing in 
relatives a new subgroup has emerged: HCM mutation carriers without clinical expression of HCM. 
These individuals are at risk of developing HCM. In the next two chapters we seek to determine 
preclinical markers of HCM by comparing these HCM mutation carriers with healthy controls and 
performing longitudinal follow-up of the mutation carriers. In chapter 4, we assess the prognostic 
significance of anterior mitral valve leaflet length for the development of HCM, and in chapter 5, we 
study the prognostic significance of global longitudinal strain using speckle tracking 
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echocardiography. In the HCM field, three-dimensional (3D) echocardiography is currently still 
primarily a research tool.(47) Studies have indeed demonstrated superior performance to two-
dimensional echocardiography for the evaluation of myocardial hypertrophy, LV volumes, LV 
ejection fraction, and LV mass. In chapter 6 we study the utility of 3D echocardiography for the 
assessment of LV hypertrophy and papillary muscle morphology. Atrial fibrillation (AF) is the most 
common arrhythmia in the HCM population and an important risk factor for heart failure and stroke. 
Its identification has direct implications for the management of HCM. Therefore, in chapter 7 we 
assess the incidence and impact of device-detected AF in patients with HCM and a cardiac implantable 
electronic device. Currently, insufficient data is available regarding the impact of gender on the long-
term outcomes of patients with HCM. In chapter 8 we compare the clinical presentation, phenotype, 
genotype, and outcome between male and female patients with HCM. Finally, in chapter 9 we go 
from bedside-to-bench by analyzing whether sex differences in the diastolic function of patients with 
HCM can be explained at a cellular level. 
 
Table 1. Overview of the chapters (continues on the next page) 
Chapter  Study population Test Outcome 
1  Patients with HCM Genetic testing Mortality 
Interventions 
2  MYBPC3 founder mutation carriers Clinical evaluation     
2D echocardiography 
Mortality 
Interventions 
3  Relatives of patients with HCM Clinical evaluation  
Genetic testing 
Development of HCM  
Mortality 
Interventions 
4  HCM mutation carriers and  
healthy controls 
Clinical evaluation 
Electrocardiography     
2D echocardiography 
Development of HCM 
5  HCM mutation carriers and  
healthy controls 
Clinical evaluation 
Electrocardiography  
Speckle tracking echocardiography 
Development of HCM  
Mortality 
6  Patients with HCM 3D echocardiography Left ventricular wall 
thickness Papillary muscle 
abnormalities             
HCM, hypertrophic cardiomyopathy; MYBPC3, myosin-binding protein C; 2D, two-dimensional; 3D, three-
dimensional 
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Table 1. Overview of the chapters (continued) 
Chapter  Study population Test Outcome 
7  Patients with HCM CIED interrogation Mortality 
Interventions  
Thromboembolism 
8  Patients with HCM Gender 
Genetic testing 
Mortality 
Interventions  
Nonfatal clinical events 
9  Patients with HCM 2D echocardiography  
Force measurements Protein 
analysis Histomorphometrical 
analysis 
Diastolic function  
Passive tension             
Titin function      
Fibrosis 
CIED, cardiac implantable electronic device; HCM, hypertrophic cardiomyopathy; 2D, two-dimensional 
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ABSTRACT 
Pathogenic gene mutations are found in about 50 % of hypertrophic cardiomyopathy (HC) patients. 
Previous studies have shown an association between sarcomere mutations and medium-term outcome. 
The association with long-term outcome has not been described. The aim of this cohort study was to 
assess the long-term outcomes of genotype positive (G+) and genotype negative (G-) HC patients. The 
study population consisted of 626 HC patients (512 probands, and 114 relatives) who underwent 
phenotyping and genetic testing between 1985 and 2014. End points were: all-cause mortality, 
cardiovascular (CV) mortality, heart failure (HF) related mortality and sudden cardiac death/aborted 
sudden cardiac death (SCD/aborted SCD). Kaplan Meier and multivariate cox regression analyses 
were performed. A pathogenic mutation was detected in 327 (52%) patients. G+ probands were 
younger than G- probands (46±15 vs 55±15 years, p<0.001), had more non sustained ventricular 
tachycardia (34% vs 13%; p<0.001), more often a history of syncope (14% vs 7%; p=0.016), and more 
extreme hypertrophy (maximal wall thickness ≥ 30 mm 7% vs 1%; p<0.001). G- probands were more 
symptomatic (NYHA ≥ II 73% vs 53%, p<0.001) and had higher left ventricular outflow tract 
gradients (42±39 vs 29±33 mmHg, p=0.001). During 12±9 years follow-up, G+ status was an 
independent risk factor for all-cause mortality (HR 1.90; 95% CI 1.14 –3.15; p=0.014), CV mortality 
(HR 2.82; 95% CI 1.49–5.36; p=0.002), HF related mortality (HR 6.33; 95% CI 1.79–22.41; p=0.004), 
and SCD/aborted SCD (HR 2.88; 95% CI 1.23–6.71; p=0.015). In conclusion, during long-term 
follow-up, G+ HC patients are at increased risk of all-cause death, CV death, HF related death, and 
SCD/aborted SCD. 
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INTRODUCTION 
Hypertrophic cardiomyopathy (HC) is the most common inherited myocardial disease, with an 
estimated prevalence of 1 in 500.(1) Although the majority of patients with HC have a good prognosis, 
a small minority may experience life-threatening complications, such as heart failure (HF), sudden 
cardiac death (SCD) and atrial fibrillation (AF) leading to stroke.(2) The difficulty in determining the 
prognosis of HC patients lies in the genetic and clinical heterogeneity. More than 1500 pathogenic 
mutations in at least 11 genes encoding thick and thin myofilament protein components of the 
sarcomere have been identified.(1) A pathogenic mutation is found in about 50% of HC patients.(3) 
Current guidelines advise to genotype HC patients in order to facilitate family screening.(4) The 
prognostic significance of genetic test results in patients with HC is still under debate. Previous studies 
have shown an association between sarcomere mutations and clinical outcome.(5-8) The follow-up 
duration in these studies varied from 1(5) to 6.6(7) years. Information on the value of genetic testing 
for the prediction of the long-term outcome in patients with HC is currently not available. Therefore, 
the aim of this study was to investigate the association between G+ status and long-term clinical 
outcome. 
 
METHODS 
This prospective cohort study included 626 HC patients (probands: n=512, 82%; relatives: n=114, 
18%), who attended the cardio-genetic outpatient clinic between May 1985 and August 2014. 
Probands were defined as patients with HC who presented with signs or symptoms of HC. Relatives 
were defined as patients with HC who were identified via family screening. Each patient had an 
established diagnosis of HC based on maximal wall thickness (MWT) ≥ 15 mm unexplained by 
loading conditions, or ≥ 13 mm for relatives of HC patients. Patients with HC linked to other causes 
were excluded. The study conforms to the principles of the Declaration of Helsinki. All patients gave 
informed consent, and review board approval was obtained.  
All patients underwent genetic counselling. Before the year 2012, DNA analysis consisted of 
direct sequencing of all coding intro-exon boundaries of the following genes: myosin binding protein 
C (MYBPC3), myosin heavy chain 7 (MYH7), regulatory myosin light chain 2 (MYL2), regulatory 
myosin light chain 3 (MYL3), troponin T (TNNT2), troponin I (TNNI3), cysteine and glycine-rich 
protein 3 (CSRP3), titin-cap/telethonin (TCAP), α-tropomyosin 1 (TPM1), cardiac muscle alpha actin 
(ACTC1), cardiac troponin C (TNNC1), and teneurin C-terminal associated peptides (TCAP). From 
2012, next-generation-sequencing was used, covering the following genes: ABCC9, ACTC1, ACTN2, 
ANKRD1, BAG3, CALR3, CAV3, CRYAB, CSRP3, CTNNA3, DES, DSC2, DSG2, DSP, EMD, FHL1, 
GLA, JPH2, JUP, LAMA4, LAMP2, LDB3, LMNA, MIB1, MYBPC3, MYH6, MYH7, MYL2, MYL3, 
MYOZ2, MYPN, NEXN, PKP2, PLN, PRDM16, PRKAG2, RBM20, SCN5A, TAZ, TCAP, TMEM43, 
TNNC1, TNNI3, TNNT2, TPM1, TTN, TTR and VCL. Variants were classified into classes: (I) benign; 
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(II) likely benign; (III) variant of unknown clinical significance; (IV) likely pathogenic; or (V) 
pathogenic, adapted from the classification proposed by Plon et al.(9) Patients were considered G+ 
when the mutation was classified as class IV or V.  
Follow-up data were obtained in November 2014, and was complete for 99 % of patients. 
Mortality was retrieved from the civil register. An electrophysiologist evaluated ICD interventions. 
The study end points were: all-cause mortality, CV mortality, HF related mortality, and SCD/aborted 
SCD. Cardiac transplantation was considered HF related mortality. CV mortality consisted of HF 
related death, SCD/aborted SCD, postoperative death after a cardiac intervention and stroke related 
death. SCD/aborted SCD was defined as: (1) instantaneous and unexpected death in patients who were 
previously in a stable clinical condition, or nocturnal death with no history of worsening symptoms; 
(2) resuscitation after cardiac arrest; or (3) ICD intervention for ventricular fibrillation or for fast 
ventricular tachycardia (>200 beats/min).  Syncope was defined according to the guidelines(4). 
Statistical analyses were performed using SPSS 21 (IBM, Armonk, New York) and Microsoft Access 
2010 (version 14.0.7143.5000). Unpaired t-test or the chi-square test were used to compare variables. 
P values < 0.05 were considered significant. Multivariate analysis was performed with a model in 
which each variable with p < 0.05 (based on univariate analysis) was entered, with a maximum of 1 
variable per 10 events. Survival curves were constructed according to the Kaplan Meier method, and 
compared using the log rank test. Due to a high prevalence of three MYBPC3 founder mutations 
(c.2373dupG, c.2827C>T and c.2864_2865delCT)(10), we adjusted for the founder effect by including 
only the first enrolled proband with a founder mutation. Founder mutations were defined according to 
Alders et al.(11) All reported annual mortality rates are in 50-year survivors. 
 
RESULTS 
The baseline characteristics are presented in table 1. A pathogenic mutation was detected in 234 (46%) 
probands, and in 93 (82%) relatives. G+ probands were younger than G- probands (46±15 vs 55±15 
years, p<0.001), had more AF (26% vs 15%; p<0.001), and a higher MWT (20±5 mm vs 18±4 mm; 
p<0.001). The following risk factors for SCD were more common in G+ probands: family history of 
SCD, non-sustained ventricular tachycardia, syncope, and MWT ≥ 30 mm. G- probands were more 
symptomatic (NYHA ≥ II 73% vs 53%, p=<0.001) and had higher LVOT gradients (42±39 vs 29±33 
mmHg, p=0.001). Relatives presented to clinic primarily through familial evaluation (n=66, 58%) and 
through positive genetic screening (n=48, 42%). Compared to probands, relatives were younger 
(46±15 vs 51±15 y, p=0.003), had fewer AF (11% vs 20%, p=0.034), were less symptomatic (NYHA 
≥ II 18% vs 64%, p<0.001), had a lower MWT (17±4 vs 19±5 mm, p<0.001), smaller left atria (41±7 
vs 45±8, p<0.001), and had lower LVOT peak gradients (11±15 vs 36±37, p<0.001). Relatives more 
often had a family history of SCD (28% vs 12%, p<0.001). There were no significant differences 
between G+ and G- relatives (table 1).  
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Table 1. Baseline characteristics of probands and relatives with hypertrophic cardiomyopathy. 
 Variable 
 
Entire 
cohort 
(n=626) 
Probands 
 
(n=512) 
 
  
Relatives 
 
(n=114)     
 
  
Genotype + 
(n=234)  
Genotype 
- (n=278) 
p-  
value 
Genotype +   
(n=93) 
Genotype 
- (n=21) 
p-
value 
Male 404 (65%) 159 (68%) 171 (62%) 0.130 61 (66%) 13 (62%) 0.749 
Age (years) 51±15 46±15 55±15 <0.001 45±15 51±13 0.092 
AF (by history) 115 (18%) 61 (26%) 41 (15%) 0.001 1 (12%) 2 (10%) 0.764 
NYHA II or higher  216 (55%) 81 (53%) 121 (73%)  <0.001 11 (16%) 3 (25%) 0.473 
Maximal wall  18±5 20±5 18±4 <0.001 17±4 17±4 0.806 
thickness 
Left atrial size 44±8 45±8 45±7 0.996 43±8 41±7 0.340 
LV end diastolic  46±6 45±6 46±7 0.438 46±5 47±7 0.541 
diameter 
Apical morphology 31 (5%) 4 (2%) 22 (8%) 0.001 3 (3%) 2 (10%) 0.203 
LVOT peak gradient 32±16 29±33 42±39 0.001 10±14 16±20 0.325 
LVOT PG > 30 mmHg 178 (28%) 67 (29%) 106 (38%) 0.024 3 (3%) 2 (10%) 0.203 
LV systolic   70 (12%) 31 (15%) 31 (12%) 0.430 7 (8%) 1 (5%) 0.632 
dysfunction 
Family history of SCD 61 (12%) 46 (20%) 15 (6%) <0.001 26 (30%) 5 (25%) 0.706 
nsVT on Holter  111 (22%) 67 (34%) 26 (13%) <0.001 14 (18%) 4 (22%) 0.675 
monitoring 
Abnormal exercise  79 (16%) 28 (14%) 41 (20%) 0.141 8 (10%) 2 (12%) 0.790 
BPR 
Syncope 52 (10%) 32 (14%) 20 (7%) 0.016 4 (4%) 1 (5%) 0.926 
MWT ≥ 30 mm 18 (4%) 16 (7%) 2 (1%) <0.001 0 0 - 
All values are mean ± SD or number (%) AF = atrial fibrillation, BPR = blood pressure response, LV = left 
ventricle, LVOT = left ventricular outflow tract, MWT = maximal wall thickness, NYHA = New York Heart 
Association functional class, nsVT = non sustained ventricular tachycardia, PG = peak gradient, SCD = sudden 
cardiac death 
 
 
The distribution of the affected genes are presented in figure 1. Next-generation sequencing was 
performed in 161 (26%) patients. Most patients had MYBPC3 mutations (n=240; 73%), followed by 
MYH7 mutations (n=47; 14%) and thin filament mutations (n=19; 6%). Figure 2 demonstrates the 
distribution of the MYBPC3 founder mutations. MYBPC3 founder mutations were present in 101 
(47%) G+ probands and 53 (57%) G+ relatives. A detailed overview of the individual pathogenic 
mutations is presented in supplementary table 1 (online only). Three patients (1%) had multiple 
mutations: one compound heterozygous MYBPC3 mutation in trans and two double heterozygous 
(MYBPC3/MYL2 and MYH7/MIB1) mutations. Most mutations were truncating mutations (n=184; 
56%) followed by missense (n=101; 31%) and splice site mutations (n=34; 10%). Supplementary table 
2 (online only) illustrates the varying types of mutations in the patients who died from HF and 
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SCD/aborted SCD. The gene most commonly affected in SCD/aborted SCD was MYBPC3 (founder: 
n=10, non-founder: n=6), followed by MYH7 (n=2), and a double mutation carrier. SCD/aborted SCD 
did not occur among TNNT2 mutation carriers (n=10; mean age 61±9).  
 
 
 
 
 
Figure 1. The distribution of pathogenic gene mutations in 512 probands (A) and 114 relatives (B). G- = 
genotype-negative HC patients. Thick = patients with thick filament associated gene mutations: myosin binding 
protein C (MYBPC3), myosin heavy chain (MYH7), regulatory myosin light chain 2 (MYL2) and regulatory 
myosin light chain 3 (MYL3). Thin = patients with thin filament associated gene mutations: troponin I, troponin 
T and α-tropomyosin 1. Rare = patients with rare mutations: calreticulin 3, cysteine and glycine-rich protein 3, 
and myopalladin. Multiple = patients with multiple mutations.  
 
Figure 2. The distribution of founder and non-founder mutations in the myosin binding protein C (MYBPC3) 
gene. MYBPC3 founder mutations include: c.2373dupG (purple); n=78 (33%), c.2827C>T (green); n=42 (18%) 
and c.2864_2865delCT (red); n=33 (14%). Non-founder MYBPC3 mutations (black): n=86 (36%). 
 
Mortality and interventions during follow-up are presented in table 2. During the mean follow-up 
period of 12±9 years, G+ probands had a greater probability of all end points: all-cause mortality, HF 
related mortality, CV mortality, and SCD/aborted SCD (figures 3 and 4). Annual rates for G+ vs G- 
patients were as follows: (1) all-cause mortality: 2.4% vs 1.0%, log rank p<0.001; (2) HF related 
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mortality: 0.9% vs 0.2%, log rank p<0.001; (3) CV mortality: 1.8% vs 0.4%, log rank p<0.001; and (4) 
SCD/aborted SCD: 1.1% vs 0.15%, log rank p=0.002. After adjustment for the founder effect, all of 
these differences remained significant. ICDs for primary prevention were implanted more often in G+ 
probands (16% vs 9%; p=0.019). There was no significant difference in the number of septal reduction 
therapies (both ASA and surgical myectomy) between G+ and G- probands (31% vs 33%; p=0.710). 
All-cause mortality for relatives was comparable to probands (10% vs 14%, p=0.247), with an annual 
all-cause mortality rate of 1.3%. Compared to probands, cardiovascular death trended lower in 
relatives (4% vs 9%, p=0.084). There were no significant differences between G+ and G- relatives. 
Multivariate cox regression analyses of G+ status in probands for the end points are presented in Table 
3. G+ status was an independent predictor of all-cause mortality (HR 1.90, p=0.014), CV mortality 
(HR 2.82, p=0.002) and HF related mortality (HR 6.33, p=0.004). G+ status was also a predictor of 
SCD/aborted SCD, after adjusting for established risk factors for SCD as described in the guidelines 
from 2003(12) and 2011(13). 
 
Table 2. Mortality and interventions during follow-up of probands and relatives 
Variable 
 
Entire 
cohort 
(n=626) 
Probands  
 
(n=512)     
Relatives  
 
(n=114)     
 
  
Genotype 
+ (n=234)  
Genotype 
– (n=278) p-value 
Genotype 
+   (n=93) 
Genotype 
– (n=21)  p-value 
All-cause mortality 81 (13%) 40 (17%) 30 (11%) 0.039 10 (11%) 1 (5%) 0.401 
Age at death, y 62±14 62±16 64±11 0.488 58±14 49 0.550 
Cardiovascular mortality 53 (9%) 32 (14%) 16 (6%) 0.002 4 (4%) 1 (5%) 0.926 
Heart failure related mortality 20 (3%) 15 (6%) 3 (1%) 0.001 2 (2%) 0 0.498 
Cardiac transplantation 7 (1%) 4 (2%) 2 (1%) 0.300 1 (1%) 0 0.633 
SCD/aborted SCD 29 (5%) 17 (7%) 9 (3%) 0.039 2 (2%) 1 (5%) 0.500 
True SCD 9 (1%) 7 (3%) 2 (1%) 0.051 0 0  
 
Aborted SCD 20 (3%) 10 (4%) 7 (3%) 0.269 2 (2%) 1(5%) 0.500 
Stroke related death 2 (0.3%) 0 2 (0.7) 0.194 0 0 
 
Post procedural cardiac death 2 (0.3%) 0 2 (0.7) 0.194 0 0 
 
Septal reduction therapy 171 (27%) 73 (31%) 91 (33%) 0.710 7 (8%) 0 0.194 
   Alcohol septal ablation 53 (9%) 21 (9%) 32 (12%) 0.348 0 0 
 
   Surgical myectomy 126 (20%) 53 (23%) 66 (24%) 0.771 7 (8%) 0 0.194 
ICD 98 (16%) 49 (21%) 35 (13%) 0.011 10 (11%) 4 (19%) 0.296 
   For primary prevention 76 (12%) 38 (16%) 26 (9%) 0.019 8 (9%) 4 (19%) 0.159 
   For secondary prevention 22 (4%) 11 (5%) 9 (3%) 0.395 2 (2%) 0 0.498 
All values are mean ± SD, median [Q1 – Q3] or number (%). ICD = implantable cardioverter defibrillator, 
SCD=sudden cardiac death 
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Figure 3. Kaplan-Meier analysis comparing (A) all-cause mortality in G+ probands and G- probands and (B) 
cardiovascular mortality in G+ probands and G- probands. * = age at presentation (red for G+ and black for G-). 
G+ = genotype-positive. G- = genotype-negative. Cardiovascular mortality is defined as death related to heart 
failure or stroke, sudden cardiac death or postoperative death after a cardiac intervention.  
 
Figure 4. Kaplan-Meier analysis comparing (A) heart failure related mortality in G+ probands and G- probands 
and (B) sudden cardiac death/aborted sudden cardiac death in G+ probands and G- probands. * = age at 
presentation (red for G+ and black for G-). G+ = genotype-positive. G- = genotype-negative. 
 
Table 3. Cox regression analysis of genotype-positive status for the clinical endpoints of 512 probands 
End point Predictor HR (95% CI) P-value 
All-cause mortality Genotype-positive status 1.90 (1.14-3.15) 0.014 
 Atrial fibrillation 2.15 (1.30-3.56) 0.003 
 Systolic left ventricular dysfunction 1.92 (1.07-3.47) 0.030 
 Extreme hypertrophy (MWT ≥ 30 mm) 6.22 (2.33-16.60) <0.001 
Cardiovascular mortality Genotype-positive status 2.82 (1.49-5.36) 0.002 
 Atrial fibrillation 3.31 (1.81-6.06) <0.001 
 Systolic left ventricular dysfunction 2.33 (1.18-4.60) 0.015 
 Extreme hypertrophy (MWT ≥ 30 mm) 10.23 (3.64-28.73) <0.001 
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Table 3. Cox regression analysis of genotype-positive status for the clinical endpoints of 512 probands 
(continued) 
Multivariate Cox proportional-hazards analysis was used. Established risk factors for sudden cardiac death 
according to the 2003 guidelines included: extreme hypertrophy (maximal wall thickness ≥ 30 mm), unexplained 
syncope, abnormal exercise blood pressure, non-sustained ventricular tachycardia, family history of sudden 
cardiac death. Established risk factors for sudden cardiac death according to the 2011 guidelines included: 
extreme hypertrophy (maximal wall thickness ≥ 30 mm), unexplained syncope and a family history of sudden 
cardiac death. MWT = maximal wall thickness. SCD = sudden cardiac death. 
 
 
Kaplan Meier curves for HF related mortality in carriers of different types of mutations are presented 
in figure 5. Thin filament mutation carriers had a greater probability of HF related death than thick 
filament mutation carriers (16% vs 5%, log rank p=0.06), and missense mutation carriers had a greater 
probability of HF related death  than truncating mutation carriers (7% vs 4%, log rank p=0.03).  
 
 
Figure 5. Kaplan-Meier analysis comparing heart failure related death in (A; top) HC patients with thick 
filament associated gene mutations and HC patients with thin filament associated gene mutations, and (B; 
bottom) HC patients with truncating gene mutations and HC patients with missense gene mutations.  
 
 
 
End point Predictor HR (95% CI) P-value 
Heart failure related mortality Genotype-positive status 6.33 (1.79-22.41) 0.004 
 Atrial fibrillation 12.66 (3.63-44.20) <0.001 
SCD/aborted SCD analysis 1 Genotype-positive status 2.88 (1.23-6.71) 0.015 
 ≥ 2 established risk factors (2003 guidelines) 2.44 (0.99-6.01) 0.052 
SCD/aborted SCD analysis 2 Genotype-positive status 2.88 (1.24-6.67) 0.014 
 ≥1 established risk factors (2011 guidelines) 2.32 (1.04-5.16) 0.039 
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DISCUSSION 
This study compared the clinical outcome of G+ and G- patients with HC. During 12±9 years follow-
up, multivariate analysis demonstrated that G+ status was an independent risk factor for all-cause 
mortality, CV mortality, HF related mortality, and SCD/aborted SCD.  
Several previous studies have evaluated the impact of sarcomere mutations on clinical 
outcome. Olivotto et al (8) studied 203 patients (G+: 62%), and found a greater probability of severe 
left ventricular systolic and diastolic dysfunction (HR 2.1; 95% CI 1.1-4.0;p=0.02), during a median 
follow up of 4.5 years. Li. et al (7) studied 558 patients (G+: 35%), and demonstrated that G+ status 
was an independent predictor of HF events (HR 4.5; 95% CI 2.1-9.3; p<0.001), during a mean follow 
up of 6.6±6.3 years. Fujita et al.(5) studied 193 patients (G+: 47%), and reported more CV events in 
G+ HC, during 1 year follow up. Lopes et al.(6) studied 874 patients (G+: 44%), and reported a higher 
proportion of CV deaths and SCD events in G+ patients, during a mean follow up of 4.8±3.5 years. 
The mean follow-up period in these previous studies varied from 1 to 6.6 years. The present long-term 
follow-up study confirms and extends the findings from these previous studies. 
G+ status in HC patients was an independent predictor of HF related mortality. The precise 
pathways through which sarcomere mutations lead to HF are unclear. In this study, 47% of G+ HC 
was caused by MYBPC3 founder mutations. These mutations are responsible for ~35% of HC cases in 
the Netherlands.(10) The pathophysiological consequences of MYBPC3 founder mutations have been 
investigated by van Dijk et al.(14) They reported a reduction of 33% in full-length cardiac MyBP-C 
protein, suggesting haploinsufficiency is part of the pathophysiology. In addition, the force generating 
capacity of cardiomyocytes was lower than myocardium from donor samples(14). This 
‘’hypocontractile sarcomere phenotype’’ seemed to be a common feature of HC patients, suggesting it 
is rather part of the remodeling process.(14, 15) This was investigated by correcting for a decrease in 
myofibril density.(16) After correction, values returned to normal for MYBPC3 mutations, but not for 
MYH7 mutations(16). And so, MYH7 mutations seem to cause hypocontractile sarcomeres directly. 
Other pathophysiological mechanisms may be a reduced phosphorylation of sarcomeric proteins, and 
enhanced Ca2+-sensitivity of the sarcomeres. Possibly, these early pathways involved in disease 
progression can be targets for future therapies.(3, 17) 
This study demonstrates a significant relationship between G+ status and SCD/aborted SCD. 
The risk of SCD/aborted SCD was low in G- probands and relatives. Lopes et al.(6) similarly reported 
an increased incidence of SCD/aborted SCD in G+ HC. However, other studies(7, 8) did not show a 
relationship between G+ status and SCD, probably related to the low number of events, or relatively 
short follow-up duration. Ho et al.(18) demonstrated that myocardial collagen synthesis was increased 
in G+ individuals compared to control subjects. This suggests that sarcomere mutations lead to 
myocardial fibrosis, which is a substrate for SCD. Since myocardial fibrosis is believed to be 
visualized by cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE), it 
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was shown that the extent of LGE on CMR was associated with an increased risk of SCD events.(19, 
20) Furthermore, an independent association between LGE and HF was reported(21).   
In this cohort, G- probands were older, more symptomatic, and had higher LVOT gradients. 
During follow-up, 33% of G- probands underwent septal reduction therapy. Previous data have shown 
excellent long-term outcomes after septal reduction therapy in symptomatic patients with HC and 
severe LVOT obstruction.(22) The survival disadvantage associated with LVOT obstruction can be 
substantially decreased by appropriate invasive therapy.(22) The G+ probands in this study had a more 
advanced cardiomyopathy, which is indicated by a higher MWT, higher incidence of AF, higher 
incidence of non-sustained ventricular tachycardia, and more often a family history of SCD (table 1). 
Therefore, the G+ probands were at an increased risk of SCD and HF related death. Part of G- HC 
patients may have undiscovered pathogenic mutations. However, the additive genetic yield of next 
generation sequencing in HC seems limited.(23, 24) Possibly, whole-exome and whole-genome 
sequencing will add more value to the discovery of new mutations(3). However, such massive 
sequencing also generates many variants of unknown significance(3, 23). Determining of the clinical 
significance of these variants is a major challenge.(23)  
In this study, relatives with HC were younger and had a more benign phenotype than 
probands. This can be explained by the way of presentation. It seems that family screening leads to the 
detection of disease in an earlier phase.(25) Although this was not reflected in a significantly better 
clinical outcome, a trend was found for fewer cardiovascular deaths among relatives. The lack of 
difference between G+ and G- relatives can be explained by the small number of G- relatives. 
The current findings demonstrate that G+ HC patients are at increased risk of progression 
towards HF and SCD/aborted SCD. Previous studies have demonstrated that genetic test results are 
predictive of medium-term outcome, and the current study demonstrates that this also holds for the 
long-term outcome of patients with HC. Due to the heterogeneous nature of HC, the therapeutic 
implications of a G+ status are currently limited. Phenotypic characterization is currently still the most 
important factor for determining prognosis in HC patients. The clinical challenge is to incorporate 
genetic test results in contemporary risk prediction models. Fundamental research on the 
pathophysiological consequences of sarcomere mutations is crucial to develop genotype-specific risk-
assessment and targeted therapies.  
This study has several limitations. Patients who died and never presented to the clinic were 
missed in the analysis. Due to significant advances in DNA-sequencing methodology during the past 
decade, there was no homogenous genotyping over the whole period. The rate of complex genotype 
(1%) could be an underestimation of the real rate of complex genotype. Previous literature reported a 
rate of 5-7%(3).  
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Supplementary table 1. Gene mutations associated with Hypertrophic Cardiomyopathy in 327 genotype-
positive patients with hypertrophic cardiomyopathy 
Nucleotide change 
Protein 
change 
Mutation 
type 
No. of 
patients 
with 
mutation 
Nucleotide 
change 
Protein 
change 
Mutation type 
No. of 
patients 
with 
mutation 
MYBPC3 Gene (n=240)                                           MYH7 Gene (n=47) 
c.2373dupG p.Trp792fs frameshift 78 c.4130C>T p.Thr1377Met missense 4 
c.2827C>T p.Arg943* nonsense 42 c.1816G>A p.Val606Met missense 4 
c.2864_2865delCT p.Pro955fs frameshift 34 c.1207C>T p.Arg403Trp missense 3 
c.1458-1G>C p.? splicesite 8 c.976G>C p.Ala326Pro missense 3 
c.3776delA 
p.Gln1259Argf
s 
frameshift 8 c.2156A>G p.Arg719Gln missense 3 
c.481C>T p.Pro161Ser missense 8 c.1727A>G p.His576Arg missense 2 
c.1624+1G>A p.? splicesite 5 c.1063G>A p.Ala355Thr missense 2 
c.2149-2delA p.? splicesite 5 c.1987C>T p.Arg663Cys missense 2 
c.927-2A>G p.? splicesite 5 c.2080C>T p.Arg694Cys missense 2 
c.654+1G>A p.? splicesite 3 c.2783A>T p.Asp928Val missense 2 
c.1831G>A p.Glu611Lys missense 4 c.2081G>A p.Arg694His missense 1 
c.2308G>A p.Asp770Asn missense 2 c.1988G>A p.Arg663His missense 1 
c.2391C>A p.Tyr797* nonsense 2 c.2104A>G p.Arg719Gln missense 1 
c.688delC p.Gln230fs frameshift 2 c.2167C>T p.Arg723Cys missense 1 
c.1484G>A p.Arg495Gln missense 2 c.2945T>C p.Met982Thr missense 1 
c.772G>A p.Glu258Lys missense 3 c.2221G>C p.Gly741Arg missense 1 
c.1696T>C p.Cys566Arg missense 2 c.3133C>T p.Arg1045Cys missense 1 
c.897delG p.Lys301fs frameshift 2 
c.3100-
2A>C 
p.? splicesite 1 
c.913_914delTT p.Phe305fs frameshift 1 c.3169G>A p.Gly1057Ser missense 1 
c.1766G>A p.Arg589His missense 1 c.1357C>T p.Arg453Cys missense 1 
c.1548-1G>A p.? splicesite 1 c.727C>T p.Arg243Cys missense 1 
c.2543_2544dupCG p.Val849fs frameshift 1 c.728G>A p.Arg243His missense 1 
c.2432A>G p.Lys811Arg missense 1 c.1532T>C p.Ile511Thr missense 1 
c.3029delA p.Glu1010fs frameshift 1 c.5135G>A p.Arg1712Gln missense 3 
c.2893C>T p.Gln965* nonsense 1 c.2146G>A p.Gly716Arg missense 1 
c.3181C>T p.Gln1061* nonsense 1 c.5786C>T p.Thr1929Met missense 1 
c.3640T>C p.Trp1214Arg missense 1 
c.2306T>C 
c.2788G>A 
p.Leu769Pro 
p.Glu930Lys 
missense 
missense 
1 
1 
c.3332_3335dup p.Trp1112* nonsense 1  
CSRP3 = cysteine and glycine-rich protein 3, CALR3 = calreticulin 3, MYBPC3 = myosin binding protein C, 
MYH7 = myosin heavy chain 7, MYL2 = regulatory myosin light chain 2, MYL3 = regulatory myosin light chain 
3, MYPN = myopalladin, TNNT2 = troponin T, TNNI3 = troponin I, TPM1 = α-tropomyosin 1 
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Supplementary table 1. Gene mutations associated with Hypertrophic Cardiomyopathy in 327 genotype-
positive patients with hypertrophic cardiomyopathy (continued) 
Nucleotide change 
Protein 
change 
Mutation 
type 
No. of 
patients 
with 
mutation 
Nucleotide 
change 
Protein 
change 
Mutation type 
No. of 
patients 
with 
mutation 
MYBPC3 Gene (n=240) MYL2 gene (n=8) 
c.3331-2A>G p.? splicesite 1 c.64G>A p.Glu22Lys missense 6 
c.3392T>C p.Ile1131Thr missense 1 
c.403-
1G>C 
p.? splicesite 1 
c.3814+1G>A p.? splicesite 1 c.286G>A p.Glu96Lys missense 1 
c.442G>A p.Gly148Arg missense 1 MYL3 gene (n=3) 
c.1800delA 
p.Lys600Asnf
s 
frameshift 1 c.452C>T p.Ala151Val missense 3 
c.1404delG p.Gln469fs frameshift 1 MYPN gene (n=1) 
c.701ins26 unknown frameshift 1 c.59A>G p.Tyr20Cys missense 1 
c.208delG p.Glu70fs frameshift 1 TNNI3 gene (n=7) 
c.1053_1054delGCin
sTT 
p.Arg351_Leu
352delinsSerP
he 
complex 1 c.433C>T p.Arg145Trp missense 4 
c.7191-1G>A p.? splicesite 1 c.497C>T p.Ser166Phe missense 1 
c.821+1G>A p.? splicesite 1 c.114dupA p.Ser39fs frameshift 1 
c.932C>A p.Ser311* nonsense 1 c.470C>T p.Ala157Val missense 1 
del exon 23-26 p.? splicesite 1 TNNT2 gene (n=10) 
c.1000G>T p.Glu334* nonsense 1 c.832C>T p.Arg278Cys missense 3 
c.3490+1G>T p.? splicesite 1 c.856C>T p.Arg286Cys missense 3 
    c.274C>T p.Arg92Trp missense 1 
 Double (n=3)   c.421delC p.Arg141fs frameshift 1 
c.1000G>T  
(MYBPC3) & 
c.64G>A (MYBPC3) 
p.Glu334* &  
p.Glu22Lys  
 1 c.874C>T p.Arg292Trp missense 1 
c.913_914delT 
(MYBPC3) & 
c.1468G>A (MYL2) 
p.Phe305fs & 
p.Gly490Arg 
 1 c.853C>T p.Arg285Cys missense 1 
c.5135G>A (MYH7) 
& 
c.2530_2532delTCTi
nsC (MIB1) 
p.Arg1712Gln 
& p.Ser844fs 
 1 
 
c.184G>C 
 TPM1 (n=2) 
p.Glu62Gln 
 
missense 
 
2 
 
CSRP3 gene 
(n=2) 
  CALR3 (n=4) 
c.131T>C p.Leu44Pro missense 2 c.564delT p.Gly189fs frameshift 4 
CSRP3 = cysteine and glycine-rich protein 3, CALR3 = calreticulin 3, MYBPC3 = myosin binding protein C, 
MYH7 = myosin heavy chain 7, MYL2 = regulatory myosin light chain 2, MYL3 = regulatory myosin light chain 
3, MYPN = myopalladin, TNNT2 = troponin T, TNNI3 = troponin I, TPM1 = α-tropomyosin 1 
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Supplementary table 2. Patients with hypertrophic cardiomyopathy that died from heart failure or sudden 
cardiac death, presented per gene affected and type of mutation 
Gene 
 
 
Mutation type 
 
 
No. of  
patients  
with mutation 
Heart failure 
related  
death 
Sudden 
cardiac death 
Total   327 17 (5%) 19 (6%) 
MYBPC3 Truncating 179 7 (4%) 12 (7%) 
 
Missense 27 2 (7%) 2 (7%) 
 
Splicesite 33 1 (3%) 2 (6%) 
 
Complex 1 0 0 
MYH7 Missense 46 3 (7%) 2 (4%) 
 
Splicesite 1 0 0 
MYL2 missense 7 1 (14%) 0 
  splicesite 1 0 0 
MYL3 missense 3 0 0 
MYPN missense 1 0 0 
TNNI3 truncating 1 0 0 
 
missense 6 0 0 
TNNT2 truncating 1   
 
missense 9 1 (11%) 0 
TPM1 missense 2 2 (100%) 0 
CALR3 truncating 4 0 0 
CSRP3 missense 2 0 0 
Complex genotype  3 0 1 (33%) 
All values are in number (%). CSRP3 = cysteine and glycine-rich protein 3, CALR3 = calreticulin 3, MYBPC3 = 
myosin binding protein C, MYH7 = myosin heavy chain 7, MYL2 = regulatory myosin light chain 2, MYL3 = 
regulatory myosin light chain 3, MYPN = myopalladin, TNNT2 = troponin T, TNNI3 = troponin I, TPM1 = α-
tropomyosin 1  
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ABSTRACT 
Background 
Myosin-binding protein C (MYBPC3) founder mutations account for 35% of hypertrophic 
cardiomyopathy (HCM) cases in the Netherlands. We compared clinical characteristics and outcome 
of MYBPC3 founder mutation (FG+) HCM with non-founder genotype positive (G+) and genotype 
negative (G-) HCM. 
Methods and results 
The study included 680 subjects: 271 FG+ carriers, 132 G+ probands with HCM and 277 G- probands 
with HCM. FG+ carriers included 134 FG+ probands with HCM, 54 FG+ relatives diagnosed with 
HCM after family screening, 74 FG+/phenotype-negative relatives, and 9 with non-compaction or 
dilated cardiomyopathy. The clinical phenotype of FG+ and G+ probands with HCM was similar. FG+ 
and G+ probands were younger with less LVOT obstruction than G- probands, however had more 
hypertrophy and non-sustained ventricular tachycardia. FG+ relatives with HCM had less hypertrophy, 
smaller left atria, and less systolic and diastolic dysfunction than FG+ probands with HCM. After 8±6 
years, cardiovascular mortality in FG+ probands with HCM was similar to G+ HCM (22 vs 14%, log 
rank p=0.14), but higher than G- HCM (22 vs 6%, log rank p<0.001) and FG+ relatives with HCM (22 
vs 4%, p=0.009). Cardiac events were absent in FG+/phenotype-negative relatives; subtle HCM 
developed in 11% during 6 years follow-up. 
Conclusions 
Clinical phenotype and outcome of FG+ HCM was similar to G+ HCM, but worse than G- HCM and 
FG+ HCM diagnosed in the context of family screening. These findings indicate the need for more 
intensive follow-up of FG+ and G+ HCM versus G- HCM and FG+ HCM in relatives. 
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INTRODUCTION  
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease with an estimated 
prevalence of 1:500 to 1:200.(1) More than 1500 mutations in at least 11 genes have been described in 
association with HCM.(2) Myosin-binding protein C (MYBPC3) is the most frequently mutated gene, 
representing 30-40% of all HCM mutations.(2) In the Netherlands, 35% of HCM cases are caused by 3 
MYBPC3 founder mutations: c.2373dupG (p.Trp792Valfs*41), c.2827C>T (p.Arg943*), and 
c.2864_2865delCT (p.Pro955fs*95).(3-5) These mutations cause C-terminally truncated protein, 
leading to haploinsufficiency.(6-8) Pathophysiologic studies have demonstrated that these mutations 
are associated with a reduced force generating capacity of cardiomyocytes, cardiomyocyte 
hypertrophy and reduced myofibril density.(8, 9) The clinical phenotype of MYBPC3 founder mutation 
(FG+) carriers varies.(10) Information on the clinical characteristics and long-term outcome of FG+ 
carriers is lacking. The aim of this study was to compare clinical characteristics and outcome of FG+ 
HCM with non-founder mutation genotype-positive (G+) HCM and genotype-negative (G-) HCM. 
 
METHODS 
Study design and population 
This retrospective cohort study included a total of 680 subjects: 271 FG+ carriers (141 FG+ probands; 
130 FG+ relatives) from 127 families, 132 G+ probands with HCM and 277 G- probands with HCM, 
who underwent clinical evaluation between 1985 and 2015. Probands were defined as patients with 
HCM, dilated cardiomyopathy (DCM), or non-compaction cardiomyopathy (NCCM), presenting with 
signs or symptoms. Relatives were defined as subjects who were evaluated in the context of family 
screening. The study conforms to the principles of the Declaration of Helsinki. All patients gave 
informed consent for inclusion in the registry and local institutional review board approval was 
obtained.  
 
Genetic analysis 
All subjects underwent genetic counselling. Before 2012, Sanger sequencing of all coding intron-exon 
boundaries of the following genes was available: MYBPC3, β-myosin heavy chain (MYH7), cardiac 
troponin C (TNNC1), cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), cardiac-regulatory 
myosin light chain (MYL2), cardiac-essential myosin light chain (MYL3), cardiac α-actin (ACTC1), α-
tropomyosin (TPM1), cysteine and glycine-rich protein 3 (CSRP3), and titin-cap/telethonin (TCAP). 
After the identification of a pathogenic mutation, genotyping was extended at the discretion of the 
treating physician. Since 2012, next-generation-sequencing covering 48 genes is used. Due to this 
change in DNA-analysis over time, subjects underwent either extensive genotyping (≥ 6 sarcomeric 
genes) or limited genotyping (MYBPC3 only). Extensive genotyping was performed in 77 (57%) FG+ 
probands with HCM, 57 (42%) G+ probands with HCM and 244 (88%) G- probands with HCM.  
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Next-generation sequencing was performed in 15 (11%) FG+ probands with HCM, 30 (22%) G+ 
probands with HCM, and 116 (60%) G- probands with HCM. Seven out of 9 (78%) individuals with 
non-HCM phenotypes underwent extensive genotyping. Relatives in FG+ families were tested for the 
familial mutation and referred for cardiac screening if the mutation was present.(11) Genetic testing 
before adulthood was offered in families with severe HCM in childhood, when cardiac symptoms were 
present, or severe anxiety among parents existed. 
 
Cardiac evaluation 
All individuals underwent periodic cardiac evaluation including history, clinical examination, 
electrocardiography (ECG) and echocardiography. Echocardiographic studies were analyzed according 
to the American Society of Echocardiography guidelines.(12) In probands, HCM was diagnosed when 
maximal wall thickness (MWT) ≥ 15 mm; a cutoff value of 13 mm was used in relatives.(13) DCM 
was diagnosed based on left ventricular (LV) dilatation and LV systolic dysfunction.(14) NCCM 
diagnosis was based on the Jenni criteria.(15) MWT, LV end-diastolic diameter (LVEDD), left atrial 
(LA) size and LV outflow tract (LVOT) pressure velocity at rest and during provocation were 
measured. LVOT gradient was calculated with the Bernoulli equation. Systolic LV function (sLVF) 
was assessed using the wall-motion score index, and described as normal, mildly reduced, moderately 
reduced, or poor, which corresponded with left ventricular ejection fractions of ≥55%, 45-54%, 30-
44%, and <30% respectively, according to echocardiography guidelines.(16) Systolic dysfunction was 
defined as mildly reduced, moderately reduced or poor systolic function. Diastolic LVF was described 
as normal, abnormal relaxation (stage I), pseudonormal (stage II) and restrictive filling (stage III).(17) 
Clinical disease stages were defined according to Olivotto et al: (1) non-hypertrophic (MWT < 13 
mm); (2) classic phenotype (MWT ≥ 13 mm and normal sLVF); (3) adverse remodeling (mildly 
reduced sLVF); and (4) overt cardiac dysfunction (moderately reduced or poor sLVF).(18) After 
cardiomyopathy diagnosis cardiac evaluation was extended with exercise testing and 24 hour 
ambulatory ECG monitoring. Non sustained ventricular tachycardia was defined as ≥ 3 consecutive 
beats at ≥ 120/min lasting <30 seconds.(13)  
 
Patient follow-up 
Follow-up data were obtained in January 2016. Follow-up was complete for 99% of patients. Patients 
who were lost to follow-up were censored at time of last follow-up. Mortality was retrieved from the 
civil service register and cause of death from the medical chart or the general practitioner. Septal 
reduction therapy (SRT) and implantable cardioverter defibrillator (ICD) were registered. ICDs were 
implanted according to the guidelines.(13, 19, 20) Cardiovascular mortality was defined as the 
combined end point of sudden cardiac death (SCD)/aborted SCD, heart failure (HF) related death 
(including heart transplantation), stroke related death, coronary artery disease related death, and 
procedure-related cardiac death. SCD/aborted SCD was defined as (1) instantaneous and unexpected 
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death in patients who were previously in a stable condition, or nocturnal death with no antecedent 
history of worsening symptoms; (2) resuscitation after cardiac arrest; or (3) appropriate ICD 
intervention for ventricular fibrillation or ventricular tachycardia > 200 beats/min.  
 
Statistical analysis 
Calculations were performed using SPSS 21 (IBM, Armonk, New York) and R Statistical Software 
version 3.2.4.-using packages ‘survival’ and ‘lme4’. Normally distributed continuous data are 
expressed as mean ± standard deviation (SD) and non-normally distributed data as median, followed 
by the interquartile range [IQ1-IQ3]. For comparing categorical variables Pearson’s chi-square test 
was used. For comparing continuous variables, student t-test was used and Mann-Whitney test in the 
case of non-normally distributed data. In order to make comparisons between FG+ probands and FG+ 
relatives, generalized linear mixed models were used, with random intercepts for family to account for 
family relatedness. Survival curves were constructed according to the Kaplan Meier method. 
Comparisons of survival and other clinical outcomes between FG+ probands with HCM and FG+ 
relatives with HCM were performed by using Cox models. To estimate the standard errors of the 
hazard ratios while taking into account family relatedness, the grouped jackknife method was used. 
Fisher’s exact test was used in case of a zero cell count in either of the groups. Log rank test was used 
for comparison of survival between FG+ patients and G+ or G- patients. For comparison of 
consecutive echocardiographic data, the paired t-test and in case of non-normally distributed data the 
Wilcoxon signed rank test were used. Statistical significance was defined by p < 0.05.  
RESULTS 
Study population 
In 141 FG+ probands (age 45±14 y, 66% male), HCM was diagnosed in 134 (95%), NCCM in 4 (3%), 
and DCM in 3 (2%), In 130 FG+ relatives (age 42±15 y, 37% male), HCM was diagnosed in 54 
(42%), NCCM in 1 (1%), and DCM in 1 (1%). The remaining 74 (57%) were FG+/phenotype-negative 
(FG+/Ph-). Baseline characteristics of the study population are presented in table 1 and 4. 
 
Genetic test results 
In FG+ carriers, the c.2373dupG mutation was most frequent (46%), followed by c.2827C>T (32%) 
and c.2864_2865delCT (22%). A complex genotype was present in 4 (1%); 3 probands and 1 relative. 
Complex genotypes were: compound heterozygosity for the c.2373dupG and c.2827C>T mutations; 
homozygosity for the c.2827C>T mutation; compound heterozygosity for the c.2373dupG and 
c.442G>A (G148R) mutations in the MYBPC3 gene, and a digenic mutation (c.2827C>T in the 
MYBPC3 gene and c.222dupA; p.Leu75fs in the Ankyrin Repeat Domain 1 [ANKRD1] gene).  
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In G+ probands, pathogenic mutations were present in the MYBPC3 gene (45%), MYH7 (29%), 
TNNT2 (7%), MYL2 (6%), TNNI3 (5%), CALR3 (2%), MYL3 (2%), CSRP3 (2%), and complex 
genotypes were present in 3 (2%). Complex genotypes were: (1) compound heterozygosity for the 
c.913_914delTT and c.1468G>A mutations in the MYBPC3 gene, (2) digenic mutations c.5135G>A in 
the MYH7 gene and c.2530_2532delTCTinsC in the MIB1 gene, and (3) digenic mutations c.1000G>T 
in the MYBPC3 gene and c.64G>A in the MYL2 gene.   
 
Table 1. Baseline characteristics of the study population. 
Variable 
 
FG+ probands with 
HCM (n=134) 
FG+ relatives 
with HCM (n=54) 
G+ HCM (n=132)  G- HCM (n=277)            
Age, years (range) 44±14 47±16 47±15 55±15*†‡ 
   <18 y 4 (3) 3 (6) 4 (4) 5 (2) 
   18-35 y 33 (25) 11 (20) 28 (21) 28 (10)*†‡ 
   36-50 y 51 (38) 17 (32) 45 (35) 58 (21)*† 
   >50 y 46 (34) 23 (43) 55 (41) 187 (67)*†‡ 
Men, n (%) 91 (67) 31 (57) 89 (66) 171 (62) 
Reasons for evaluation     
  Symptoms, n (%) 75 (56) 0  70 (56) 181 (65) 
  Abnormal ECG, n (%) 23 (17) 0  27 (22) 36 (13) 
  Systolic murmur, n (%) 32 (24) 0  26 (21) 50 (18) 
  Sudden death, n (%) 3 (2)|| 0  1 (1) 1 (0.4) 
  Incidental finding, n (%) 1 (1) 0  1 (1) 3 (1) 
  Familial evaluation, n (%) 0  54 (100) 0 0 
NYHA class ≥ II, n (%) 48 (48) 3 (8)* 71 (56) 164 (61)*‡ 
History of AF, n (%) 28 (21) 4 (7)* 36 (27) 41 (15)† 
History of stroke, n (%) 12 (9) 4 (8) 11 (8) 22 (8) 
MWT, mm 20±5 16±4* 20±5 17±4*†‡ 
LA size, mm 45±8 40±7* 45±7 45±7‡ 
Systolic dysfunction 23 (17) 0*§ 22 (18) 30 (12)‡ 
Diastolic dysfunction 50 (56) 19 (38)* 53 (71) 159 (80)*‡ 
MWT ≥ 30 mm, n (%) 5 (4) 0§ 11 (9) 2 (1)*† 
LVOTO ≥ 30 mmHg 31 (28) 2 (4)* 36 (32) 101 (45)*†‡ 
LVOTO ≥ 50 mmHg 18 (16) 2 (4) 24 (21) 85 (38)*†‡ 
Non-sustained VT, n (%) 44 (42) 6 (16)* 35 (32) 26 (13)*† 
Data are expressed as mean ± SD or as absolute and %. AF = atrial fibrillation, FG+ = Dutch MYBPC3 founder 
mutation, LVOTO = left ventricular outflow tract obstruction at rest, MWT = maximal wall thickness, NYHA = 
New York Heart Association functional class, VT = ventricular tachycardia. * = p<0.05 versus FG+ probands 
with HCM. †= p<0.05 versus G+ HCM. ‡ p<0.05 vs FG+ relatives with HCM. § = Fisher’s exact test was used 
because of zero cell count. || = one was not successfully resuscitated. 
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Baseline clinical and echocardiographic characteristics 
Main reasons for evaluation in probands were cardiac symptoms (61%), systolic murmur (20%), and 
abnormal ECG (16%). Five (1%) probands presented with cardiac arrest. All FG+ relatives were 
evaluated in the context of family screening. Men predominated in all groups.  
The clinical phenotype of FG+ probands with HCM was similar to G+ probands with HCM. Both FG+ 
and G+ probands were younger than G- probands with HCM and had less LVOT obstruction, however 
they had more hypertrophy and non-sustained ventricular tachycardia. FG+ relatives with HCM had 
less hypertrophy, smaller left atria, and less systolic and diastolic dysfunction in comparison to FG+ 
probands with HCM. Among FG+ relatives with HCM, MWT was not different between males and 
females after indexing for body surface area (6.6±2.1 vs 6.4±2.6 mm/m2, p=0.776).  
Echocardiographic findings during follow-up of FG+ carriers 
Echocardiographic findings during 10±6 years follow-up of FG+ probands and FG+ relatives with 
HCM are presented in table 2. Figure 1 demonstrates the clinical HCM disease stages(18) at baseline 
and during follow-up of FG+ probands and FG+ relatives. A significant proportion of FG+ probands 
(29%) progressed to stage III (adverse remodeling), and 18% to stage IV (overt dysfunction); in FG+ 
relatives only 5% progressed to stage III and none to stage IV. Systolic dysfunction during follow-up 
was frequently present in G+ and FG+ HCM (46% vs 46%, log rank p=0.23), and less frequent in G- 
HCM than in FG+ HCM (31% vs 46%, log rank p<0.001). Moderate to severe systolic dysfunction 
was also frequently present in G+ and FG+ HCM (15% vs 25%, log rank p=0.54), and less frequent in 
in G- HCM than in FG+ HCM (7% vs 25%, log rank p<0.001).  
 
Table 2. Echocardiographic findings during follow-up of FG+ probands and FG+ relatives with hypertrophic 
cardiomyopathy 
Variable                                                         FG+ probands with HCM                               FG+ relatives with HCM 
  Baseline Follow-up P-value Baseline Follow-up P-value 
Maximal wall thickness, mm 20±5  17±4 <0.001 16±4 15±4 0.053 
Left atrial size, mm 45±8 49±9 <0.001 40±7 41±6 0.044 
LVEDD, mm 46±7 48±7 <0.001 47±5 45±6 0.107 
LVOTO ≥ 30 mmHg, n (%) 32 (28) 6 (6) <0.001 2 (4) 2 (4) 1.000 
LVOTO ≥ 50 mmHg, n (%) 18 (16) 4 (4) 0.005 2 (4) 2 (4) 1.000 
Systolic dysfunction, n (%) 23 (17) 47 (40) <0.001 0  4 (8) 0.046 
Diastolic dysfunction, n (%) 50 (56) 75 (84) <0.001 18 (37) 26 (59) 0.011 
Data are expressed as mean ± SD or as absolute and %. LVOTO = left ventricular outflow tract obstruction at 
rest; LVEDD = left ventricular end-diastolic diameter. 
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Figure 1. Clinical characteristics of individuals with a Dutch MYBPC3 founder mutation. Stage I: Non-
hypertrophic stage in a c.2864_2865delCT mutation carrier. Stage II: Classic HCM phenotype in a c.2373dupG 
mutation carrier. Stage III: Adverse remodeling in a c.2373dupG mutation carrier. Stage IV: Overt dysfunction 
(hypokinetic dilated form) in a c.2373dupG mutation carrier. 
 
 
Mortality and interventions during follow-up  
Mortality and interventions are presented in table 3. Cardiovascular mortality was 21% in FG+ 
probands with HCM and 14% in G+ probands (p=0.14), and cardiovascular mortality was significantly 
lower in FG+ relatives with HCM (4%) and G- probands (7%) (figure 2). During 8±6 years follow-up, 
annual cardiovascular mortality was 2.1%, 1.6%, 1.0%, and 0.5% for FG+ probands with HCM, G+ 
probands, G- probands, and FG+ relatives with HCM respectively. By multivariate Cox analysis 
taking into account age, sex and family relatedness, FG+ relatives with HCM exhibited a lower risk of 
cardiovascular death than FG+ probands with HCM (hazard ratio 0.15 95% confidence interval 0.04; 
0.64, p=0.01). Both HF related death and SCD/aborted SCDs were more frequent in FG+ HCM than in 
G- HCM (8% vs 1%, log rank p<0.001 and 14% vs 4%, log rank p<0.001 respectively). In FG+ HCM, 
SCD/aborted SCD occurred at ages ranging from 11 to 77 years, and HF-related death generally 
occurred after the age of 50 years. SRT was performed more often in G- HCM than in FG+ HCM 
(33% vs 23%, p=0.004). ICDs for the primary and secondary prevention of SCD were implanted with 
similar proportions in all groups. 
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Table 3. Long-term outcome of the study population   
Variable 
FG+ probands with 
 HCM (n=134) 
FG+ relatives with  
HCM (n=54) 
G+ HCM  
(n=132)  
G- HCM  
(n=277) 
All-cause mortality, n (%) 39 (29) 3 (6)* 20 (15)* 38 (14)*† 
CV mortality, n (%) 29 (22) 2 (4)* 19 (14) 20 (7)* 
HF related deaths, n (%) 10 (8) 0‡ 10 (8) 4 (1)*† 
    Cardiac transplants, n (%) 1 (0.7) 0‡ 3 (2) 2 (1) 
SCD/Aborted SCD, n (%) 18 (14) 2 (4)* 9 (7) 12 (4)*† 
    True SCD, n (%) 11 (8) 1 (2) 4 (3) 4 (1)*† 
Stroke related deaths, n (%) 0 0 0 2 (1) 
Procedure-related deaths, n (%) 0 0 0 2 (1) 
CAD related deaths, n (%) 0 0 0 0 
Non-cardiac deaths, n (%) 8 (6) 1 (2) 1 (1)* 15 (5) 
SRT, n (%) 31 (23) 2 (4)* 39 (30) 91 (33)* 
ICD 1st prevention, n (%) 26 (19) 5 (10) 16 (12) 26 (9) 
ICD 2nd prevention, n (%) 5 (4) 2 (4) 6 (5) 7 (3) 
Data are expressed as mean ± SD or as absolute and %. CAD = coronary artery disease, FG+ = Dutch MYBPC3 
founder mutation, HCM = hypertrophic cardiomyopathy, ICD = internal cardioverter defibrillator, SCD = sudden 
cardiac death, SRT = septal reduction therapy (alcohol septal ablation or surgical myectomy). * = p<0.05 vs FG+ 
probands with HCM †=log rank p<0.05 vs G+ HCM. ‡Cox model with grouped jackknife method did not 
converge because of insufficient number of events. 
 
 
Figure 2. Kaplan-Meier survival analysis for cardiovascular mortality. P =  p-value calculated with log rank test 
in FG+ versus G+ probands, and in FG+ versus G- probands. In FG+ probands versus FG+ relatives with HCM, 
the p-value was calculated with a cox model with grouped jackknife method. In FG+/phenotype negative 
relatives the Cox model with grouped jackknife method did not converge because of insufficient number of 
events. 
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FG+/phenotype-negative relatives 
Characteristics and outcomes of FG+/Ph- relatives versus FG+ HCM are presented in table 4. FG+/Ph- 
relatives were predominantly female (63% vs 35%; p<0.001); there was no significant age difference. 
During 6±4 years follow-up, there were no cardiovascular deaths among FG+/Ph- relatives. 
Echocardiographic follow-up was available in 44 (59%) FG+/Ph- relatives (table 5). After 6±3 years, 5 
(11%) FG+/Ph- subjects developed HCM. These 5 subjects were asymptomatic and without LVOT 
obstruction; conversion occurred at a median age of 37 (range 25-71) years. Baseline ECG 
abnormalities were present in 3 (2 pathological Q’s inferior/lateral and 1 non-pathological Q inferior), 
and anterior mitral valve leaflet elongation ≥ 30 mm in 1 (20%). Systolic anterior motion and diastolic 
dysfunction were absent in all 5. Hypertrophy developed at a pace of a median 0.5 [0.2-0.8] mm per 
year during a median 6 [3.5-9] year follow-up, in which MWT increased from a median 11 [9.5-11.5] 
to 13 [13-13.5] mm.  
 
 
Table 4. Characteristics of FG+/phenotype negative relatives versus FG+ HCM (probands and relatives 
combined) 
 Variable 
 
FG+ HCM 
(n=188) 
FG+/Ph- relatives 
(n=74) P-value 
 
Baseline 
Age, years (range) 45±15 (9-80) 42±15 (4-83) 0.077 
   <18 y 7 (4) 3 (4) 0.205 
   18-35 y 44 (23) 22 (30) 0.249 
   36-50 y 71 (38) 35 (47) 0.163 
   >50 y 66 (35) 14 (19) 0.013 
Women, n (%) 66 (35) 47 (64) < 0.001 
NYHA ≥ II, n (%) 51 (37) 2 (3) <0.001 
History of stroke, n (%) 16 (9) 0 0.008* 
History of AF, n (%) 32 (17) 1 (1) 0.008 
Follow-up   
All-cause mortality, n (%) 43 (23) 1 (1) 0.036 
Cardiovascular mortality, n (%) 31 (16) 0 † 
Data are expressed as mean ± SD, or as absolute and %. AF = atrial fibrillation, FG+ = Dutch MYBPC3 founder 
mutation, NYHA = New York Heart Association functional class. * = Fisher’s exact test was used because of 
zero cell count. †Cox model with grouped jackknife method did not converge because of insufficient number of 
events.  
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Non-compaction and dilated cardiomyopathy in FG+ carriers 
NCCM was diagnosed in 5 (3%) FG+ carriers; 4 probands and 1 relative. A complex genotype was 
present in 3 (60%): 2 FG+ probands who suffered HF related death within two months after birth and 
one 18-year-old asymptomatic FG+ relative. One NCCM patient suffered HF related death at 50 years 
of age. DCM was diagnosed in 4 (2%) FG+ carriers; 3 probands and 1 relative. A complex genotype 
was present in 1 (25%), leading to cardiac transplantation at the age of 8 years. Another FG+ proband 
with DCM died of HF at one year of age. Figure 3 presents cardiac magnetic resonance and 
echocardiographic imaging, demonstrating the overlap of HCM and NCCM within one family and the 
presence of NCCM in a FG+ carrier. 
 
Figure 3. Cardiac magnetic resonance images of non-compaction cardiomyopathy and hypertrophic 
cardiomyopathy, measured in apical 3 chamber view and short-axis view at apical level during end-diastole. 
Non-compaction cardiomyopathy was diagnosed in an 18-year old FG+ relative (image A and B) after family 
screening; asides from the familial mutation c.2827C>T, next-generation sequencing revealed a second mutation 
c.222dupA in the Ankyrin Repeat Domain 1 gene. Mild hypertrophy (13 mm) of the left ventricular posterior 
wall was also present. His father (image C and D) had hypertrophic cardiomyopathy based on the c.2827C>T 
mutation. Another FG+ individual presented with non-compaction cardiomyopathy on echocardiography (image 
E) and cardiac magnetic resonance imaging (image F); this individual carried the c.2827C>T mutation. Left 
ventricular systolic function was poor. 
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Table 5. Echocardiographic follow-up of FG+/phenotype negative relatives  
Variable  Baseline Follow-up P-value 
MWT, mm  9.9±1.6 10.2±2.0 0.188 
LA size, mm  37±4 36±6 0.715 
LVEDD, mm  48±4 46±4 0.021 
Maximal LVOT gradient, mmHg  5 [4-8] 6 [6-7] 0.072 
Systolic dysfunction, n (%)  0 1 (2) 1.000 
Diastolic dysfunction, n (%)  4 (10) 6 (15) 0.625 
Data are expressed as mean ± SD, median [interquartile range], or as absolute and %. LA = left atrial; LVOT = 
left ventricular outflow tract, LVEDD = left ventricular end-diastolic diameter; MWT = maximal wall thickness. 
 
 
DISCUSSION 
Key findings from the current long-term follow-up study are: (1) clinical phenotype and outcome of 
FG+ HCM was similar to G+ HCM, but worse than G- HCM and FG+ HCM diagnosed in the context 
of family screening, and (2) cardiac events were absent in FG+/Ph- relatives; 11% of FG+/Ph- 
relatives developed HCM during 6±3 years follow-up. 
 
FG+ HCM 
This study demonstrates that the prognosis of FG+ carriers is primarily defined by the presenting 
phenotype and the reason for evaluation. Cardiovascular mortality was significantly higher in FG+ 
HCM than in FG+/Ph- relatives and significantly lower in FG+ relatives diagnosed with HCM in the 
context of family screening. Adverse remodeling and progression to end-stage HCM was highly 
prevalent among FG+ probands with HCM, resulting in significantly more HF related deaths in 
comparison to FG+ relatives with HCM. This finding is in line with the findings of Kubo et al.(21) We 
also observed a higher cardiovascular mortality rate in FG+ HCM in comparison to G- HCM. Several 
studies have previously demonstrated an increased risk of cardiac death in G+ versus G- HCM(22-24), 
including studies of MYBPC3 founder mutations.(25, 26) G- probands in this study were older and 
more symptomatic most likely related to LVOT obstruction and diastolic dysfunction. Possibly, G- 
HCM represents a separate disease with a different pathophysiology. Unlike previous 
observations(27), we did not observe a lower complication rate in FG+ versus G+ patients. 
Initial cardiac screening revealed HCM in 42% of FG+ relatives, which is comparable to previous 
studies (24% to 62%).(26, 28-31) Extreme hypertrophy was absent in FG+ relatives and there was less 
adverse remodeling. Identification of HCM leads to lifestyle modifications, periodic SCD risk 
stratification and close clinical follow-up, with the opportunity to implant an ICD for primary 
Hypertrophic cardiomyopathy in individuals with a MYBPC3 founder mutation 
 
51 
 
prevention and timely referral for SRT. In the future, early disease identification might lead to novel 
therapies to prevent hypertrophy(32) or delay progression to advanced disease stages.(33) 
In this study the clinical phenotypes of FG+ carriers showed substantial variation. The clinical 
heterogeneity in subjects carrying the same pathogenic mutation is intriguing. Basic studies have 
shown a decrease in the force generating capacity of cardiomyocytes in G+ HCM patients.(8, 9) For 
MYBPC3 mutations, the force generating capacity normalized after correction for myofibril density.(9) 
The drop in force was associated with cardiomyocyte hypertrophy and reduced myofibril density, 
suggesting sarcomere dysfunction is secondary to cardiomyocyte remodeling.(9) Other triggers e.g. 
altered Ca2+ handling and disturbances in myocardial energetics(34) are additionally being 
investigated. The exact pathways from mutation to disease remain largely unknown. The relatively 
large population of FG+ carriers is useful for translational research in which clinical data are combined 
with data from basic research to further unravel the pathomechanism and identify secondary disease-
modifiers such as additional (epi)genetic variations and environmental disease triggers.  
 
FG+/Ph- individuals 
Because of the known age-related penetrance in HCM(29), long-term follow-up of FG+/Ph- subjects is 
recommended.(13, 20, 35) The interval at which clinical evaluation should be repeated is subject to 
debate. The American guideline recommends a 1-2 year interval for family members aged 10-20 years 
and 2-5 year interval for those > 20 years, whereas the European guideline does not advise a specific 
interval.(13, 20) In this study, 11% of FG+/Ph- relatives developed a subtle form of HCM after 6 years 
follow-up. Additionally, comparable to previous studies(31, 36, 37), the prognosis of FG+/Ph- 
relatives was good. These findings support cardiac follow-up of adult FG+/Ph- relatives with a low 
frequency, as advised by the American guideline.(20) The number of family members aged < 18 years 
in our cohort was too small to propose screening intervals for this group. However, Jensen et al 
reported a similarly low manifestation rate (6%) in 36 at-risk relatives <18 years of age during 12 
years follow-up.(36) The main advantage of genetic testing in relatives is reassurance in case the 
mutation is absent. However, the identification of FG+/Ph- subjects currently has limited therapeutic 
and prognostic consequences, because at present no therapy is available to retard or prevent the 
development of HCM(32, 33), and clinical manifestation cannot be predicted.(35) Moreover, a 
FG+/Ph- status may have psychological and socio-economic implications.(38) Clearly, cardio-genetic 
counseling of relatives should include a balanced discussion of the advantages and potential 
disadvantages of genetic testing. 
 
NCCM and DCM in FG+ carriers 
MYBPC3 mutations are associated with various forms of cardiomyopathies, such as DCM and 
NCCM.(5) In this study, a significantly poor outcome was observed in a minority of young  NCCM 
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and DCM patients, partly explained by homozygous and compound heterozygous mutations.(39) Since 
MYBPC3 founder mutations are truncating mutations leading to haploinsufficiency(8), compound 
heterozygous or homozygous mutations would theoretically result in human MYBPC3 knockouts (no 
functional MYBPC3 protein), leading to severe HF at a young age.(39) The likelihood of compound 
heterozygotes or homozygotes in countries with founder mutations is increased.(5) The finding of 
NCCM and DCM in the FG+ population and within one family, supports previous suggestions that the 
various cardiomyopathies are part of a cardiomyopathy spectrum with similar pathogenesis. Lorca et 
al. similarly described the overlapping of HCM and NCCM phenotypes within one family.(40) 
 
Male predominance in HCM 
The male predominance in HCM patients was previously partly explained by a referral bias.(41) In this 
study, there was also a male predominance in FG+ relatives with HCM eliminating referral bias. Other 
theories explaining gender differences in HCM include differential gene regulation and the protective 
effect of estrogens.(41) Another explanation might be the use of the 13 mm cutoff value to diagnose 
HCM in relatives.(13) In this study, the difference in MWT between male and female relatives 
disappeared after indexing for body surface area, suggesting that women are clinically underdiagnosed 
or men over diagnosed. Recommendations for cardiac chamber quantification report different normal 
ranges for septal and posterior wall thickness in males (6-10 mm) and females (6-9 mm).(42) 
Therefore, either indexing to body surface area or creating gender specific cutoff values for family 
members might lead to a higher diagnostic accuracy.  
 
Limitations 
This FG+ population is specific for the Netherlands, and therefore it might be difficult to extrapolate 
these findings to other countries. Follow-up echocardiography was not available in all subjects. Due to 
developments in genetic testing methodology over time, extended genotyping was not performed in all 
subjects. Because autopsy was not routinely performed in SCD cases, comorbidities such as coronary 
artery disease cannot be fully excluded. 
 
CONCLUSION 
Clinical phenotype and outcome of FG+ HCM was similar to G+ HCM, but worse than G- HCM and 
FG+ HCM diagnosed in the context of family screening. These findings indicate the need for more 
intensive follow-up of FG+ and G+ HCM versus G- HCM and FG+ HCM in relatives. 
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CLINICAL PERSPECTIVE 
In hypertrophic cardiomyopathy (HCM), extreme genetic and clinical heterogeneity challenge the use 
of genotype as a prognostic factor. The gene most frequently affected in HCM is myosin-binding 
protein C (MYBPC3). In the Netherlands, 3 MYBPC3 founder mutations represent 35% of HCM cases. 
To investigate the impact of genotype on the clinical course of HCM, we compared clinical phenotype 
and outcome of MYBPC3 founder mutation (FG+) HCM with non-founder mutation genotype-positive 
(G+) HCM and genotype-negative (G-) HCM. Also, a distinction was made between FG+ HCM in 
probands who presented with signs or symptoms of disease, and in relatives who were diagnosed with 
HCM in the context of family screening. We observed a more severe phenotype at a younger age in 
FG+ and G+ HCM than in G- HCM and FG+ HCM in relatives, including more hypertrophy and non-
sustained ventricular tachycardia, and more adverse remodeling during follow-up. Cardiovascular 
mortality was more frequent in FG+ and G+ HCM than in G- HCM and FG+ HCM in relatives. FG+ 
relatives without a phenotype suffered no cardiac events; although 11% developed subtle HCM during 
6 years follow-up. The findings of the current study are important for the practicing clinician because 
it contradicts previous reports that observed a more benign clinical course in FG+ HCM. The results 
indicate the need for more intensive follow-up of FG+ and G+ HCM versus G- HCM and FG+ HCM 
in relatives. Moreover, adult FG+ carriers without a phenotype can be screened at low frequency. 
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ABSTRACT 
Background  
Contemporary hypertrophic cardiomyopathy (HCM) family screening includes clinical evaluation and 
genetic testing (GT). This screening strategy requires the identification of a pathogenic mutation in the 
proband. Our aim was to examine the results of this HCM screening strategy. 
Methods and Results  
Between 1985 and 2016, 777 relatives of 209 probands were assessed in the context of HCM 
screening. A pathogenic mutation was identified in 72% of probands. After counseling, GT was 
performed in 620 (80%) relatives: 264 (43%) were genotype-positive (G+), and 356 (57%) were 
genotype-negative (G-). G+ relatives (n=264, age 41±18 y) and relatives without GT (n=157, age 
30±17 y) underwent clinical screening. In G- relatives (age 48±17 y) mortality was assessed. At first 
screening, HCM was diagnosed in 98 (37%) G+ relatives and 28 (17%) relatives without GT 
(p<0.001). During 9 years follow-up of relatives diagnosed with HCM, 8 (6%) underwent septal 
reduction therapy, 16 (16%) received primary prevention ICDs, and cardiac mortality was 0.3%/year. 
During 7 years follow-up of relatives without HCM, 29 (16%) developed HCM. Survival at 5/10 years 
was 99%/95% in G+ relatives, 97%/94% in G- relatives (p=0.8), and 100%/100% in relatives without 
GT.  
Conclusions  
HCM was identified in 30% of relatives at first screening, and 16% developed HCM during 7 years of 
repeated evaluation. GT led to a discharge from clinical follow-up in 46% of the study population. 
Survival in the relatives was good.
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INTRODUCTION 
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease with a 
prevalence of 1:500 to 1:200.(1) It is mainly transmitted in an autosomal dominant pattern, and the 
primary presentation may be sudden cardiac death (SCD).(2) Guidelines have encouraged family 
screening by electrocardiography (ECG) and echocardiography since 2003.(2-4) The latest European 
guidelines recommend to include genetic testing (GT) in the screening strategy.(2) However, in 
several countries, the routine use of GT is hampered by insufficient health care insurance coverage. In 
the Netherlands, GT in HCM is covered by the national basic health-care plan, and therefore can be 
routinely used for family screening. This strategy requires the identification of a pathogenic mutation 
in the proband, which is fulfilled in 40-60% of cases.(2) Genotype-positive (G+) relatives and relatives 
without GT are advised to undergo repeated cardiac evaluation. Genotype-negative (G-) relatives can 
be discharged.(2) Data regarding results of HCM screening including GT are scarce.(5, 6) The aim of 
this study was to examine the results of contemporary family screening in HCM, using GT and 
repeated cardiac evaluation.  
 
METHODS 
Study design and population 
This retrospective cohort study included 777 relatives from 209 unrelated probands with HCM who 
visited the cardio-genetic outpatient clinic of the Erasmus Medical Center for screening purposes 
between 1985 and 2016. A median of 1 (interquartile range, 1-2) relative per proband was screened 
with a range of 1 to 17 relatives per proband. Relatives who presented symptomatically were excluded 
from the study. Relatives who were screened in another center and subsequently referred to our center 
were included. Families with HCM caused by Anderson-Fabry disease, Danon disease, Noonan 
syndrome or amyloidosis were excluded. The study conforms to the principles of the Declaration of 
Helsinki. Subjects gave informed consent for inclusion in the Erasmus MC Inherited Cardiomyopathy 
registry and local institutional review board approval was obtained. The data, analytic methods, and 
study materials will not be made available to other researchers for purposes of reproducing the results 
or replicating the procedure. Requests for collaboration will be handled on an individual basis. 
Genetic analysis and family screening 
Genetic counseling and testing was offered to all probands with HCM. Before the year 2012, genetic 
analysis consisted of direct sequencing of all coding intro-exon boundaries of the following genes: 
myosin binding protein C (MYBPC3), ß-myosin heavy chain (MYH7), cardiac-regulatory myosin light 
chain (MYL2), cardiac-essential myosin light chain (MYL3), cardiac troponin T (TNNT2), cardiac 
troponin I (TNNI3), cysteine and glycine-rich protein 3 (CSRP3), titin-cap/telethonin (TCAP), α-
tropomyosin (TPM1), cardiac muscle α-actin (ACTC1), and cardiac troponin C (TNNC1). From the 
year 2012, next-generation-sequencing covering 48 cardiomyopathy-associated genes was used. 
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Classification of variants was done at time of initial testing. Variants were interpreted using a protocol 
adapted from the American College of Medical Genetics and Genomics recommendations(7), and 
classified into 5 categories: (I) benign; (II) likely benign; (III) uncertain significance; (IV) likely 
pathogenic; and (V) pathogenic. The potential pathogenicity of variants was assessed using Alamut 
Visual software (Interactive Biosoftware, Rouen, France), that integrates data from several large-scale 
population studies, evolutionary conservation of nucleotides and amino acids, in silico missense 
predictions (Align GVGD, SIFT, MutationTaster and PolyPhen-2) and splicing prediction modules 
(SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer and Human Splicing Finder). The 
criteria for classification of variants included the allele frequency in the dbSNP/ESP/ExAC/GoNL 
(cutoff minor allele frequency 1% in at least 300 ethnically matched control alleles equals benign), 
predicted effects on splicing, the in silico prediction of effect on the protein, and previously described 
links to disease. Furthermore, segregation analysis in families with more affected individuals and 
information considering presence in Human Gene Mutation Database (HGMD®) Professional 2017.3 
(Qiagen) is taken into account. Variant reclassifications during follow-up were registered, and variant 
classification as assessed at the end of follow-up was used for the analyses. Patients with a reclassified 
variant were informed about the reclassification and if applicable about the indication for renewed 
evaluation. Patients were considered G+ when the mutation was classified as likely pathogenic or 
pathogenic (class IV and V). First-degree relatives were informed by means of a family letter provided 
by the proband about the presence of HCM in the family including the indication for cardiac 
evaluation, and if applicable about the possibility of GT. GT was offered to relatives of probands with 
likely pathogenic or pathogenic variants, and to relatives of probands without pathogenic mutations 
only in case HCM was revealed in the relative during cardiac screening. Based on this family letter 
relatives with interest for screening were referred to the clinical geneticist by their general practitioner 
for counseling. G+ relatives and relatives who refused GT were referred for cardiac evaluation. G- 
relatives did not routinely undergo cardiac evaluation. Cardiac evaluation < 10 years of age or GT 
before adulthood was offered in families with severe HCM in childhood, when cardiac symptoms were 
present, or severe anxiety among parents existed. Cardiac evaluation was repeated every 2-4 years in 
phenotype-negative children and every 3-5 years in phenotype-negative adults. Genetic and cardiac 
screening was extended after identification of a G+ relative and/or HCM diagnosis in a relative 
(cascade screening). 
 
Cardiac evaluation 
Cardiac evaluation included medical history, clinical examination, ECG and echocardiography. 
Cardiac symptoms were defined as ≥ 1 of the following: (1) Typical or atypical angina (with disregard 
of non-anginal chest pain); (2) New York Heart Association functional class ≥ 2; or (3) a history of 
cardiac syncope. The diagnosis of HCM in relatives was based on a maximal wall thickness ≥ 13 mm 
or z-score > 2, unexplained by loading conditions.(2) Maximal wall thickness, left atrial size, left 
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ventricular (LV) end-diastolic diameter, and LV outflow tract (LVOT) gradient at rest and during 
provocation were measured, according to the guidelines.(8) LVOT gradient was calculated with the 
Bernoulli equation, and LVOT obstruction defined as a gradient ≥ 30 mmHg at rest or during 
provocation. Systolic dysfunction was visually assessed and defined as mildly reduced, moderately 
reduced, or poor function. Diastolic dysfunction was defined as abnormal relaxation, pseudonormal 
filling, or restrictive filling(9), based on the Doppler mitral inflow pattern parameters including early 
(E) and late (A) LV filling velocities, E/A ratio, and tissue Doppler imaging-derived septal early 
diastolic velocities (e’).  
 
Follow-up and outcome measures 
Follow-up data were obtained in July 2017, and was available in 99% of cases. Mortality was retrieved 
from the civil service register and cause of death from the medical chart or the general practitioner. 
Survival of the Dutch general population was obtained from the Central Agency for Statistics.(10) 
Cardiac mortality was defined as the combined end point of SCD, appropriate implantable cardioverter 
defibrillator (ICD) shock, and heart failure related death (including cardiac transplantation). SCD was 
defined as instantaneous death in individuals who were previously in a stable condition or successful 
resuscitation after cardiac arrest. Appropriate ICD shock was defined as shock or antitachycardia 
pacing for ventricular fibrillation or ventricular tachycardia >200/min. Septal reduction therapy and 
ICD implantation for primary or secondary prevention of SCD were registered.  
 
Statistical analysis 
Calculations were performed using SPSS 21 (IBM, Armonk, New York) and R Statistical Software 
version 3.4.1 using packages nlme, lme4 and survival. Normally distributed continuous data are 
expressed as mean ± standard deviation and non-normally distributed data as median followed by 
interquartile range (IQR). Relationship to the patient was categorized into sibling, child, parent and 
other, and the overall p-value of this categorical variable was examined. To compare baseline 
characteristics between G+ relatives and relatives without GT, and between subjects with and without 
HCM at initial evaluation, generalized linear mixed models were used with random intercepts for 
family to account for family relatedness. For covariates with suspicion of collinearity, we screened for 
multicollinearity and ran the multivariate model twice. Fisher’s exact test was used in case of a zero 
cell count in either of the groups. For comparison of consecutive echocardiographic data  the paired t-
test was used and the Wilcoxon signed rank test in case of non-normally distributed data. Survival 
analyses were performed using the jackknife version of the Cox proportional hazards model to account 
for correlations caused by family relatedness. Results are presented with hazard ratio (HR) and 95% 
confidence interval (CI). All analyses were two-sided; P-values < 0.05 were considered significant. 
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RESULTS 
Genetic testing 
Figure 1 presents a flowchart of the results of GT in probands and relatives. GT was performed in 196 
(94%) probands: 149 (76%) were G+, 33 (17%) had a variant with uncertain significance, and 14 (7%) 
were G-. GT was not performed in 13 (6%) probands, due to premature death in 7 and refusal in 6. 
Figure 2A presents the affected genes in G+ probands. A complex genotype was present in 8 (5%), 
including 4 homozygous, 2 digenic, and 2 compound heterozygous mutations. During follow-up, the 
following 3 (2%) pathogenic mutations were reclassified into variants with uncertain significance after 
data sharing between different centers in the Netherlands: (1) CALR3 gene mutation c.564delT, (2) 
ABCC9 gene mutation c.4537G>A, and (3) MYPN gene mutation c.59A>G. An overview of 
pathogenic mutations and complex genotypes is provided in supplementary tables 1 and 2 respectively.  
In the 47 (24%) probands without an identified pathogenic mutation ≥ 8 sarcomeric genes were tested, 
and next-generation-sequencing was performed in 34 (72%). In 24 (12%) probands without an 
identified pathogenic mutation there was no family history of HCM. GT was performed in 620 (80%) 
relatives: 264 (43%) were G+, and 356 (57%) were G-. Figure 2B presents the affected genes in G+ 
relatives. A complex genotype was found in 6 (2%); 3 digenic and 3 homozygous mutations. GT was 
not performed in 157 relatives due to the following reasons: (1) G- proband (n=78, 50%), (2) refusal of 
GT despite the presence of a pathogenic mutation in the proband (n=35, 22%), (3) GT not offered due 
to age < 18 years (n=25, 16%), and (4) no GT performed in the proband (n=19, 12%). Relatives 
without GT included 39 (25%) relatives who related to probands without an identified pathogenic 
mutation and no family history of HCM. Relatives who refused GT had a mean age of 29±11 years at 
time of evaluation. 
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Figure 1. Flowchart of the study population. GT = genetic testing, VUS = variant with uncertain significance 
 
 
 
Figure 2a. Distribution of affected genes in 149 
genotype-positive probands. MYBPC3 = myosin-
binding protein C; MYH7 = β-myosin heavy chain.  
Figure 2b. Distribution of affected genes in 264 
genotype-positive relatives. MYBPC3 = myosin-
binding protein C; MYH7 = β-myosin heavy chain
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First cardiac screening 
Cardiac screening was performed in 421 relatives: 264 G+ relatives (age 41±18 y, 46% male) and 157 
relatives without GT (age 30±17 y, 48% male) (table 1). A small proportion of male and female 
relatives had cardiac symptoms (6% vs 11%, p=0.09). At first evaluation, HCM was diagnosed in 126 
(30%) relatives: 98 (37%) G+ and 28 (17%) relatives without GT (p<0.001). Mean age at HCM 
diagnosis was 44±16 (range 1-75) years and 57% was male. MWT was ≥ 20 mm in 11 (9%) and ≥ 30 
mm in none. Four (6%) had LVOT obstruction, and 41 (40%) had diastolic dysfunction. One (0.2%) 
relative with a non-founder MYBPC3 mutation had end-stage HCM, and another (with a digenic 
mutation) had non-compaction cardiomyopathy.  
 
Table 1. Baseline characteristics of the study population 
Variable 
 
Whole cohort  
(n=421) 
G+ relatives 
(n=264) 
Relatives without GT 
(n=157) P-value 
 
Age (y) 37±18 41±18 30±17 <0.001 
- Age < 12 years (n, %) 41 (10) 20 (8) 21 (13)  
- Age 12 - 18 years (n, %) 42 (10) 13 (5) 29 (19)  
- Age 19 - 35 years (n, %) 113 (27) 67 (25) 46 (29)  
- Age 36 - 50 years (n, %) 127 (30) 90 (34) 37 (24)  
- Age > 50 years (n, %) 98 (23) 74 (28) 24 (15)  
Men (n, %) 198 (47) 122 (46) 76 (48) 0.66 
Proband age at diagnosis (y) 40±18 39±18 41±17 0.29 
Cardiac symptoms 31 (9) 21 (9) 10 (8) 0.56 
- Angina 12 (3) 9 (4) 3 (2) 0.38 
- NYHA ≥ 2 15 (4) 11 (5) 4 (3) 0.40 
- Cardiac syncope 8 (2) 4 (2) 4 (3) 0.47 
Relationship to proband 
   
0.002 
- Sibling (n, %) 121 (29) 82 (31) 39 (25) 
 
- Child (n, %) 169 (40) 86 (33) 83 (53) 
 
- Parent (n, %) 44 (10) 32 (12) 12 (8) 
 
- Other (n, %) 87 (21) 64 (24) 23 (15) 
 
Data are expressed as mean ± standard deviation, or as absolute n (%). G+ = genotype-positive, GT = genetic 
testing, NYHA = New York Heart Association functional class.  
 
Among G+ relatives, the HCM prevalence was higher in non-founder MYBPC3 mutation carriers than 
in Dutch founder MYBPC3 mutation carriers (49% vs 35%, p=0.04), despite similar age (43±17 vs 
41±18 y, p=0.56). In 16 (57%) relatives with HCM, extensive GT in the proband failed to identify a 
pathogenic mutation. As presented in figure 3, the HCM prevalence increased with advancing age. In 
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41 children who were screened < 12 years, 6 (15%) had HCM. All 6 children were asymptomatic; 5 
had a cardiac murmur, and 3 had a malignant family history of HCM.  
 
 
Figure 3. The proportion of genotype-positive relatives and the proportion of relatives diagnosed with 
hypertrophic cardiomyopathy at first screening are shown in different age groups. HCM = hypertrophic 
cardiomyopathy. 
 
 
Predictors of HCM during first screening 
Characteristics of relatives diagnosed with HCM versus those without HCM, are summarized in table 
2. Relatives diagnosed with HCM were more likely G+, were older at time of screening (44±16 vs 
34±18 years, p<0.001), more likely male, more frequently symptomatic, related to probands with a 
younger age at diagnosis (37±17 vs 41±18 years, p=0.045), and were differently related to the proband 
(e.g. sibling, child, parent, other). Multivariate analysis demonstrates that G+ status (adjusted odds 
ratio 4.23; 95% CI 2.88-5.58; p<0.001), male sex (adjusted odds ratio 2.13; 95% CI 1.51-2.76; 
p=0.02), proband age at diagnosis (adjusted odds ratio 0.98; 95% CI 0.96-0.99, p=0.02) and age at 
time of screening (adjusted odds ratio 1.04; 95% CI 1.02-1.06; p<0.001) were independent predictors 
of HCM diagnosis. Symptomatic status lost significance in the multivariate analysis. The results of the 
multivariable model did not differ with inclusion of relation to the proband and age had a more 
significant effect in the models than relation to the proband. 
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Table 2. Characteristics of subjects with and without hypertrophic cardiomyopathy at initial evaluation 
Variable HCM at initial evaluation? P-value 
 YES (n=126) NO (n=295)  
Age, y (range) 44 ± 16 (1-75) 34 ± 18 (1-83) <0.001 
Men, n (%) 72 (57) 126 (43) 0.01 
Proband age at diagnosis (y) 37±17 41±18 0.045 
Cardiac symptoms 13 (14) 18 (7) 0.04 
Relationship to proband 
  
<0.001 
- Sibling, n (%) 51 (40) 70 (24) 
 
- Child, n (%) 29 (23) 140 (47) 
 
- Parent, n (%) 21 (17) 23 (8) 
 
- Other, n (%) 25 (20) 62 (21) 
 
Genotype-positive status, n (%) 98 (78) 166 (56) <0.001 
Maximal wall thickness, mm (range) 16±3 (10-25) 9±2 (5-12) <0.001 
LVEDD, mm (range) 47±5 (33-60) 47±5 (32-61) 0.96 
LA size, mm (range) 41±6 (27-60) 35±5 (21-53) <0.001 
LVOT obstruction ≥ 30 mmHg 4 (4) 0 (0) 0.008* 
Diastolic dysfunction, n (%) 41 (41) 33 (12) <0.001 
Systolic dysfunction, n (%) 1 (1) 2 (1) 0.81 
Data are expressed as mean ± standard deviation, or as absolute n (%). HCM = hypertrophic cardiomyopathy; 
LA = left atrial; LVEDD = left ventricular end-diastolic diameter; LVOT = left ventricular outflow tract. * 
Fisher’s exact test was used because of zero cell count.  
 
 
Clinical outcome of relatives with HCM  
Mortality and interventions are presented in table 3. Relatives with HCM at baseline were followed for 
a median 9 (IQR 6, 12) years. Annual all-cause and cardiac mortality was 0.7% and 0.3% respectively. 
Cardiac mortality occurred in 7 (7%) relatives with HCM (all were G+), and included 3 cardiac 
transplants, 3 SCDs, and 1 appropriate ICD shock. There was no difference in either all-cause or 
cardiac mortality between Dutch founder MYBPC3 and non-founder MYBPC3 mutation carriers 
(p=0.7 and p=0.6 respectively). Septal reduction therapy was performed in 8 (6%) relatives with HCM. 
ICDs for the primary prevention of SCD were implanted in 12 (12%) G+/HCM+ and 4 (14%) HCM+ 
relatives without GT (p=0.9). There was one appropriate ICD shock in a G+/HCM+ relative 3 years 
after implantation. 
Echocardiographic follow-up with a median of 6.6 (IQR 3.2, 10.8) years was available in 103 
(82%) relatives with HCM. LV end-diastolic diameter decreased (47±5 to 44±4 mm; p=0.006), 
presence of diastolic dysfunction (40% to 68%; p=0.003) and systolic dysfunction (1% to 17%; 
p=0.001) increased. Seven (6%) patients developed end-stage HCM. Maximal wall thickness was 
overall stable (16±3 to 16±3 mm; p=0.54).  
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Table 3. Medium-term clinical outcome of relatives with and without hypertrophic cardiomyopathy 
Variable             HCM diagnosis No HCM diagnosis 
 G+  Without GT G+ Without GT 
 (n=98) (n=28) (n=165) (n=129) 
All-cause mortality (n, %) 13 (13) 0 4 (2) 0 
Cardiac mortality (n, %) 7 (7) 0 1 (0.6) 0 
SCD (n, %) 3 (3)* 0 1 (0.6) 0 
Appropriate ICD shock (n, %) 1 (1) 0 0 0 
Cardiac transplant (n, %) 3 (2) 0 0 0 
Septal reduction therapy (n, %) 6 (6) 2 (7) 0 0 
ICD (n, %) 14 (14) 4 (14) 5 (3)† 0 
- primary prevention (n, %) 12 (12) 4 (14) 5 (3) 0 
- secondary prevention (n, %) 2 (2) 0 0 0 
Data are expressed as absolute n (%).* two were successfully resuscitated. † 3 (60%) received an ICD after 
HCM had developed during follow-up. G+ = genotype-positive, GT = genetic testing. HCM = hypertrophic 
cardiomyopathy; ICD = implantable cardioverter defibrillator; SCD = sudden cardiac death. P-values are not 
presented due to low number of events. 
 
 
Clinical outcome of relatives without HCM  
Relatives without HCM at baseline were followed for a median 8 (IQR 3-11) years. Annual all-cause 
mortality was 0.1%. Annual cardiac mortality in G+/HCM- subjects was 0.06% (1 SCD event) and 0% 
in HCM- relatives without GT (table 3). SCD occurred in a 21-year old non-founder (c.1624+1G>A, 
p.?) MYBPC3 mutation carrier. Autopsy confirmed the absence of HCM. Post mortem analysis 
revealed a pathogenic mutation (c.1708G>T, p.Ala570Ser) in the KCNH2 (Potassium Voltage-Gated 
Channel Subfamily H member 2) gene associated with long-QT syndrome. The ECG demonstrated no 
evidence of long-QT and there was no family history of long-QT syndrome. Two (1%) G+/HCM- 
subjects received an ICD for primary prevention; 1 had symptomatic non-sustained ventricular 
tachycardia, the other a troponin T mutation and family history of SCD. During a median 3 (IQR 2, 
11) year follow-up, there were no appropriate ICD shocks and 1 inappropriate ICD shock due to lead 
failure.  
Echocardiographic follow-up was available in 178 relatives without HCM (age 32±19 y, 46% male, 
65% G+). During a median 7 (IQR 4, 10) years follow-up, HCM developed in 29 (16%) relatives at 
the mean age of 40±20 (range 9-77) years. The majority, 24 (83%) were G+ (20 MYBPC3 carriers, 2 
MYH7 carriers, 1 MYL2 carrier and 1 digenic MYBPC3/MYL2 carrier). G+ relatives were more likely 
to develop HCM than relatives without GT (HR 2.44, 95% CI 1.02-5.85, p=0.04) (figure 4a); however, 
not after adjusting for age (HR 1.20, 95% CI 0.46-3.14, p=0.71) (figure 4b).  
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Adults (n=126, age 41±14 y, 44% male, 77% G+) were followed for 6±4 years and 19 (15%) 
developed HCM at mean age 50±16 (range 21-77) years. The majority, 15 (79%) were G+ (14 
MYBPC3 carriers; 1 digenic MYBPC3/MYL2 carrier) and 68% was male. G+ adults were not more 
likely to develop HCM than adults without GT (HR 1.44, 95% CI 0.53-3.92, p=0.48). Maximal wall 
thickness increased from a median of 12 (IQR 10, 12) mm to a median of 14 (IQR 13, 15) mm at an 
average rate of 0.55 (0.2, 1.0) mm/year. Baseline median maximal wall thickness was higher in adults 
who developed HCM than in those who did not (12 (IQR 10, 12) vs 10 (IQR 8, 11) mm, p=0.004), and 
diastolic dysfunction was equally present (19% vs 13%, p=0.49). 
Children (n=52, age 10±5 y, 49% male, 36% G+) were followed for 14±8 years and 10 (19%) 
developed HCM at mean age 20 ± 8 (range 9-31) years. Conversion mostly occurred between 19 and 
31 years of age (n=7; 70%), and did not occur between 12 and 18 years of age. The majority, 9 (90%) 
were G+ (6 MYBPC3 carriers, 2 MYH7 carriers and 1 MYL2 carrier), and 70% was male. G+ children 
were not more likely to develop HCM than children without GT (HR 3.26, 95% CI 0.59-17.97, 
p=0.17).  
 
 
 
Figure 4. (A) Kaplan Meier curve demonstrating the cumulative hypertrophic cardiomyopathy incidence during 
follow-up of relatives without hypertrophic cardiomyopathy at baseline, stratified by genotype. (B) Kaplan Meier 
curve demonstrating the cumulative hypertrophic cardiomyopathy incidence during follow-up of relatives 
without hypertrophic cardiomyopathy at baseline, stratified by genotype and age. P-values are calculated using 
the jackknife version of the Cox model to account for family relatedness. G+ = genotype-positive; GT = genetic 
testing; HCM = hypertrophic cardiomyopathy. 
 
 
Survival of G- relatives 
All-cause mortality in G- relatives (age 48±17 y, 45% male) was assessed 7.5±3.6 years after GT. 
Eighteen (5%) G- relatives died at the mean age of 69±15 [range 49-88] years. As seen in figure 5, 
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survival from all-cause mortality in G- relatives (97% at 5 years, 94% at 10 years), G+ relatives (99% 
at 5 years, 95% at 10 years), and relatives without GT (100% at 5 and 10 years) was similar. In 
multivariate cox regression analysis adjusting for age, gender, and family relatedness, survival from 
all-cause mortality in G- relatives was not significantly different from that in G+ relatives (adjusted 
HR 0.92, 95% CI 0.43-1.94, p=0.8). There was an insufficient number of events in the relatives 
without GT (n=0) to compare survival between these relatives and G+ and G- relatives.  
 
 
Figure 5. Survival of G+ relatives, G- relatives, and relatives without genetic testing.. P-value is calculated using 
the jackknife version of the multivariable Cox model to account for family relatedness, age, and gender. There 
was an insufficient number of events (n=0) in the relatives without GT to compare survival with G+ and G- 
relatives. G+ = genotype-positive; G- = genotype-negative, GT - = without genetic testing 
 
 
DISCUSSION 
The key findings of this study on HCM family screening are: (1) at first cardiac screening, HCM was 
diagnosed in 37% of G+ relatives and 17% of the relatives without GT (p<0.001), (2) G+ status, male 
sex, age at time of screening, and proband age at diagnosis were independent predictors of HCM 
diagnosis, (3) 16% of relatives without abnormalities at baseline developed HCM during 7 years of 
follow-up, and (4) survival in G- relatives, G+ relatives, and relatives without GT was good. 
 
GT facilitates HCM screening 
In the current study, 93% of probands and 80% of relatives underwent GT, which led to the 
reassurance of 356 G- relatives (46% of the total study population), and significantly reduced the 
number of clinical screening visits to the outpatient clinic. This supports previous studies that 
demonstrated the cost-effectiveness of family screening including GT.(1, 2) As expected, the HCM 
prevalence was higher in G+ relatives due to the exclusion of G- relatives from cardiac evaluation.  
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The genetic yield in the probands was high (76%) in comparison to previous studies.(3, 4) This could 
partly be due to the large Dutch MYBPC3 founder population,(5) and partly due to a referral bias, 
because relatives from G+ families are informed about the confirmed heritability of HCM, and the 
HCM burden in G+ families is likely to be higher.(4) The rate of complex genotypes was relatively 
high (5%) in comparison with recent studies which used contemporary variant classification 
methods.(6, 7) This might be related to the high prevalence of Dutch MYBPC3 founder mutations, the 
tertiary nature of our center, and the inclusion of children with more severe phenotypes. 
HCM was found to be familial in families without an identified pathogenic mutation despite extensive 
genotyping. This finding suggests that genetic causes are still unrecognized. This information can be 
useful for counselling purposes. Unfortunately, expanded gene panels using next generation 
sequencing have offered limited additional pathogenic variants,(8) and have increased the prevalence 
of variants with uncertain significance.(9) Potentially, whole exome sequencing will have added value 
in the identification of novel HCM-causing genes, although this approach also has major 
challenges.(9) In 12% of the families, HCM was not familial and no pathogenic mutation was 
identified. Relatives in these families may not have a mendelian risk of disease, and so the utility of 
clinical screening may be impacted.(10) The inclusion of GT in family screening strategies allows the 
identification of this nonfamilial HCM subtype, which was reported to have later disease-onset and 
better clinical outcome.(10, 11)  
It is important to be aware of the potential for variant reclassification. In this study, variants were 
classified according the most recent knowledge. Reclassification occurred during follow-up after data 
sharing between different centers in the Netherlands. All G- relatives who were initially discharged 
from clinical evaluation, should be informed about a reclassification and the indication for a renewed 
evaluation.   
GT was refused by 6% of the relatives aged 29±11 years, likely due to socio-economic consequences. 
The Dutch Medical Examination Act protects unaffected HCM mutation carriers for life insurance 
below 268.000 Euro(12); above this amount carriers will have to disclose their HCM risk status, 
potentially resulting in an increased life insurance premium.(13, 14) Since health care insurance is 
obligatory in the Netherlands and covers the costs of GT, a lack of insurance coverage is not an issue. 
Other reasons for GT refusal include limited therapeutic implications. In the future, novel 
therapies(15) might increase the implications of GT.  
 
Predictors of HCM during screening 
More male than female relatives were diagnosed with HCM, a finding that is in line with the described 
male predominance in HCM cohorts.(3, 16) Previous studies suggest that the underrepresentation of 
women may reflect reduced patient awareness regarding cardiovascular risk, referral bias, or clinician 
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bias.(16) Referral bias in the current study is probably limited, because all relatives presented in the 
context of HCM screening. It was left to the decision of the relative whether to accept the invitation 
for screening, which is influenced by many factors including family and personal characteristics 
(symptomatic status, gender, race, education).(17) Other possible explanations for male predominance 
in HCM may be related to genetic and endocrine factors. Studies in mice models of HCM-associated 
mutations have shown that male sex predisposes to an earlier onset of disease, however the underlying 
pathophysiological mechanisms are not fully understood.(18, 19) HCM diagnosis was associated with 
advancing age, a feature that is in line with the described age-related penetrance of HCM.(20, 21) A 
younger age at diagnosis in the proband was associated with HCM in the relative. This illustrates the 
use of obtaining a family history and indicates a higher yield of screening in those families with more 
severe disease expression. 
 
Clinical outcome of relatives with HCM and G+/HCM- relatives 
In relatives diagnosed with HCM during screening, cardiac mortality was low (0.3%/y) in comparison 
to the reported cardiac mortality in probands with HCM (1-2%/y).(3) Since relatives are referred by 
familial evaluation instead of signs or symptoms, HCM in relatives is probably diagnosed in an earlier 
disease stage(22). Lifestyle modifications, periodic SCD risk evaluation and close clinical follow-up, 
resulting in ICD implantations, and timely referral for septal reduction therapies might have led to a 
better clinical outcome.(23) Given the low event rate in HCM larger numbers and longer follow-up are 
needed to really show an impact on clinical outcome. One G+/HCM- relative died suddenly and a 
long-QT mutation was identified post-mortem.  
 
Family screening strategies evaluated 
Current guidelines(3, 24, 25) recommend cardiac evaluation from age 10-12 years and repeat 
evaluation every 1-2 years until 18-21 years of age, and every 2-5 years thereafter. Younger children 
can be screened in case of a severe family history, competitive sports participation, or when cardiac 
symptoms are present.(3) In this cohort, 6 out of 41 (15%) children < 12 years of age were diagnosed 
with HCM during clinical screening, which is more than expected and may be related to the tertiary 
nature of our center. Three of these cases did not have a severe family history, cardiac symptoms, or 
competed in sports, and so these cases would have been missed if current guidelines were followed. 
Simple cardiac auscultation would have raised suspicion because a cardiac murmur was present in 
almost all cases. The prevalence and prognosis of sarcomeric childhood HCM is currently unknown 
and requires investigation.(3) A multigenerational pedigree study demonstrated an increased mortality 
risk for untreated relatives aged 10-19 years with a 0.5 probability of truncating MYBPC3 
carriership.(26) This supports clinical evaluations from 10 years of age. Interestingly, our data 
demonstrates no conversion during adolescence but rather < 12 and > 18 years of age. This questions 
the need for more frequent evaluations during adolescence(24), rather illustrates the need for earlier 
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screening i.e. at the age of 8 years, and continued screening into adulthood, similar to the conclusions 
of Jensen et al.(20) (3) Whether or not to perform GT in children is disputable. Although we 
demonstrated in this study that GT has an impact on clinical screening strategies, the impact on 
management and lifestyle is limited due to the lack of prognostic value of genotype for disease-onset 
and risk. Moreover, due to the potential social, emotional, psychosocial, educational and financial 
consequences of GT and the advantage of integrating patients into medical decision making(27) we 
prefer to postpone GT until the legal age of 18 years. However, there are some situations in which the 
psychological or social benefits outweigh the risks of GT.  For example, parents who cannot deal with 
the anxiety of ‘not knowing’ might have a more negative impact on the child than would complying 
with the request for GT. In addition, early knowledge of carrier status might increase coping with the 
information.(27) Our HCM program makes decisions on a case-by-case basis after extensive 
counseling of the family and the child, including psychological support and taking all of the above 
considerations into account. We feel that screening frequencies should not be different in G+ children 
or children without GT, because untested children may have a 50% probability of carriership.(26) In 
adults, we support intervals with a low frequency e.g. 5-yearly, as is advised by the 2011 American 
guidelines(24), because the HCM incidence was low, and the development of hypertrophy slow.  
 
Limitations 
The efficiency of clinical screening is dependent on the uptake of GT in probands and relatives. The 
uptake of GT in the current study was high, because in the Netherlands GT is covered by the national 
basic health care insurance, and because all probands were seen at our cardio-genetic outpatient clinic 
where cardiac evaluation and genetic counseling and testing is offered simultaneously. This limits 
generalizability of results to other countries with different financial and organizational approaches 
regarding GT in the HCM population. The high proportion of Dutch MYBPC3 founder mutation 
carriers limits representation of broader populations with HCM. The number of screened children was 
relatively small. Due to significant advances in DNA-sequencing methodology during the past decade, 
there was no homogenous genotyping over the whole period. Since 12% of the study population was 
referred after HCM was diagnosed in another center, this has created a selection bias. Clinical 
phenotyping was not performed in G- relatives, limiting the ability to identify non-penetrance and/or 
second variants, which may be an important caveat in some families. 
 
CONCLUSION 
HCM was identified in 30% of relatives at first screening, and 16% developed HCM during 7 years of 
repeated cardiac evaluation. GT led to a discharge from clinical follow-up in 46% of the study 
population. Survival in the relatives was good. 
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CLINICAL PERSPECTIVE 
In hypertrophic cardiomyopathy (HCM) family screening, guidelines recommend repeated clinical 
evaluations from age 10-12 years until advanced age. The latest European guidelines recommend to 
include genetic testing (GT) in the screening strategy. GT allows the identification of genotype-
positive relatives without HCM and the reassurance and discharge of genotype-negative relatives. We 
retrospectively analyzed the results of this contemporary family screening strategy in 777 relatives of 
209 probands who were evaluated at our cardio-genetic outpatient clinic where cardiac evaluation and 
genetic counseling and testing is offered simultaneously. After performing GT in 94% of the probands 
and 80% of the relatives, we were able to reassure 356 (46%) genotype-negative relatives, thereby 
significantly reducing the number of clinical screening visits. First cardiac evaluation in genotype-
positive relatives (n=264) and relatives without GT (n=157) revealed HCM in 37% and 17% 
respectively. During follow-up, cardiac mortality among relatives with HCM was low (0.3%/year) 
reflecting early disease stages. One genotype-positive relative without HCM died suddenly and a long-
QT mutation was identified post-mortem. During 7 years follow-up 16% of the relatives without HCM 
at first evaluation developed subtle HCM. The findings of the current study are important for the 
practicing clinician, because it demonstrates the impact of GT on the HCM clinical screening process, 
and it shows current challenges associated with GT in families with HCM. Moreover, evaluating the 
HCM prevalence at first evaluation and after repeated evaluations in adults and children and reporting 
the prognosis of relatives with and without HCM helps to determine the preferred clinical screening 
strategy.  
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ABSTRACT 
Purpose  
Previous studies suggest that anterior mitral valve leaflet (AMVL) elongation is a primary phenotypic 
feature in hypertrophic cardiomyopathy (HCM). Our aim was to assess AMVL length in individuals 
with HCM gene mutations and in healthy controls and to identify predictors of the development of 
HCM during follow-up.  
Methods  
A total of 133 HCM mutation carriers and 135 controls underwent cardiac examination including 
electro- and echocardiography. AMVL length was measured in the parasternal long axis and apical 3 
chamber view during diastole. Univariate and multivariable cox proportional hazard regression 
analyses were performed to identify predictors of HCM.  
Results  
There were no significant differences between HCM mutation carriers and controls regarding age and 
sex. In the parasternal long axis view, AMVL length was similar in mutation carriers and controls 
(24±4 vs 24±4 mm, p=0.8). In the apical 3 chamber view, AMVL were shorter in mutation carriers 
(29±4 vs 30±4 mm, p=0.02). When averaged for both views, AMVL length was similar in mutation 
carriers and controls (27±3 vs 27±3 mm, p=0.2). During 5.8±3.0 years follow-up, 13 (14%) HCM 
mutation carriers developed HCM. Pathological Q wave (hazard ratio 9.89, p=0.004), E/e’ ratio 
(hazard ratio 2.52, p=0.001), and maximal wall thickness (hazard ratio 2.15, p=0.001) were 
independent predictors of HCM. AMVL length was not predictive of the development of HCM. 
Conclusions  
AMVL length is similar in HCM mutation carriers and controls. AMVL length is not predictive of the 
development of HCM, in contrast to pathological Q wave, E/e’ ratio, and maximal wall thickness. 
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INTRODUCTION 
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease with an estimated prevalence of 
1:500 to 1:200.(1-3) The diagnosis is based on the presence of a maximal wall thickness ≥ 15 mm in 
index patients and ≥ 13 mm in relatives, that is not solely explained by abnormal loading 
conditions.(2) A pathogenic HCM mutation is identified in 40-60% of patients with HCM.(2, 4) 
Presymptomatic genetic testing of relatives has led to the identification of HCM gene mutation carriers 
who do not fulfill the echocardiographic criterion of HCM.(5) HCM mutation carriers are at risk of 
developing HCM.(5) Conflicting data exists on whether the anterior mitral valve leaflets (AMVL) are 
elongated in mutation carriers and whether AMVL elongation is a predictor of the development of 
HCM during follow-up.(6-11) The aim of this study was to assess AMVL length in HCM mutation 
carriers and healthy controls and to determine the prognostic significance of AMVL length in HCM 
mutation carriers for the development of HCM during follow-up.  
 
METHODS 
Study design and population 
This single-center retrospective case-control and cohort study included 133 HCM mutation carriers 
without clinical expression of HCM who were clinically evaluated at our cardio-genetic outpatient 
clinic between the years 2004-2017. Genetic assessment and the family screening strategy at our center 
have been described previously.(12, 13) For comparison, 135 healthy controls underwent cardiac 
evaluation.(14) Controls were recruited via an advertisement. Inclusion criteria were normal physical 
examination, normal electrocardiography (ECG), and left ventricular (LV) ejection fraction > 51%; 
exclusion criteria were prior cardiovascular disease or risk factors consisting of hypertension, diabetes 
mellitus, and hypercholesterolemia, systemic disease, medication known to influence cardiac function 
including thyroid medication (with the exception of asthma inhalers), professional athletes, body mass 
index > 40 and women with breast implants.(14) The study conforms to the principles of the 
Declaration of Helsinki. All patients gave informed consent for inclusion in the registry and local 
institutional review board approval was obtained.  
 
Clinical evaluation 
Clinical evaluation included medical history, physical examination, ECG, and transthoracic 
echocardiography. Standard 12-lead ECG was performed in the supine position during quiet 
respiration. LV hypertrophy was evaluated with the Romhilt-Estes criteria. Pathological Q waves were 
defined as duration > 40 ms or depth > 30% R wave in ≥ 2 leads. T-wave inversion was defined as ≥ 3 
mm in ≥ 2 leads. Echocardiographic studies were analyzed according to the guidelines.(15, 16) 
Maximal wall thickness, left atrial size, leaflet and chordal systolic anterior motion of the mitral valve, 
and resting LV outflow tract peak velocity were assessed. LV outflow tract gradient was calculated 
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with the Bernoulli equation. LV systolic function was categorized as: good (LV ejection fraction > 
51%), mildly reduced (LV ejection fraction 41% to 51%), moderately reduced (LV ejection fraction 
30% to 40%), and poor (LV ejection fraction < 30%).(16) LV diastolic function was defined as 
normal, abnormal relaxation, pseudonormal or restrictive filling, based on Doppler mitral inflow 
pattern parameters including early (E) and late (A) LV filling velocities, E/A ratio, and tissue Doppler 
imaging-derived septal early diastolic velocities (e’).(17) HCM during follow-up was defined as a 
maximal wall thickness ≥ 13 mm according to the guidelines.(2) 
 
AMVL measurements 
AMVL length was measured in the parasternal long axis (PLAX) view and in the apical 3 chamber 
(A3C) view, during diastole and with the leaflet maximally extended. In the PLAX view, leaflet length 
was defined as the distance from the tip of the leaflet to the junction between the anterior leaflet and 
the posterior aortic wall (hinge point), according to Klues et al.(18) In the A3C view, leaflet length 
was defined as the distance from the tip of the leaflet to the insertion of the noncoronary aortic leaflet, 
according to Alhaj et al.(19) Examples of AMVL measurements in both views are shown in figure 1. 
All AMVL measurements were performed by one reader. For intraobserver variability, one reader 
independently measured 40 AMVLs in the PLAX view and 40 AMVLs in the A3C view in an 
identical fashion on 2 occasions. For interobserver variability, 2 readers independently measured 20 
AMVLs in the PLAX view and 20 AMVLs in the A3C view.  
 
 
 
Fig. 1 Example of anterior mitral valve leaflet length (AMVL) measurements in a hypertrophic cardiomyopathy 
gene mutation carrier without hypertrophic changes. In the parasternal long-axis view (a), the AMVL measured 
26 mm, and in the apical 3 chamber view (b), the AMVL measured 26 mm 
 
 
Statistical methods 
The statistical analysis was performed using SPSS 21 (IBM, Armonk, New York). Normally 
distributed continuous data are expressed as mean ± standard deviation and non-normally distributed 
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data as median followed by interquartile range. For comparing categorical variables Pearson’s chi-
square test was used. For comparing continuous variables t-test was used, and Mann-Whitney U in 
case of non-normally distributed data. All analyses were two-sided; P-values < 0.05 were considered 
significant. Inter-observer and intra-observer agreement was defined as the mean of the difference 
between two measurements ± standard deviation. Univariate and multivariable cox proportional hazard 
regression was performed to determine hazard ratios (HR) and 95% confidence intervals (CI). After 
screening for multicollinearity, the univariate significant variables with the highest HR were entered 
into the multivariable regression model. To calculate the allowed number of variables for inclusion in 
the multivariable analysis, the square root of the number of events was used. This is an alternative 
method to determine the number of variables allowed for inclusion in the multivariable analysis.(20)  
 
RESULTS 
Clinical evaluation 
HCM gene mutation carriers represented mutations in 10 different genes. The MYBPC3 gene was most 
frequently affected (77%), followed by the MYH7 gene (11%). Other genes affected were TNNT2 
(3%), MYL2 (2%), FHL1 (2%), ALPK3 (2%) MIB1 (0.75%), TNNI3 (0.75%), TPM1 (0.75%), and 
MYL3 (0.75%). Clinical and echocardiographic characteristics in mutation carriers and controls are 
presented in table 1. Mutation carriers and controls had similar age, gender, and body surface area. 
Compared to controls, more mutation carriers had pathological Q waves (4% vs 0%, p=0.02), and 
mutation carriers had a higher E/e’ ratio (8.2±1.9 vs 7.7±1.9, p=0.03), and a higher maximal wall 
thickness (8.9±1.9 vs 8.0±1.8 mm, p=0.001).  
 
Table 1. Clinical and echocardiographic characteristics of the study population (continues on the next page) 
Variable Mutation carrier (n=133) Control (n=135) P-value 
Age, (y) 41±14 44±14 0.11 
Female gender, n (%) 85 (64) 73 (54) 0.18 
Body surface area (m2) 1.9±0.2 1.9±0.2 0.86 
Electrocardiography 
   
   Romhilt-Estes ≥ 4, n (%) 10 (8) 4 (3) 0.09 
   T wave inversion, n (%) 1 (1) 0 (0) 0.31 
   Pathological Q wave, n (%) 5 (4) 0 (0) 0.02 
Echocardiography 
   
   Maximal wall thickness (mm) 8.9±2.0 8.0±1.8 <0.001 
   Left atrial size (mm) 34±5 34±4 0.24 
   LVOT gradient ≥ 30 mmHg*, n (%) 0 (0) 0 (0) 0.50 
   AMVL, PLAX (mm) 24±4 24±4 0.85 
   AMVL, A3C (mm) 29±4 30±4 0.02 
   AMVL, averaged (mm) 27±3 27±3 0.17 
   Chordal systolic anterior motion, n (%) 5 (4) 1 (1) 0.09 
   Leaflet systolic anterior motion, n (%) 0 (0) 0 (0) 0.50 
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Table 1. Clinical and echocardiographic characteristics of the study population (continued). 
Variable Mutation carrier (n=133) Control (n=135) P-value 
   E/A ratio 1.4±0.5 1.6±0.7 0.03 
   E/e' ratio 8.2±1.9 7.7±1.9 0.03 
   Septal e' (cm/s) 9.5±2.5 9.6±2.6 0.61 
Diastolic function 
   
  Normal, n (%) 105 (83) 111 (85) 0.66 
  Abnormal relaxation, n (%) 10 (8) 7 (5) 0.39 
  Pseudonormal filling, n (%) 11 (9) 13 (10) 0.76 
  Restrictive filling, n (%) 0 (0) 0 (0) 0.50 
 Systolic function 
   
  Good, n (%) 132 (99) 135 (100) 0.31 
  Mildly reduced, n (%) 1 (1) 0 (0) 0.31 
  Moderately reduced, n (%) 0 (0) 0 (0) 0.50 
  Poor, n (%) 0 (0) 0 (0) 0.50 
Data are expressed as mean ± standard deviation or as absolute and %. AMVL = anterior mitral valve leaflet; 
A3C = apical 3 chamber view; LVOT = left ventricular outflow tract; PLAX = parasternal long-axis view; *at 
rest 
 
 
AMVL measurements 
Beeswarm plots of AMVL measurements in the PLAX and the A3C view are presented in figure 2. In 
the PLAX view, AMVL length did not differ between mutation carriers and controls (24±4 vs 24±4 
mm, p=0.8). In the A3C view, AMVL were shorter in the mutation carriers (29±4 vs 30±4 mm, 
p=0.02). When averaged for both views, AMVL length was similar in mutation carriers and controls 
(27±3 vs 27±3 mm, p=0.2). Overall, AMVL were significantly longer in the A3C view than in the 
PLAX view (30±4 vs 24±4 mm, p<0.001). 
 
 
Fig. 2 Beeswarm plot of anterior mitral valve leaflet (AMVL) length measurements in hypertrophic 
cardiomyopathy gene mutation carriers without hypertrophic changes versus healthy controls, assessed with 
transthoracic echocardiography in the (a) parasternal long-axis view and (b) apical 3 chamber view 
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Intra-observer and inter-observer agreement  
In the PLAX view, the inter-observer agreement was -2.7±2.6 mm and the intra-observer agreement 
was -1.0±3.5 mm. In the A3C view, the inter-observer agreement was 2.0±2.5 mm and the intra-
observer agreement was 0.5±2.6 mm.  
 
Follow-up  
During 5.8±3.0 years follow-up, 13 (14%) mutation carriers developed HCM. Mean age at HCM 
diagnosis was 52±17 years. In these 13 mutation carriers, maximal wall thickness increased from a 
median 10 (interquartile range 8, 11) mm to 13 (interquartile range 13, 14) mm, with a mean rate of 
0.7±0.3 mm/year. Table 2 presents the baseline characteristics in those who developed HCM during 
follow-up and those who did not. Univariate significant predictors of the development of HCM were 
pathological Q wave (HR 9.74, 95% CI 2.53-37.46, p=0.001), maximal wall thickness (HR 1.64, 95% 
CI 1.12-2.39, p=0.01), E/e’ ratio (HR 1.63, 95% CI 1.20-2.23, p=0.002), left atrial size (HR 1.16, 95% 
CI 1.03-1.31, p=0.01), and age (HR 1.06, 95% CI 1.02-1.11, p=0.01). AMVL length was not 
predictive of the development of HCM in the PLAX view (HR 1.03, 95% CI 0.87-1.22, p=0.72) or in 
the A3C view (HR 0.99, 95% CI 0.86-1.15, p=0.92). Multivariable cox regression analysis which 
included 3 variables demonstrates that pathological Q wave (adjusted HR 9.89, 95% CI 2.09-46.95, 
p=0.004), E/e’ ratio (adjusted HR 2.52, 95% CI 1.48-4.29, p=0.001), and maximal wall thickness 
(adjusted HR 2.15, 95% CI 1.36-3.42, p=0.001) all were independent predictors of HCM during 
follow-up. 
 
Table 2. Baseline characteristics of HCM gene mutation carriers who did and did not develop hypertrophic 
cardiomyopathy during follow-up. 
Variable                Developed HCM  
 
YES (n=13) NO (n=77) P-value 
Age (y) 47±19 39±13 0.05 
Male gender, n (%) 8 (62) 25 (33) 0.04 
Romhilt-Estes ≥ 4, n (%) 1 (8) 5 (7) 0.87 
T wave inversion, n (%) 1 (8) 0 (0) 0.01 
Pathological Q, n (%) 3 (23) 2 (3) 0.003 
Left atrial size (mm) 39±5 33±5 <0.001 
Maximal wall thickness (mm) 10±2 9±2 0.02 
AMVL, PLAX (mm) 25±5 24±3 0.47 
AMVL, A3C (mm) 29±5 29±4 0.90 
Chordal systolic anterior motion, n (%) 1 (8) 3 (4) 0.54 
E/e' ratio 9.3±1.8 8.1±1.7 0.03 
Septal e' (cm/s) 8.5±2.7 9.5±2.6 0.20 
Abnormal diastolic function, n (%) 4 (31) 11 (16) 0.21 
Data are expressed as mean ± standard deviation or as absolute and %. AMVL = anterior mitral valve leaflet; 
A3C = apical 3 chamber view; HCM = hypertrophic cardiomyopathy; PLAX = parasternal long axis view. 
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DISCUSSION 
During HCM family screening, individuals who carry a HCM gene mutation may not fulfil the 
echocardiographic diagnostic criterion of HCM.(5) Because of the age-related penetrance of HCM, 
long-term clinical follow-up including ECG and echocardiography is recommended.(2, 3) Currently, it 
is unclear which HCM mutation carriers will develop HCM.(2, 11) We aimed to assess AMVL length 
in mutation carriers and controls, and determine the prognostic value of AMVL length for the 
development of HCM during follow-up. Our main findings are: (1) AMVL length is similar in 
mutation carriers and controls, (2) AMVL length is not predictive of the development of HCM, and (3) 
pathological Q wave, E/e’ ratio, and maximal wall thickness are independent predictors of the 
development of HCM. 
 
AMVL elongation is not a primary phenotypic feature of HCM  
In patients with HCM, AMVL elongation has been demonstrated pathologically, on echocardiography, 
and on cardiovascular magnetic resonance imaging.(10, 18, 21-23) Among other factors, AMVL 
elongation contributes to systolic anterior motion of the mitral valve and LV outflow tract 
obstruction.(23-25) The etiology of AMVL elongation in patients with HCM is unclear. Both the 
pathological study of Klues et al. and the in vivo study of Kim et al. found that AMVL elongation is 
not secondary to LV outflow tract obstruction or systolic anterior motion of the mitral valve, since it 
also occurs in patients without LV outflow tract obstruction or systolic anterior motion.(19, 21, 22) 
Therefore, it was suggested that AMVL elongation is a primary phenotypic expression of HCM. 
Several studies have indeed reported AMVL elongation in mutation carriers as measured by magnetic 
resonance imaging(6, 7, 10), and echocardiography.(9) The current study contradicts these findings. In 
line with our findings, a recent magnetic resonance imaging study similarly reported no difference in 
AMVL length between mutation carriers and controls.(8) The discrepancy between the studies may be 
related to the small number of participants, different imaging modalities used, different distribution of 
genetic mutations, or different methodologies used for AMVL measurements.                                        
For several reasons, we believe it is unlikely that HCM gene mutations cause AMVL 
elongation. First, there are no sarcomeric proteins in the mitral valve leaflet.(25) Second, a HCM 
animal model including heterozygous cardiac myosin-binding protein C targeted knock-out mice 
embryos did not show mitral leaflet elongation.(26) Third, Captur et al. observed AMVL elongation in 
genotype-negative patients with HCM.(10) And finally, most morphological studies demonstrate that 
mitral leaflets are intrinsically normal.(21, 27) Other potential etiologies of AMVL elongation are 
being investigated, such as the paracrine effects from the abnormal LV wall which influences 
valvulogenesis, or the abnormal differentiation of pluripotent epicardial-derived cells into fibroblast-
cells with increased synthesis of periostin which might drive leaflet elongation.(25)  
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Predicting the development of HCM 
The current study demonstrates that AMVL length had no predictive value for the development of 
HCM. Hence, AMVL length cannot be used as a preclinical marker of the development of HCM. 
Similar observations were made in a prior smaller study by Ho et al.(28) Pathological Q wave had a 
high predictive value for the development of HCM. Indeed, prior investigation of ECGs in genotyped 
HCM populations demonstrated that Q waves and repolarization abnormalities are the most 
distinguishing ECG manifestations of sarcomere mutations.(29) However, the clinical utility of Q 
waves is probably limited because of the low negative predictive value; 10 out of 13 mutation who 
developed HCM did not have pathological Q waves at baseline. Our study did not demonstrate a 
prognostic value of septal e’, in contrast to Ho et al.(28) The age difference between the studies (16 vs 
41 y) and differences in genetic mutations might explain this discrepancy. However, we did observe a 
predictive value of E/e’ ratio, which supports the suggestion that diastolic dysfunction is a primary 
phenotypic feature of HCM.(28, 30)  
 
Technical challenges associated with AMVL measurement by echocardiography 
Previous studies most commonly used magnetic resonance imaging to measure AMVL length.(6-8, 
10) Since transthoracic echocardiography is the advised imaging modality in HCM clinical screening 
strategies and has a higher spatial and temporal resolution than cardiac magnetic resonance 
imaging(31, 32), we used echocardiography to determine AMVL length. Overall, inter-observer 
variability in both views was 2 to 3 mm, similar to previous studies.(6, 8, 18) The difference between 
observers may be explained by the technical difficulty of distinguishing the mitral leaflet from the 
chordae tendineae, and by the frame-to-frame variability in AMVL length caused by AMVL 
movement during diastole and respiration. Intra-observer agreement was best for the A3C view, which 
was unexpected because in the PLAX view the distance to the transducer is shorter. It may be 
explained by the landmarks that were used; in the A3C view the insertion of the noncoronary aortic 
leaflet is more easily identifiable in comparison to the hinge point in the PLAX view. Finally, AMVL 
were significantly longer in the A3C view than in the PLAX view; the measurement in the A3C view 
included the intervalvular fibrosa.  
 
Limitations 
This study has several limitations. First, although the study population is large compared to previous 
studies, a higher sample size would reduce the risk of sampling error. Second, the proportion of HCM 
gene mutation carriers that developed HCM during follow-up was limited.  
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CONCLUSIONS 
AMVL length is similar in HCM mutation carriers and healthy controls. AMVL length is not a 
predictor of the development of HCM during follow-up, in contrast to pathological Q wave, E/e’ ratio, 
and maximal wall thickness.  
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ABSTRACT 
Background 
Hypertrophic cardiomyopathy (HC) is characterized by left ventricular (LV) hypertrophy and 
associated with papillary muscle (PM) abnormalities. The aim of this study was to evaluate the utility 
of three-dimensional echocardiography (3DE) for the geometric assessment of LV hypertrophy and 
PM morphology.  
Hypothesis 
3DE allows assessment of PM morphology and LV hypertrophy in HC 
Methods 
The study included 24 patients with an established diagnosis of HC and 31 healthy controls. 3DE was 
performed using an iE33 or EPIQ 7C ultrasound system with an X5-1 transducer. QLAB software was 
used for the 3D analysis of LV wall thickness (LVWT) and PM morphology and hypertrophy; the 
number and cross-sectional area (CSA) of anterolateral and posteromedial PMs; and the presence of 
bifid or accessory PMs. 
Results 
Patients with HC had a larger LVWT compared to controls in all segments (P<0.001), and LVWT was 
largest in the mid-ventricular septal segment (2.12±0.68 cm). The maximum LVWT followed a spiral 
pattern from the LV base to the apex. The CSA of both anterolateral and posteromedial PMs was 
larger in patients with HC than in controls (1.92 vs. 1.15 cm2; P=0.001 and 1.46 vs. 1.08 cm2; P=0.033 
respectively). The CSA of the posteromedial PM was larger in patients with LVOT obstruction than in 
those without (2.64 vs 1.16 cm2, p=0.021).  
Conclusions 
3DE allows the assessment of LV geometry and PM abnormalities in patients with HC. 3DE 
demonstrated that the maximum hypertrophy was variable and generally located in a spiral from the 
LV base to the apex. 
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INTRODUCTION 
Hypertrophic cardiomyopathy (HC) is the most common inherited cardiac disease, with an estimated 
prevalence of 1 in 500(1). HC is characterized by a broad clinical and morphological spectrum 
including left ventricular (LV) hypertrophy and abnormal LV papillary muscle (PM) morphology and 
thickness(2-7). Currently, two-dimensional echocardiography (2DE) is the most frequently used 
imaging modality for the diagnosis and follow-up of patients with HC.(8, 9) Clearly, 2DE has inherent 
limitations that may be overcome by three-dimensional echocardiography (3DE). There are indications 
that 3DE allows a better geometric assessment of PM morphology and LV hypertrophy, and may 
provide information that alters clinical decision making.(9, 10) The aim of this study was to assess the 
utility of 3DE for the assessment of LV geometry and PM abnormalities in patients with HC as 
compared to healthy controls. Additionally the relation between PM abnormalities and left ventricular 
outflow tract (LVOT) obstruction was studied. 
 
METHODS 
Patient population and study protocol 
This study included 24 consecutive patients with an established diagnosis of HC and 31 age-matched 
healthy controls. All patients underwent standard 2DE in conjunction with 3DE. Only patients with 
sufficient image quality were included in this study. The diagnosis of HC was based on a LV wall 
thickness (LVWT) ≥15 mm, that was not explained by loading conditions. LVOT obstruction was 
defined as a resting or provocable gradient ≥30 mmHg assessed by Doppler echocardiography. 
Patients with HC linked to Noonan’s syndrome, Fabry’s disease, or congenital heart defects were 
excluded. Approval from the local ethics committee was obtained. The study was conducted according 
to the Declaration of Helsinki. All subjects consented participation in this study. 
 
Echocardiography 
3DE was performed using an iE33 or EPIQ 7C ultrasound system (Philips, Best, The Netherlands) 
with a X5-1t matrix-array transducer. Electrocardiographically gated full volume datasets of the LV 
(built from 4 subvolumes) were acquired in the parasternal long-axis and apical views during breath-
hold. Care was taken to include the complete LV including the PM, and septum within the imaging 
volume throughout the acquisition by adjusting the lateral and elevation widths of the acquisition 
sector. Each full-volume dataset was digitally stored and exported to QLAB 3DQA software (Philips, 
Best, The Netherlands) for offline analysis. 
 The full volume LV 3DE dataset was displayed as 3 orthogonal multiplanar reconstruction 
views. For the analysis of end-diastolic LVWT, a 16-segment model was used, according to EAE/ASE 
recommendations.(11) The short-axis end-diastolic frames that provided the best visualization of the 
endocardial and epicardial borders were selected. The LVWT was assessed at the center of each 
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myocardial segment from the leading endocardial edge to the leading epicardial edge. The geometric 
pattern of LV hypertrophy was determined by the location and extent of hypertrophy at basal, 
midventricular and apical level. For the PM analysis, the anterolateral PM (ALPM) and posteromedial 
PM (PPM) were identified. Subsequently, morphology of the PMs was assessed: individual PMs were 
assessed using long and short axis images on different levels to identify bifid, double bifid and 
accessory PMs. The cross-sectional area (CSA) of each PM was measured in the short-axis view at 
midventricular level, and total CSA was calculated for the ALPM and PPM. 
  
Statistical analyses 
Statistical analyses were performed using SPSS 21 (IBM, Armonk, New York). Continuous variables 
are reported as mean ± standard deviation. Categorical variables are expressed as number (%). Mann-
Whitney U test was used to compare the continuous variables and the Chi-square test was used to 
compare categorical variables. A p value <0.05 was considered statistically significant.  
 
RESULTS 
Patient characteristics 
The clinical characteristics of patients with HC and controls are summarized in table 1. The age of the 
patients with HC and controls was comparable (35±14 vs 33±7 y, p=0.173), and the patient group 
included significantly more men (88% vs 42%, p<0.05).  
 
 
Table 1: Characteristics of patients with hypertrophic cardiomyopathy (HC) and healthy controls 
Variable  Patients with HC (n=24) Controls (n=31) P-value 
Age (years) 35 ± 14 33 ± 7 0.173 
Men 21 (88%) 13 (42%) <0.05 
BMI (kg/m2) 23 ± 5 23 ± 2 
 
BSA (m2) 1.83 ± 0.32 1.85 ± 0.18 
 
Angina 3 (13%) 0 
 
Dyspnea 6 (25%) 0 
 
NYHA class ≥ II 6 (25%) 0 
 
Palpitations 6 (25%) 0 
 
LVOT obstruction (≥30 mmHg) 6 (25%) 0 
 
Pathogenic mutations 
   
   Myosin-binding protein C 8 (33%) - 
 
   Myosin heavy chain 2 (8%) - 
 
   Troponin I 1 (4%) - 
 
   Mitochondrial DNA 1 (4%) - 
 
Data are presented as mean ± standard deviation or number (%). BSA = body surface area, LVOT =  left 
ventricular outflow tract, NYHA = New York Heart Association functional class. 
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Echocardiographic findings 
Measurements of LVWT obtained from 3DE are presented in table 2. Overall, LVWT in all 16 
segments was larger in patients with HC than in controls (p<0.001). The maximal LVWT in patients 
with HC at basal LV level was observed in the inferoseptal segments (1.87 ± 0.62 cm) and anteroseptal 
segments (1.87 ± 0.38 cm); at midventricular level in the anteroseptal segments (2.18 ± 0.67 cm); and 
at apical level in the lateral segment (1.76 ± 0.55 cm). The segments with maximal hypertrophy 
formed a spiral pattern from the base to the apex of the LV.  
 
 
Table 2: Left ventricular wall thickness (LVWT) assessed by three-dimensional echocardiography (3DE) 
Variable   Patients with HC (n = 24) Controls (n = 31) P-value 
Basal level Anterior  1.43 ± 0.37  0.84 ± 0.12  < 0.001 
 Anteroseptal  1.87 ± 0.38  0.86 ± 0.21  < 0.001 
 Inferoseptal 1.87 ± 0.62  0.85 ± 0.16  < 0.001 
 Inferior  1.41 ± 0.49  0.80 ± 0.15  < 0.001 
 Inferolateral  1.25 ± 0.26  0.76 ± 0.15  < 0.001 
 Anterolateral  1.25 ± 0.31  0.73 ± 0.14  < 0.001 
Midventricular level  Anterior  1.54 ± 0.36  0.86 ± 0.17  < 0.001 
 Anteroseptal  2.18 ± 0.67  0.87 ± 0.20  < 0.001 
 Inferoseptal  2.17 ± 0.73  0.89 ± 0.14  < 0.001 
 Inferior  1.47 ± 0.42  0.85 ± 0.16  < 0.001 
 Inferolateral  1.53 ± 0.51  0.75 ± 0.14  < 0.001 
 Anterolateral  1.46 ± 0.46  0.73 ± 0.15  < 0.001 
Apical level Anterior 1.52 ± 0.28  1.03 ± 0.43 < 0.001 
 Septal  1.69 ± 0.71  1.01 ± 0.23  < 0.001 
 Inferior 1.49 ± 0.45  0.85 ± 0.21  < 0.001 
 Lateral  1.76 ± 0.55  0.94 ± 0.35  < 0.001 
Data are presented as mean ± standard deviation in centimeter. HC = hypertrophic cardiomyopathy 
 
 
Measurements of PMs obtained from 3DE are presented in table 3. The total ALPM and total PPM 
CSA were significantly larger in patients with HC than in controls (1.92 ± 0.81 vs. 1.15 ± 0.47 cm2; P 
= 0.001 and 1.46 ± 0.62 vs. 1.08 ± 0.37 cm2; P = 0.031 respectively). Figure 1 demonstrates an 
example of the 3DE analysis of the PM area. There was no significant difference in the number of 
ALPMs and PPMs between patients with HC and controls. Moreover, bifid and accessory PMs were 
not observed more frequently in patients with HC than in controls. Figure 2 shows an example of a 
patient with HC and a bifid PM and figure 3 demonstrates an  example of an accessory PM visualized 
by 3DE. 
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Table 3.  Papillary muscle (PM) evaluated by three-dimensional echocardiography (3DE) 
Variable Patients with HC (n = 24) Controls  (n = 31) P-value 
ALPM Number 1.7 ± 0.5 1.5 ± 0.6 0.172 
 CSA (cm2) 1.92 ± 0.81 1.15 ± 0.47  0.001 
 Bifid appearance 3 (13%) 2 (6%) 0.352 
PPM Number 1.9 ± 0.4 2.1 ± 0.4 0.288 
 CSA (cm2) 1.46 ± 0.62  1.08 ± 0.37  0.031 
 Bifid appearance 3 (13%) 1 (3%) 0.144 
Accessory PM  5 (21%) 3 (10%) 0.276 
Data are presented as mean ± standard deviation or number (%). ALPM = anterolateral papillary muscle, CSA = 
cross-sectional area, HC = hypertrophic cardiomyopathy, PM = papillary muscle, PPM = posteromedial papillary 
muscle 
 
 
 
Figure 1. 3DE assessment of anterolateral papillary muscle (ALPM) cross-sectional area in a patient with HC. a 
Long-axis plane; b Short-axis plane; c Coronal plane; d Alternative real time 3D. ALPM anterolateral papillary 
muscle, LV left ventricle, RV right ventricle, VS ventricular septum 
APM 
LV VS 
RV 
LV 
RV 
B A 
C D 
RV 
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Figure 2. 3DE assessment of a bifid PM in a patient with HC (yellow arrows). a Long-axis plane, b Short-axis 
plane; c Coronal plane; d Real time 3D. LV left ventricle, MV mitral valve, VS ventricular septum 
 
 
 
Figure 3. 3DE assessment of an accessory papillary muscle in a patient with HC (yellow and red 
arrows). a Long-axis plane; b Short-axis plane; c Coronal Plane; d Real time 3D. Aoascending aorta, LV left 
ventricle, MV mitral valve, RV right ventricle, VS ventricular septum 
VS 
A 
LV 
MV 
B 
C D 
RV 
A 
AO 
MV 
B 
C D 
LV 
VS 
LV 
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In the group of 24 patients with HC, the median maximal LVOT gradient was 7 [IQR 4-30] mmHg. 
Six (25%) patients with HC demonstrated significant LVOT obstruction (≥30 mmHg). The PPM CSA 
was larger in patients with LVOT obstruction than in patients without (median 2.64 vs 1.16 cm2; 
p=0.021). The ALPM CSA was not different between patients with and without LVOT obstruction 
(2.00 cm2 vs 1.92 cm2, p=0.88). 
 
DISCUSSION 
This study demonstrates the utility of 3DE for the assessment of the geometric pattern of LV 
hypertrophy and PM morphology in patients with HC. Maximal LV hypertrophy was present at basal 
level in the infero- and anteroseptal segments, at midventricular level in the anteroseptal segments, and 
at apical level in the lateral segments. The hypertrophy in patients with HC followed a spiral pattern 
from the LV base to the apex. 3DE allowed evaluation of the PM morphology and hypertrophy, and 
showed that patients with HC had significantly hypertrophied PMs as compared to healthy controls. 
Moreover, the amount of hypertrophy of the PPM was related to significant LVOT obstruction. 
Previous studies have demonstrated that 3DE may be superior to 2DE, and has a comparable 
accuracy to that of CMR for determining LV volumes, mass, and ejection fraction in various patient 
groups (10, 12-14). Shimada and Shiota(15) performed a meta-analysis of the accuracy of 3DE for the 
measurement of LV mass, including 18 articles with 25 studies. The meta-analysis showed that a 
significant improvement of the accuracy of the 3DE technique has been achieved over time. The 
improved accuracy in most recent studies on 3DE is probably related to an improvement in the 
temporal and spatial resolution of the probe, and a more developed data analysis method using updated 
software. The meta-analysis included 2 studies on the use of 3DE for the assessment of LV mass in 
patients with HC(10, 16). Oe et al.(16) studied the accuracy of 3DE in 21 patients with LV 
hypertrophy (17 with HC, and 4 patients with hypertensive heart disease) using CMR as a reference 
technique. LV mass was estimated accurately and easily by 3DE, whereas LV mass assessed by 2DE 
correlated less well with CMR. Bicudo et al.(10) studied 20 patients with HC who underwent 2DE, 
3DE and CMR. In that study, 3DE had a better performance than 2DE for the evaluation of LV 
hypertrophy, volumes, ejection fraction, and mass when compared to CMR. The current study extends 
the findings from these previous studies and demonstrates the utility of 3DE in patients with HC for 
the assessment of the geometric pattern of LV hypertrophy and PM morphology and hypertrophy. 
Hence, 3DE allows both the assessment of global LV hypertrophy (as measured by LV mass) as well 
as local hypertrophy (as measured by LV segmental wall thickness and PM CSA).  
In this study, the amount and location of LV hypertrophy varied among patients with HC. 
Generally, a longitudinal spiral trajectory of the hypertrophy was observed. This is in line with a recent 
study by Florian et al.(17), who studied the geometry of hypertrophy on CMR in 132 patients with HC. 
Using 3D analysis, the majority of patients exhibited a spiral pattern of hypertrophy. As in the present 
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study, the magnitude of hypertrophy and rotation was variable. This spiral distribution of the 
hypertrophy may be caused by predominant involvement of the subendocardial layers of the 
myocardium. These findings are in agreement with necropsy studies in patients who died from HC, 
showing that the greatest cellular hypertrophy was in the layers closest to the cavity.(18) Likely, the 
distribution of hypertrophy is related to the stress distribution in the LV endocardium and sub 
endocardium.  
Approximately 30% to 60% of the patients with HC has a resting or provable LVOT 
obstruction, which may cause symptoms(19). LVOT obstruction in patients with HC may be caused by 
several factors. Clearly, basal septal hypertrophy and systolic anterior movement of the mitral valve 
leaflet may cause LVOT obstruction. But also anatomical variations and hypertrophy of the PM may 
contribute.(20) Anatomical variations such as anterior displacement of the PM, the presence of a 
double bifid PM, anomalous insertion of the PM onto the anterior mitral valve leaflet, or fusion of the 
PM and the septum or LV free wall, may have hemodynamic consequences. 
Traditionally, 2DE has been used to assess the factors causing LVOT obstruction, but 
additional information may be obtained by 3DE and CMR. Our study demonstrates that the PPM CSA 
was larger in HC patients with LVOT obstruction than in those without. Previous studies have reported 
similar findings. Harrigan et al.(21) obtained CMR images in 201 patients with HC and 43 controls, in 
order to characterize PM morphology. PM mass index was significantly increased in patients with HC 
compared with controls, and PM hypertrophy was most severe in patients with LVOT obstruction. 
Furthermore, Kwon et al.(22) studied 56 patients with HC and 30 controls using CMR. The presence 
of PM abnormalities on CMR was correlated with resting LVOT gradients obtained by Doppler 
echocardiography. Patients with HC and abnormal PMs had significantly higher resting LVOT 
gradients, independent of septal LVWT. The identification of PM abnormalities may be relevant to 
understand the pathophysiology of LVOT obstruction and could have therapeutic consequences in 
patients with HC and significant LVOT obstruction who are considered for septal reduction surgery. 
Kwon et al(23) have suggested that symptomatic patients with HC and significant LVOT obstruction 
with abnormal PM morphology may need surgical PM reorientation instead of or combined with 
standard surgical procedures. According to a large surgical series reported by Minakata et al(6), 
patients with HC associated with anomalous PMs or chordae, including accessory PMs, can be 
successfully treated by surgical relief of morphological anomalies and an extended septal myectomy 
without mitral valve replacement. Finally, the utility of 3DE was also shown for the measurement of 
mitral leaflet surface area and subvalvular geometry in patients with HC. (24) Kim et al. studied 47 
patients with HC and 32 controls using 3DE, and demonstrated that abnormal PM-mitral valve 
geometry assessed by 3DE may provide reasonable new targets for individualized surgical 
intervention.  
This study has several limitations. First, the study population was relatively small, which may 
have affected the results. Second, only patients with sufficient image quality were included in the 
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study. Third, the study was conducted in a referral center for patients with HC, and may have therefore 
caused a bias. Fourth, the patient group included significantly more men than the control group. 
Finally, research is needed to integrate the findings from 3DE imaging in clinical decision making in 
order to improve outcome of patients with HC.  
In conclusion, 3DE allows the assessment of LV geometry and PM abnormalities in patients 
with HC. 3DE demonstrated that the maximum hypertrophy was variable and generally located in a 
spiral from the LV base to the apex. A better visualization of these structures may improve the 
understanding of the pathophysiology and may influence the surgical treatment of left ventricular 
outflow tract obstruction in these patients. 
 
Conflict of interest: none declared. 
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ABSTRACT 
Atrial fibrillation (AF) is a common complication of hypertrophic cardiomyopathy (HC), and 
associated with adverse clinical outcomes, such as thromboembolisms. Cardiac implantable electronic 
devices (CIED) enable early detection of AF. The aim of this study was to assess the incidence of 
device-detected AF and the impact on long-term outcomes in patients with HC. The cohort consisted 
of 132 patients (63% male, mean age 52±16 years) with a diagnosis of HC and a CIED. Follow-up 
started at the date of CIED implantation to assess the incidence of device-detected AF. Patients with 
persistent AF at the time of implantation were excluded from the analysis of the incidence of AF. End 
points were all-cause and cardiac mortality, device-detected AF, and thromboembolism (stroke, 
transient ischemic attack or peripheral arterial embolism). In total, 114 patients were in sinus rhythm at 
time of CIED implantation. During the median 2.8 [1.2-5.4] year follow-up, device-detected AF 
occurred in 29 (25%) patients, resulting in an annual incidence of 7.0%/year. Device-detected AF led 
to a change in the clinical management in 22 (76%) patients. Anticoagulation therapy was started in 13 
(45%), anti-arrhythmic medication in 9 (31%), and 8 (28%) patients underwent electrical 
cardioversion. Six (5%) patients suffered a thromboembolic complication. All-cause mortality was 27 
(20%), and cardiac mortality was 21 (16%). A history of AF at time of implantation was an 
independent predictor of cardiac death (HR 4.7, p=0.003). In conclusion, the incidence of device-
detected AF in patients with HC was 7.0%/year, leading to a change in clinical management in the 
majority (76%) of cases in order to reduce the risk of thromboembolic complications. These findings 
stress the importance of AF detection in HC and advocate vigilant interrogation of the device. 
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INTRODUCTION 
Hypertrophic cardiomyopathy (HC) is the most prevalent genetic cardiac disease.(1) Atrial fibrillation 
(AF) is a common complication of HC, and associated with adverse clinical outcomes, such as stroke 
and heart failure.(2, 3) Not just symptomatic, but also subclinical AF is associated with a substantially 
increased risk of stroke.(4) Since the incidence of stroke is high in patients with HC and AF, current 
guidelines recommend lifelong treatment with oral anticoagulants (OAC), even when sinus rhythm is 
restored.(5) The detection of AF may be challenging, because AF is often asymptomatic, and the 
diagnosis may be missed using traditional intermittent monitoring strategies.(6) A subset of patients 
with HC has a cardiac implantable electronic device (CIED), allowing the detection of AF. This 
patient group frequently has advanced disease and is at increased risk of developing AF.(2, 7, 8) The 
aim of this study was to assess the incidence of device-detected AF and the impact on long-term 
outcomes in patients with HC. 
 
METHODS 
The study population consisted of 132 consecutive patients with HC who received a CIED 
(implantable cardioverter defibrillator [ICD] in 116 and a pacemaker [PM] in 16 patients) between 
1988 and 2015. The study protocol conforms to the Declaration of Helsinki.(9) The study was 
approved by the institutional review board and all patients gave informed consent. Each patient had an 
established diagnosis of HC, based on unexplained left ventricular (LV) hypertrophy of ≥ 15 mm. 
Patients with HC linked to Noonan’s syndrome, Fabry’s disease, mitochondrial disease, or congenital 
heart defects were excluded.  
The indication for CIED implantation was made by a team consisting of ≥ 1 
electrophysiologist and ≥ 1 cardiologist dedicated to the care of patients with HC. ICDs were 
implanted for primary prevention of sudden cardiac death (SCD) based on the presence of established 
major risk factors for SCD, or for secondary prevention of SCD in patients with a history of 
ventricular fibrillation or sustained VT.(5, 10) PMs were implanted in patients with a third or second 
degree type 2 atrioventricular block and in patients with symptomatic sinus node disease.(11) The 
selection of the CIED was made according to the practice guidelines.(5, 10, 11) Patients received 
single or dual-chamber ICDs or PMs, or biventricular ICDs if cardiac resynchronization therapy 
(CRT) was indicated, with transvenous lead systems. The rate cutoff for detection of ventricular 
fibrillation or ventricular tachycardia and activation of antitachycardia pacing was set at the discretion 
of the treating electrophysiologist. A select group of patients received a subcutaneous ICD system in 
case no bradycardia or tachycardia pacing, or CRT was indicated. 
Device-detected AF was defined as AF (paroxysmal or persistent), which was detected by 
interrogation of the device or using the home-monitoring function of the device during follow-up. 
Patients with persistent AF at the time of CIED implantation were excluded from the analysis of the 
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incidence of AF. An electrophysiologist evaluated all high-rate episodes (>180 beats per minute) 
lasting more than 30 seconds(12, 13) documented by intracardiac electrograms. AF detected only by 
device diagnostics (without electrograms) was not considered for the present study. Inappropriate ICD 
intervention triggered by AF was also considered device-detected AF. Atrial high-rate episodes were 
classified as AF, atrial flutter, atrial tachycardia, and sinus tachycardia. AF was assumed to occur if the 
atrial electrogram showed a changing morphology. The diagnosis of atrial flutter was based on regular 
AA intervals and no changes in morphology of the atrial electrogram. The prerequisite of sinus and 
atrial tachycardia was an atrial electrogram preceding the ventricular electrogram. Sinus tachycardia 
was diagnosed if the ventricular rhythm showed a gradual increase in heart rate with unchanged 
morphology of the atrial and ventricular electrogram. The diagnosis of atrial tachycardia was based on 
a sudden increase of the ventricular rate and a change in morpholology of the atrial electrogram. All 
electrocardiograms (ECG), ambulatory ECG monitoring results, telemetry reports and hospital patient 
records were investigated for AF in all patients with single-chamber ICDs and PMs, and subcutaneous 
ICDs. The decision to start OAC was made at the discretion of the treating physician. 
Follow-up started at the time of CIED implantation. End points were all-cause and cardiac 
mortality, device-detected AF, thromboembolism (defined as stroke, transient ischemic attack or 
peripheral arterial embolism), and appropriate and inappropriate ICD intervention. End points were 
retrieved from hospital patient records, from civil service population registers, and from information 
provided by general practitioners. Cardiac mortality was defined as SCD, death from stroke, death 
from end-stage heart failure and heart transplantation.  
SPSS version 21 (IBM, Armonk, NY) was used for statistical analyses. Normality of the 
distribution was assessed using the Shapiro-Wilks test. Normally distributed continuous data are 
expressed as mean ± standard deviation and non-normally distributed data as median [interquartile 
range]. For comparing variables either χ2-test or unpaired t-test were used, for categorical and 
continuous data respectively. The Mann-Whitney U test was used in case the data was non-normally 
distributed. Estimated survival and actuarial event-free rates from device-detected AF were calculated 
according to the Kaplan-Meier method. Patients who underwent heart transplantation were censored 
on the day of transplantation. Cox regression analysis was used to determine predictors of outcome. 
Variables were selected for multivariable analysis if univariate P value was <0.10. Variables were 
expressed as hazard ratio (HR) with 95% confidence interval. P < .05 was considered statistically 
significant. 
 
RESULTS 
A flowchart of the study population is presented in figure 1. Overall, 132 patients (63% male) were 
included in the study. The majority (116, 87%) had an ICD and the remaining 16 (13%) patients had a 
PM. The indication for ICD therapy was primary prevention in 99 (85%) patients and secondary 
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prevention in 17 (15%). The implanted ICD systems were: DDD (45; 39%), VVI (39; 34%), VDD (16; 
14%), subcutaneous ICD (12; 10%), and CRT (4; 3%). The implanted PM systems were: DDD (10, 
65%) and VVI (6, 35%). The baseline characteristics of the study population are presented in table 1. 
The mean age at CIED implantation was 52±16 (range 8-85) years, and 21 (16%) patients were in 
NYHA class ≥ III. Twenty-four (18%) patients had a history of surgical septal myectomy, and 23 
(17%) alcohol septal ablation. A history of stroke was noted in 10 (8%) patients and transient ischemic 
attack in 4 (3%) patients. 
 
 
 
 
 
Figure 1. Flowchart of the study population. 
 
 
In total, 114 (86%) patients were in sinus rhythm at time of implantation. Twenty-two (17%) of these 
patients had a history of paroxysmal AF, 18 of whom (78%) were using OAC at the time of 
implantation. During the median follow-up period of 2.8 [1.2-5.4] years, 33 (29%) patients had AF. 
Twenty-nine (88%) of cases were device-detected. The systems that detected AF were the DDD-ICD 
(n=17), the DDD-PM (n=5), the VDD-ICD (n=2), and the CRT (n=2), and 3 cases of AF were 
detected by inappropriate ICD intervention because of AF (2 had a VVI-ICD and 1 had a subcutaneous 
ICD). Four (12%) cases of AF were not device-detected (all had VVI systems), but were detected 
through evaluation of symptoms with ECG. In the 29 patients with device-detected AF, 10 (34%) 
developed permanent AF, and 19 (66%) had a median of 3 [interquartile range 1-5.5] paroxysms of AF 
during follow-up, with a median duration of 188 [interquartile range 3.5-930] minutes. From the 18 
patients with AF at implant, 15 (78%) had permanent AF. The other 3 (22%) converted to sinus 
rhythm during follow-up (1 after pulmonary venous isolation, 1 after defibrillator threshold testing, 1 
spontaneously). 
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Table 1. Baseline characteristics of the study population  
Variable 
 
 
Total 
(n=132) 
 
      AF During Follow-up 
  YES                               NO 
 P-
value 
Age (years) 52±16  58±15 48±15  <0.001 
Men  83 (63%) 17 (52%) 57 (70%)  0.056 
NYHA class ≥ II 59 (45%) 19 (58%) 26 (32%)  0.012 
NYHA class ≥ III 21 (16%) 3 (9%) 12 (15%)  0.412 
LV ejection fraction 48%±12% 41%±12% 51%±11%  0.008 
Left atrial size, mm 48±10 49±7 44±7  0.001 
Hypertension 38 (29%) 10 (30%) 20 (25%)  0.537 
Stroke 10 (8%) 2 (6%) 4 (5%)  0.808 
Transient ischemic attack 4 (3%) 1 (3%) 1 (1%)  0.508 
Coronary artery disease 10 (8%) 2 (6%) 7 (9%)  0.643 
Diabetes Mellitus 9 (7%) 4 (12%) 4 (5%)  0.173 
Surgical septal myectomy 24 (18%) 10 (30%) 9 (11%)  0.013 
Alcohol septal ablation 23 (17%) 7 (21%) 15 (19%)  0.741 
Vitamin K antagonist 43 (33%) 16 (49%) 9 (11%)  <0.001 
Aspirin 27 (21%) 5 (15%) 21 (26%)  0.214 
Beta blocker 72 (55%) 18 (55%) 45 (56%)  0.922 
Calcium antagonist 23 (17%) 4 (12%) 16 (21%)  0.281 
Digoxin 5 (4%) 1 (3%) 0  0.116 
Sotalol 11 (8%) 6 (18%) 3 (4%)  0.009 
Amiodarone 16 (12%) 6 (18%) 7 (9%)  0.146 
Diuretic 34 (29%) 19 (58%) 10 (12%)  <0.001 
Ace inhibitor 40 (30%) 14 (42%) 17 (21%)  0.020 
Statin 21 (18%) 5 (19%) 14 (18%)  0.969 
All values are mean ± SD or number (%).  
LV = left ventricular, NYHA = New York Heart Association functional class  
 
 
Figure 2 demonstrates the event-free survival from device-detected atrial fibrillation during follow-up. 
The annualized incidence of device-detected AF was 7.0%/year, and of symptomatic AF 0.7%/year. 
The annualized incidence of de novo AF in 92 patients without either persistent or paroxysmal AF at 
baseline was 4.4%/year. Characteristics of patients with AF and patients without AF are presented in 
table 1. Patients with AF were older (58±15 vs 48±15 y, p<0.001), had more symptoms of heart failure 
(NYHA class ≥ II 58% vs 32%, p=0.012), lower LV ejection fraction (41%±12% vs 51%±11%, 
p=0.008), larger left atria (49±7 vs 44±7 mm, p=0.001) and more often had a history of surgical 
myectomy (30% vs 11%, p=0.013).  
 
Device-detected atrial fibrillation in hypertrophic cardiomyopathy 
113 
 
 
Figure 2. Kaplan Meier analysis demonstrating event-free survival from device-detected atrial fibrillation during 
follow-up, among patients with hypertrophic cardiomyopathy who were in sinus rhythm at the time of 
implantation of the device. 
 
The occurrence of device-detected AF led to a change in the clinical management in 22 (76%) patients. 
OAC was initiated in 13 (45%) patients, anti-arrhythmic therapy was initiated or adjusted in 9 (31%) 
patients, and 8 ( 28%) underwent electrical cardioversion. One (3%) patient was prescribed low 
molecular weight heparin instead of OAC because of pregnancy, and 15 (52%) were already using 
OAC. Figure 3 presents the intracardiac electrogram of a 56 year old male with a VDD-ICD system, in 
whom paroxysmal AF was detected using the home-monitoring function of the device. New OAC 
(dabigatran) was started. 
 
 
Figure 3. An intracardiac electrogram of a 56 year old male with a VDD-ICD system, in whom paroxysmal 
atrial fibrillation was detected using the home-monitoring function of the device. New oral anticoagulation 
(dabigatran) was started. 
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Long term outcomes of the patients are summarized in table 2. During 2.8 [1.2-5.4] years follow-up, 
the all-cause mortality was 27 (20%), and cardiac mortality was 21 (16%). The dominant cause of 
death was heart failure, which was the cause of death in 17 (63%) patients. Eight (6%) patients 
received a heart transplant, two of whom died due to transplant-related complications (rejection and 
infection).  
 
Table 2. Long-term outcomes during follow-up of the study population (n=132) 
 Crude incidence Annualized incidence  
All-cause mortality 27 (20%) 5.1% 
Cardiac mortality 21 (16%) 4.1% 
Thromboembolism 
 
6 (5%) 1.3% 
Stroke  3 (2%) 0.7% 
Transient ischemic attack  2 (2%) 0.5% 
Peripheral arterial embolism  1 (1%) 0.2% 
Heart transplant  8 (6%) 1.5% 
Appropriate ICD intervention 26 (22%) 5.6% 
Inappropriate ICD intervention 18 (16%) 4.1% 
Electrical cardioversion 12 (10%) 2.6% 
Pulmonary venous isolation 1 (1%) 0.3% 
All values are number (%). ICD = implantable cardioverter defibrillator 
 
 
A thromboembolic event occurred in 6 (5%) patients. Characteristics of these patients at the time of 
the event are presented in table 3. Two patients had no atrial high rate episodes at the time of the 
thromboembolic event or during follow-up. The etiology of the embolic event in these two patients 
was unknown. The annual incidence of thromboembolic events was 1.3%/year (0.65% for patients 
with AF and 0.65% for patients without AF).  
 
Table 3. Characteristics of the 6 patients with a thromboembolic event 
Patient Gender, age AF at AF during Oral Antiarrhythmic Event 
  implant follow-up anticoagulation therapy  
1 Female, 54 - +* + + Ischemic stroke 
2 Female, 43 +† + + + Ischemic stroke 
3 Female, 43 - +‡ - - Peripheral arterial embolism  
4 Male, 52 - +‡ - + Transient ischemic attack 
5 Female, 48 - - - - Ischemic stroke 
6 Male, 73 - - - + Transient ischemic attack 
+ =  present, - = absent, * = symptomatic paroxysmal AF, † = permanent AF, ‡ = device-detected paroxysmal 
AF after the event 
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Appropriate ICD intervention occurred in 26 (22%) patients (shock in 9 patients; antitachycardia 
pacing in 16 patients; both in 1 patient). Appropriate ICD intervention did not occur more often in 
patients with AF (7 out of 29 [24%] vs 15 out of 85 [18%], p=0.444), or in patients using sotalol (3 out 
of 11 [27%] vs 23 out of 121 [19%], p=0.509). Inappropriate ICD intervention occurred in 18 (16%) 
patients. Besides AF in 3 (17%) patients, reasons for inappropriate ICD intervention were atrial 
tachycardia in 6 (33%), sinus tachycardia in 4 (22%), noise in 3 (17%), and T-top oversensing in 2 
(11%) patients.  
Cardiac death occurred more often in patients with a history of paroxysmal or persistent AF at 
the time of implantation (40% vs 7%, p<0.001). A history of paroxysmal or persistent AF at the time 
of implantation was a predictor of cardiac death during follow-up (HR 4.7, 95% CI 1.7-12.8, p=0.003), 
independent of age and gender.  
 
DISCUSSION 
This study analyzed the incidence of device-detected AF and its impact on long-term outcomes among 
patients with HC and a CIED. The main findings of this study are that the incidence of device-detected 
AF was 7.0%/year, and the incidence of symptomatic AF was 0.7%/year. Hence, most cases (88%) of 
AF were subclinical and device-detected. The occurrence of device-detected AF led to a change in the 
clinical management in 76% of the patients. A history of paroxysmal or persistent AF at the time of 
implantation was an independent predictor of cardiac death during 2.8 [1.2-5.4] years follow-up. The 
annualized rate of thromboembolic complications was relatively low (1.3%), possibly because the 
majority of patients with device-detected AF were treated with OAC and due to the young age of the 
study population. 
Previous studies have addressed the incidence of AF and thromboembolic complications in 
patients with HC.(12, 14, 15) The annualized incidence of AF in this study was higher than the pooled 
annualized incidence of 3.1% that was reported in a meta-analysis by Guttman et al.(15) Recently, 
Wilke et al. reported an annualized incidence of de novo AF of 33% in 30 patients with HC and a 
CIED.(12) The high incidence of AF in this study and the study of Wilke et al. can be explained by 
several factors. First, the type of population that we studied consisted of patients with HC and a CIED. 
Patients with HC and a CIED generally have an advanced form of cardiomyopathy and are at a 
substantially increased risk of developing AF.(2, 7, 8) Second, the majority of the cases (88%) were 
device-detected. These cases probably would have been missed if surveillance was performed by 
routine ECG or traditional intermittent monitoring strategies.(6) Subclinical AF was previously shown 
to be associated with an increased risk of ischemic stroke or systemic embolism (HR 2.49, 
p=0.007).(4) Therefore, the detection of subclinical AF appears to be of equal relevance as the 
detection of symptomatic AF. However, subclinical AF is not always detected before the 
thromboembolic event. In this study, in 2 out of 6 cases with a thromboembolic event, AF was 
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detected after the event. This is in line with the findings of the ASSERT trial(16) which studied the 
temporal relationship of subclinical AF and embolic events in 51 patients with a CIED.  In that study 
subclinical AF was associated with an increased risk of ischemic stroke and systemic embolism, 
although very few patients had subclinical AF in the month before their stroke. This suggests that AF 
is a risk marker, but not always a direct cause of stroke and embolism. 
Patients with HC are at increased risk of developing AF because of several factors, including 
diastolic dysfunction  with increased left atrial pressure and size, LV outflow tract obstruction and 
mitral regurgitation.(5) Olivotto et al. analyzed the prognostic implications of AF in 480 patients with 
HC.(3) During 9.1±6.4 years follow-up, patients with AF had increased risk for HC-related death 
(3%/year vs 1%/year in controls) because of excess heart failure-related mortality. AF patients were 
also at increased risk of stroke (21% vs 2.6%) and functional deterioration to NYHA class III and 
IV.(3). Stroke is associated with significant mortality and morbidity.(3, 17) Maron et al. reported that 
10 out of 44 patients (23%) with HC and a stroke died within 4 months, and that among the 34 
survivors, 11 (32%) had permanent neurologic impairment such as aphasia or hemiparesis.(17) 
Moreover, stroke has a major burden on health care systems and society.(18) Detecting AF with a 
device may therefore be important in the clinical management of patients with HC in order to initiate 
OAC and possibly antiarrhythmic therapy. An early detection of AF by a CIED may reduce the 
incidence of thromboembolic complications including stroke. 
Overall, the incidence of thromboembolism in this cohort was relatively low (1.3%/year) 
compared to previous studies (3.8%/year).(15) Possibly, the detection of AF with a device reduced the 
incidence of thromboembolisms, since therapy with OAC was initiated in the majority of cases. 
Current guidelines recommend lifelong therapy with OAC in all patients with HC and AF (regardless 
of the CHADSVASC score), even when sinus rhythm is restored.(5) This stresses the need for 
attention for device-detected AF in patients with HC and a CIED. Clearly, a good collaboration 
between the device-specialist or electrophysiologist and the treating physician is needed to further 
improve the clinical management of patients with device-detected AF. 
ICD implantation is recommended for secondary prophylaxis of SCD in patients with a history 
of cardiac arrest or sustained ventricular tachycardia, and for primary prophylaxis in patients who are 
at high risk for SCD.(5, 10) The risk for SCD can be estimated through evaluation of the known risk 
factors(10) or using the recently introduced HCM Risk-SCD calculator.(5) Current guidelines 
recommend a single ventricular lead system, unless there is an indication for dual-chamber pacing or 
CRT in case of reduced LV function.(5, 10) However, a device that is capable of atrial sensing may be 
considered, since atrial electrograms facilitate the detection of AF. Disadvantages of systems with 
atrial leads are longer procedure times and higher complication risk.(19-24) Therefore, a novel single-
chamber system was developed containing a floating bipole in the atrium allowing atrial sensing 
without the need for an atrial lead.(25) Sticherling et al. reported that this device was non-inferior to a 
dual-chamber device with regard to the detection and therapy of ventricular tachycardia and 
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supraventricular tachycardia.(25) Further research is needed to assess the value of this device in 
detection of AF in patients with HC.  
The study has some limitations. First, the study population is relatively small. Second, patients 
with single-chamber devices and subcutaneous ICDs were included in the study. Since these devices 
do not have atrial sensing capabilities, an underestimation of the incidence of AF might have occurred. 
Third, this study was performed in a referral center for patients with HC, and most of these patients 
had an advanced cardiomyopathy. Therefore the cohort was at an increased risk of developing AF.  
 
Conflicts of interest: none.  
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ABSTRACT 
Gender has been proposed to impact the phenotype and prognosis of hypertrophic cardiomyopathy 
(HC). Our aims were to study gender differences in the clinical presentation, phenotype, genotype, and 
outcome of HC. This retrospective single-center cohort study included 1007 patients with HC (62% 
male, 80% genotyped) evaluated between 1977 and 2017. Hazard ratios (HR) were calculated using 
multivariable Cox proportional hazard regression models. At first evaluation, female patients 
presented more often with symptoms (43% vs 35%, p=0.01), were older than male patients (56±16 vs 
49±15 y, p<0.001), and more frequently had hypertension (38% vs 27%, p<0.001), left ventricular 
outflow tract obstruction (37% vs 27%, p<0.001) and impaired left ventricular systolic (17% vs 11%, 
p=0.01) and diastolic (77% vs 62%, p<0.001) function. Overall, the genetic yield was similar between 
genders (54% vs 51%, p=0.4), however in patients ≥ 70 years the genetic yield was less in females 
(15% vs 36%, p=0.03). During 6.8 (interquartile range, 3.2-10.9) years follow-up, female gender was 
not independently associated with all-cause mortality (HR 1.25 [0.91 - 1.73]), cardiovascular mortality 
(HR 1.22 [0.83 - 1.79]), heart failure related mortality (HR 1.77 [0.95 - 3.27]), or sudden cardiac 
death/aborted sudden cardiac death (HR 0.75 [0.44 - 1.30]). Interventions and nonfatal clinical events 
did not differ between the genders. In conclusion, female patients with HC present at a more advanced 
age with a different clinical, phenotypic, and genetic status. There is no independent association 
between female gender and all-cause, cardiovascular, heart failure related, or sudden cardiac death.  
  
Effect of gender and genetic mutations on outcomes 
123 
 
INTRODUCTION 
Hypertrophic cardiomyopathy (HC) is a heterogeneous monogenic cardiac disease known to lead to 
sudden cardiac death (SCD), heart failure (HF), and atrial fibrillation with the increased risk of 
stroke.(1, 2) Gender has been proposed to impact the age of onset and the phenotype of HC.(3-14) 
Studies which assessed gender and clinical outcome of HC report conflicting results.(5, 15-17) Some 
studies report an independent association between female sex and all-cause mortality(16, 17) or heart 
failure related events.(15, 16, 18, 19) Genotype has been shown to impact the phenotypic expression 
and clinical outcome of HC.(7, 20-22) In the Netherlands, genetic counselling and testing is offered to 
all patients with HC, because it is covered by the national basic health-care program. The aim of this 
study was to assess gender-related differences in the genetic test results, clinical presentation, 
phenotype, and outcome of HC. 
 
METHODS 
This single-center retrospective cohort study included 1007 patients with HC who were 
evaluated at the Erasmus Medical Center in Rotterdam, the Netherlands, between the years 1977 and 
2017. The diagnosis of HC was based on a maximal wall thickness (MWT) ≥ 15 mm in probands, ≥ 13 
mm in relatives, and a z-score > 2 in children, not solely explained by loading conditions. Patients with 
HC caused by Anderson-Fabry disease, Danon disease, Noonan syndrome, amyloidosis, or other 
confirmed metabolic or mitochondrial disorders or malformation syndromes were excluded. The study 
conforms to the principles of the Declaration of Helsinki. All patients gave informed consent for 
inclusion in the registry and local institutional review board approval was obtained. 
Genetic counseling and testing was offered to all patients. Before the year 2012, genetic 
analysis consisted of direct sequencing of all coding exons and intron-exon boundaries of the 
following eight genes: myosin binding protein C (MYBPC3), ß-myosin heavy chain (MYH7), cardiac-
regulatory myosin light chain (MYL2), cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), 
cysteine and glycine-rich protein 3 (CSRP3), titin-cap/telethonin (TCAP), and α-tropomyosin (TPM1). 
From the year 2012, a next-generation-sequencing targeted approach including 48-52 cardiomyopathy-
associated genes was used. Classification of variants was done at time of initial testing. Variants were 
interpreted using a protocol adapted from the American College of Medical Genetics and Genomics 
recommendations(23), and classified into 5 categories: (I) benign; (II) likely benign; (III) uncertain 
significance; (IV) likely pathogenic; and (V) pathogenic. The potential pathogenicity of variants was 
assessed using Alamut Visual software (Interactive Biosoftware, Rouen, France), that integrates data 
from several large-scale population studies, evolutionary conservation of nucleotides and amino acids, 
in silico missense predictions (Align GVGD, SIFT, MutationTaster and PolyPhen-2) and splicing 
prediction modules (SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer and Human 
Splicing Finder). The criteria for classification of variants included the allele frequency in the 
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dbSNP/ESP/ExAC/GoNL (cutoff minor allele frequency 1% in at least 300 ethnically matched control 
alleles equals benign), predicted effects on splicing, the in silico prediction of effect on the protein, 
and previously described links to disease. Furthermore, segregation analysis in families with more 
affected individuals and information considering presence in Human Gene Mutation Database 
(HGMD®) Professional 2017.3 (Qiagen) is taken into account. Variant reclassifications during follow-
up were registered, and variant classification as assessed at the end of follow-up was used for the 
analyses. Patients with a reclassified variant were informed about the reclassification and if applicable 
about the indication for renewed evaluation. Patients were considered genotype-positive when the 
mutation was classified as likely pathogenic or pathogenic (class IV and V).  
Clinical assessment included medical history, physical examination, electrocardiography and 
transthoracic echocardiography. Echocardiographic studies were analyzed according to the 
guidelines.(1, 24, 25) MWT, left atrial dimension, left ventricular (LV) end-diastolic diameter, and 
resting LV outflow tract velocity were assessed.(1, 24) LV outflow tract gradient was calculated with 
the Bernoulli equation. LV systolic function was categorized as: good (LV ejection fraction > 51%), 
mildly reduced (LV ejection fraction 41% to 51%), moderately reduced (LV ejection fraction 30% to 
40%), and poor (LV ejection fraction < 30%).(25) LV diastolic function was defined as normal, 
abnormal relaxation, pseudonormal or restrictive filling, based on Doppler mitral inflow pattern 
parameters including early (E) and late (A) LV filling velocities, E/A ratio, and tissue Doppler 
imaging-derived septal early diastolic velocities (e’).(26) Body surface area was calculated with the 
Du Bois & Du Bois formula. 
Mortality data was retrieved from the civil service register in August 2017. Patients were 
followed for a median 6.8 (interquartile range 3.2-10.9) years (7 363 total personyears; 0.01% missing 
due to loss of follow-up). Patients who were lost to follow-up were censored at time of last follow-up. 
The cause of death was retrieved from the medical chart or the general practitioner and was obtained in 
171 (87%) of mortality cases. Those with unknown causes of death were classified as all-cause 
mortality. Cardiovascular mortality included SCD/aborted SCD, HF related death, postoperative death 
after a cardiac intervention and stroke related death. SCD/aborted SCD was defined as: (1) 
instantaneous and unexpected death in patients who were previously in a stable clinical condition, or 
nocturnal death with no antecedent history of worsening symptoms; (2) resuscitation after cardiac 
arrest; or (3) appropriate implantable cardioverter defibrillator (ICD) intervention. Appropriate ICD 
intervention was defined as shock or antitachycardia pacing for ventricular fibrillation or ventricular 
tachycardia >200/min. Cardiac transplantation was considered HF related mortality and patients were 
censored at the time of transplantation. The following nonfatal clinical events and interventions were 
registered: atrial fibrillation (paroxysmal, persistent or permanent), stroke, transient ischemic attack, 
hospital admission for HF, septal reduction therapy (surgical myectomy and alcohol septal ablation), 
and ICD and pacemaker implantations. ICDs and pacemakers were implanted according to the 
guidelines.(1, 24). 
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Calculations were performed using SPSS 21 (IBM, Armonk, New York) and R statistical Software 
version 3.4.2 using packages nlme, lme4, survival, and smcfcs. Normally distributed continuous data 
are expressed as mean ± standard deviation and non-normally distributed data as median followed by 
interquartile range. In order to make comparisons between male and female patients, generalized linear 
mixed models were used, with random intercepts for family to account for family relatedness. Hazard 
ratios (HR) and 95% confidence intervals (CI) were calculated using univariable and multivariate Cox 
proportional hazard regression models with adjustment for family relatedness. For this purpose the 
grouped jackknife method was used. Missing values of variables included in the multivariable analyses 
were imputed using 10 imputed datasets. All analyses were two-tailed; P-values < 0.05 were 
considered significant.  
 
RESULTS 
Baseline characteristics are presented in table 1. Overall, there was a male predominance of 62%. The 
male predominance was present in all age groups, except in patients ≥ 70 years where females 
predominated (figure 1). Male patients presented more often via routine medical examinations, and 
female patients presented more often with symptoms (table 2). Female patients were significantly 
older than male patients both at time of diagnosis and at first evaluation (table 1), also after excluding 
patients who presented via routine medical examinations (51±18 vs 46±17 y, p<0.001 and 55±17 vs 
49±16 y, p<0.001 respectively). Female patients more frequently had a history of hypertension and 
stroke/transient ischemic attack. 
 
Table 1. Baseline characteristics according to gender (continues on the next page) 
Variable 
 
Overall 
(n=1007) 
Male 
(n=620) 
Female  
(n=387) P-value 
 
Age at evaluation (years) 52±16 49±15 56±16 <0.001 
   < 30 102 (10%) 68 (11%) 34 (9%) 0.26 
   30 - 50 338 (34%) 241 (39%) 97 (25%) <0.001 
   > 50 567 (56%) 311 (50%) 256 (66%) <0.001 
Age at diagnosis (years) 46±17 44±16  50±19  <0.001 
BSA (mm/m2) 1.94±0.23 2.05±0.17 1.80±0.17 <0.001 
Arterial hypertension 310 (31%) 164 (27%) 146 (38%) <0.001 
Coronary artery disease 62 (6%) 43 (7%) 19 (5%) 0.21 
Atrial fibrillation 213 (21%) 123 (20%) 90 (23%) 0.41 
Septal reduction therapy 51 (5%) 30 (5%) 21 (5%) 0.67 
ICD/PM implantation 47 (5%) 24 (4%) 23 (6%) 0.14 
Stroke/TIA 61 (6%) 25 (4%) 36 (9%) 0.02 
HF admission  24 (4%) 11 (3%) 13 (5%) 0.17 
SCD/aborted SCD 16 (2%) 11 (2%) 5 (1%) 0.33 
Medication     
   Betablockers 497 (49%) 292 (47%) 205 (53%) 0.07 
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Table 1. Baseline characteristics according to gender (continued) 
Variable 
 
Overall 
(n=1007) 
Male 
(n=620) 
Female  
(n=387) P-value 
 
   Other anti-arrhythmic* 58 (6%) 31 (5%) 27 (7%) 0.19 
   Calcium antagonists 298 (30%) 183 (30%) 115 (30%) 0.95 
   Statins 196 (20%) 110 (18%) 86 (22%) 0.08 
   Diuretics 188 (19%) 84 (14%) 104 (27%) <0.001 
   Aspirin 159 (16%) 80 (13%) 79 (20%) 0.001 
   Oral anticoagulants† 123 (12%) 64 (10%) 59 (15%) 0.02 
   ACE-i 124 (12%) 72 (12%) 52 (13%) 0.39 
   ATIIA 102 (10%) 54 (9%) 48 (12%) 0.06 
   ACE-i / ATIIA 222 (22%) 123 (20%) 99 (26%) 0.03 
Genetic testing performed 810 (80%) 511 (82%) 299 (77%) 0.05 
   Pathogenic mutation 430 (53%) 277 (54%) 153 (51%) 0.39 
Echocardiography 
    
   MWT (mm) 19±4 19±4 18±4 0.03 
      < 13** 8 (1%) 5 (1%) 3 (1%) 0.96 
      13 - 15 208 (21%) 108 (18%) 100 (26%) 0.001 
      16 - 19 428 (43%) 271 (45%) 157 (41%) 0.33 
      20 - 24 253 (26%) 167 (27%) 86 (23%) 0.09 
      25 - 29 68 (7%) 41 (7%) 27 (7%) 0.82 
      ≥ 30 24 (2%) 17 (3%) 7 (2%) 0.35 
   MWT/BSA (mm/m2) 9.6±2.3 9.2±2.0 10.3±2.6 <0.001 
   LA (mm) 45±8 45±8 44±8 0.001 
   LA/BSA (mm/m2) 23.2±4.1 22.5±3.9 24.5±4.1 <0.001 
   LVEDD (mm) 46±6 47±6 44±6 <0.001 
   LVEDD/BSA (mm/m2) 23.3±3.4 22.7±3.2 24.3±3.5 <0.001 
   LVOT ≥ 30 mmHg‡ 300 (31%) 160 (27%) 140 (37%) <0.001 
   Diastolic function 
    
     Normal 285 (32%) 206 (38%) 79 (23%) <0.001 
     Impaired relaxation 276 (31%) 147 (27%) 129 (38%) <0.001 
     Pseudonormal filling 269 (30%) 169 (31%) 100 (30%) 0.60 
     Restrictive filling 55 (6%) 25 (5%) 30 (9%) 0.01 
   Systolic function 
    
     Good 857 (87%) 543 (89%) 314 (83%) 0.01 
     Mildly reduced 95 (10%) 51 (8%) 44 (12%) 0.10 
     Moderately reduced 24 (2%) 8 (1%) 16 (4%) 0.01 
     Severely reduced 11 (1%) 7 (1%) 4 (1%) 0.87 
Data are expressed as mean ± standard deviation or as absolute n (%). Generalized linear mixed models were 
used, with random intercepts for family to account for family relatedness. * = includes flecainide, amiodarone, 
disopyramide, and ritmoforin. † = includes 1 new oral anticoagulant. ** = end stage hypertrophic 
cardiomyopathy or post septal reduction therapy. ‡ = at rest. ATIIA, angiotensin II antagonist; ACE-i, ACE 
inhibitor; BSA, body surface area; HF, heart failure; LA, left atrial size; LVEDD, left ventricular end diastolic 
diameter; LVOT, left ventricular outflow tract gradient; MWT, maximal wall thickness; ICD, implantable 
cardioverter defibrillator; PM, pacemaker; SCD, sudden cardiac death; TIA, transient ischemic attack. 
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Table 2. Triggers for diagnosis in male and female patients with hypertrophic cardiomyopathy 
Variable 
 
Overall 
(n=1007) 
Male  
(n=620) 
Female  
(n=387) P-value 
 
Precordial murmur 149 (18%) 106 (20%) 43 (14%) 0.03 
Abnormal ECG 111 (13%) 76 (15%) 35 (11%) 0.20 
Other* 33 (4%) 20 (4%) 13 (4%) 0.75 
Chest pain 145 (18%) 88 (17%) 57 (19%) 0.52 
Dyspnea 112 (14%) 61 (12%) 51 (16%) 0.04 
Palpitations 65 (8%) 30 (6%) 35 (12%) 0.004 
Dizziness 37 (5%) 21 (4%) 16 (5%) 0.45 
Syncope 39 (5%) 29 (6%) 10 (3%) 0.14 
Fatigue 65 (8%) 27 (5%) 38 (13%) <0.001 
Sudden cardiac death† 11 (1%) 9 (2%) 2 (1%) 0.19 
Atrial fibrillation 21 (3%) 11 (2%) 10 (3%) 0.33 
Heart failure 5 (0.6%) 3 (0.6%) 2 (0.7%) 0.95 
Acute myocardial infarction 11 (1%) 7 (1%) 4 (1%) 0.99 
Stroke/TIA/embolism 5 (0.6%) 4 (0.8%) 1 (0.3%) 0.45 
HC family screening 165 (20%) 103 (20%) 62 (20%) 0.81 
Data are expressed as absolute n (%). Generalized linear mixed models were used, with random intercepts for 
family to account for family relatedness. * = during preoperative screening, prescan, cardiac echo for other 
cardiac diseases. † = two sudden cardiac deaths were not successfully resuscitated. ECG, electrocardiography; 
HC, hypertrophic cardiomyopathy; TIA, transient ischemic attack.  
 
 
 
Figure 1. Male/female distribution among several age groups. 
 
In patients ≥ 70 years old, the genetic yield was significantly less in female patients than in 
male patients (15% vs 36%, p=0.03) (figure 2). Genes most frequently affected were MYBPC3 (74%) 
and MYH7 (14%) (figure 3). Other genes affected were TNNI3 (3%), TNNT2 (3%), MYL2 (2%), 
ALPK3 (1%), TPM1 (0.7%), MYL3 (0.7%), CSRP3 (0.7%), FHL1 (0.5%), MIB1 (0.2%), and TNNC1 
(0.2%). There was no significant difference regarding the proportion of MYBPC3 mutations (77% vs 
69%, p=0.08) or MYH7 mutations (12% vs 18%, p=0.09) in male or female patients respectively.       
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A complex genotype was present in 8 (3%) female patients and 8 (2%) male patients (p=0.3), and 
included 8 homozygous mutations, 4 digenic, and 4 compound heterozygous mutations 
(supplementary table 1). 
 
 
Figure 2. Genetic yield in male and female patients among several age groups. * indicates statistical significance 
with a p<0.05.  
 
 
 
 
 
Figure 3. Distribution of pathogenic mutations in genotype-positive patients. MYBPC3, myosin binding protein 
C; MYH7, ß-myosin heavy chain. Other includes mutations in cardiac troponin T (3%), cardiac troponin I (3%), 
cardiac-regulatory myosin light chain (2%), alpha-protein kinase 3 (1%), cysteine and glycine-rich protein 3 
(0.7%), cardiac-essential myosin light chain (0.7%), α-tropomyosin (0.7%), four and a half LIM domains protein 
1 (0.5%), mindbomb E3 ubiquitin protein ligase 1 (0.2%), and cardiac troponin C (0.2%). 
 
The MWT was higher in male patients, but the MWT corrected for body surface area was higher in 
female patients. Similar observations were made for left atrial dimension and LV end-diastolic 
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diameter. A greater proportion of female patients had LV outflow tract obstruction, and systolic and 
diastolic function was more often impaired in female patients. 
Mortality during a median 6.8 (interquartile range, 3.2-10.9) year follow-up is presented in 
table 3. In multivariable analysis (tables 4 and 5), there was no independent association between 
gender and all-cause mortality (HR 1.25, p=0.16), cardiovascular mortality (HR 1.22, p=0.31), HF 
related death (HR 1.77, p=0.08) or SCD/aborted SCD (HR 0.75, p=0.31). Missing values for the 
following variables were imputed: pathogenic mutation (20%), diagnosis by routine examination 
(18%), and body surface area (19%). Clinical follow-up was performed in 691 (69%) patients; the 
remaining 316 (31%) patients were followed up in other hospitals. Interventions and nonfatal clinical 
events did not differ significantly between male and female patients (table 6).  
 
Table 3. Outcome differences in males and females with hypertrophic cardiomyopathy 
Variable 
 
Overall  
(n=1005) 
Male  
(n=618) 
Female  
(n=387) 
HR  
(95% CI) 
P-value 
Follow-up  6.8 [3.2-10.9] 7.7 [3.5-11.1] 5.8 [2.3-10.1] - 0.003 
All-cause mortality 183 (19%) 91 (15%) 92 (24%) 1.85 (1.40-2.44) <0.001 
Cardiovascular mortality 110 (11%) 56 (9%) 54 (15%) 1.76 (1.22-2.54) 0.002 
SCD/Aborted SCD 57 (6%) 37 (6%) 20 (5%) 0.99 (0.57-1.71) 0.97 
   Appropriate ICD shock 20 (2%) 15 (3%) 5 (1%) 0.63 (0.23-1.71) 0.36 
   Cardiac arrest  37 (4%) 22 (4%) 15 (4%) 1.23 (0.64-2.39) 0.53 
HF related mortality 46 (5%) 19 (3%) 27 (7%) 2.50 (1.42-4.39) 0.001 
   Cardiac transplantation 16 (2%) 5 (1%) 11 (3%) 3.65 (1.22-10.9) 0.02 
Stroke related death 4 (0.4%) 1 (0.2%) 3 (0.8%) 5.57 (0.55-56.8) 0.15 
CIRD 6 (0.6%) 0 (0%) 6 (2%) *  
Non-cardiac mortality 47 (5%) 22 (4%) 25 (7%) 2.11 (1.21-3.69) 0.009 
Data are expressed as absolute n (%). Hazard ratios (HR) were calculated using univariable Cox proportional 
hazard regression models with adjustment for family relatedness. *Hazard ratio is not presented due to low 
number of events. CIRD, cardiac intervention related death; HF, heart failure; ICD, implantable cardioverter 
defibrillator; SCD, sudden cardiac death; For all-cause mortality, cardiovascular mortality, SCD/Aborted SCD, 
and intervention-related death survival analyses the patients with a history of SCD/Aborted SCD were excluded.  
 
Table 4. Multivariate cox proportional hazard regression analyses for all-cause and cardiovascular mortality 
(continues on the next page) 
Variable             All-cause mortality          Cardiovascular mortality  
 
HR (95% CI) P-value HR (95% CI) P-value 
Female gender 1.21 (0.88 - 1.66) 0.23 1.21 (0.82 - 1.78) 0.33 
Age at evaluation 1.03 (1.01 - 1.04) <0.001 0.99 (0.98 - 1.02) 0.98 
Diagnosis by routine examination 0.83 (0.58 - 1.19) 0.31 0.73 (0.46 - 1.15) 0.17 
Arterial hypertension 0.88 (0.63 - 1.23) 0.47 0.79 (0.51 - 1.24) 0.31 
CI, confidence interval; HR, hazard ratio 
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Table 4. Multivariate cox proportional hazard regression analyses for all-cause and cardiovascular mortality 
(continued) 
Variable             All-cause mortality          Cardiovascular mortality  
 
HR (95% CI) P-value HR (95% CI) P-value 
Atrial fibrillation  1.31 (0.96 - 1.80) 0.09 1.99 (1.35 - 2.94) <0.001 
Abnormal systolic function 2.83 (1.97 - 4.08) <0.001 3.19 (2.04 - 4.98) <0.001 
MWT/BSA (mm/m2) 1.03 (0.95 - 1.10) 0.49 1.02 (0.94 - 1.102) 0.67 
Left atrial size/BSA (mm/m2) 1.05 (1.01 - 1.09) 0.01 1.07 (1.02 - 1.11) 0.003 
Pathogenic mutation 1.01 (0.72 - 1.43) 0.94 1.07 (0.68 - 1.69) 0.75 
BSA, body surface area; CI, confidence interval; HR, hazard ratio; MWT, maximal wall thickness  
 
 
Table 5. Multivariate cox proportional hazard regression analyses for SCD/Aborted SCD and HF related 
mortality. 
Variable                 SCD/Aborted SCD  HF related mortality 
 
HR (95% CI) P-value HR (95% CI) P-value 
Female gender 0.75 (0.44 - 1.28) 0.29 1.73 (0.92 - 3.24) 0.09 
Age at evaluation 0.99 (0.97 - 1.01) 0.27 1.00 (0.97 - 1.03) 0.99 
Atrial fibrillation  1.39 (0.78 - 2.48) 0.27 3.65 (1.80 - 7.41) <0.001 
Abnormal systolic function 2.60 (1.36 - 4.95) 0.004 6.56 (3.34 - 12.85) <0.001 
MWT/BSA (mm/m2) 1.06 (0.95 - 1.17) 0.29 - 
 
LA size/BSA (mm/m2) 1.05 (0.99 - 1.11) 0.08 1.09 (1.02 - 1.17) 0.009 
Pathogenic mutation 1.21 (0.66 - 2.22) 0.54 1.32 (0.67 - 2.60) 0.43 
BSA, body surface area; CI, confidence interval; HF, heart failure; HR, hazard ratio; MWT, maximal wall 
thickness; SCD, sudden cardiac death 
 
 
Table 6. Differences in interventions and nonfatal clinical events in male and female patients with hypertrophic 
cardiomyopathy during follow-up 
Variables 
 
Overall  
(n=691) 
Male  
(n=431) 
Female  
(n=260) 
HR 
(95% CI)  
P-value 
Septal reduction therapy 223 (32%) 131 (30%) 92 (36%) 1.29 (0.98-1.69) 0.07 
  Surgical myectomy 173 (25%) 101 (23%) 72 (28%) 1.32 (0.97-1.79) 0.08 
  Alcohol septal ablation 63 (9%) 38 (9%) 25 (10%) 1.13 (0.68-1.87) 0.64 
ICD implantation 155 (23%) 102 (24%) 53 (21%) 0.89 (0.64-1.24) 0.49 
PM implantation 29 (4%) 14 (3%) 15 (6%) 1.96 (0.95-4.01) 0.07 
AF de novo 49 (9%) 36 (11%) 13 (7%) 0.66 (0.36-1.23) 0.19 
Stroke 22 (3%) 13 (3%) 9 (4%) 1.22 (0.52-2.85) 0.65 
TIA 23 (3%) 17 (4%) 6 (2%) 0.57 (0.23-1.42) 0.23 
HF admission 44 (6%) 22 (5%) 22 (9%) 1.71 (0.95-3.07) 0.07 
Data are expressed as absolute n (%). Hazard ratios (HR) were calculated using univariable Cox proportional 
hazard regression models with adjustment for family relatedness. AF, atrial fibrillation; HF, heart failure; ICD, 
implantable cardioverter defibrillator; PM, pacemaker; TIA, transient ischemic attack.  
 
Effect of gender and genetic mutations on outcomes 
131 
 
DISCUSSION 
In this study we report the following gender differences in patients with HC: (1) at presentation female 
patients were older, more frequently had a history of hypertension, and presented more frequently with 
symptoms; (2) female patients more frequently had an impaired systolic and diastolic function and 
more frequently exhibited LV outflow tract obstruction; (3) in the whole cohort there was a male 
predominance, however among patients ≥ 70 years old females predominated in whom the genetic 
yield was significantly lower than in male patients, and (4) during 6.8 years follow-up, there was no 
independent association between gender and all-cause mortality, cardiovascular mortality, HF related 
mortality, or SCD/aborted SCD. 
In this study, female patients had a delayed clinical presentation in comparison to male 
patients, also after excluding those who presented via routine medical examinations. Several previous 
studies have similarly reported a delayed clinical presentation in female patients with HC.(3, 7, 12, 15-
17, 19) Olivotto et al. studied gender differences among 969 patients with HC and reported that female 
patients were 9 years older at time of initial evaluation(15), similar to Bos et al. who reported a 9 year 
delay in female patients among 382 patients with HC.(7) Wang et al. reported a 3 year delay in female 
patients among 621 patients with HC(16) and recently Geske et al. reported a 7 year delay in female 
patients in a large cohort of 3673 HC patients.(17)  Sociocultural processes (i.e. lack of attention to 
early clinical signs in women or diagnostic bias) may account for the delay. However, Dimitrow et al. 
reported that not just diagnosis but also the onset of symptoms was delayed in females with HC.(3) 
Therefore, differences in sexual hormones and gene expression may play a role.(27)  
Female patients were older and had different clinical and phenotypic features including more 
hypertension, more LV outflow obstruction, and a higher indexed MWT. Indeed, hypertensive HC is 
known to occur predominantly in the elderly, particularly female.(28) Krumholz et al. reported that 
women adapt differently to hypertension than men, namely women develop concentric hypertrophy 
with normal or reduced LV size and men develop LV dilatation without increased LV wall 
thickness.(29) It may be due to these differences that LV outflow obstruction was more common in 
female patients. In addition, the underlying HC mutation most likely has an important impact on the 
phenotypic expression of HC. Bos et al. demonstrated that patients with sigmoidal HC were generally 
older women with hypertension and LV outflow obstruction.(7) The majority of these patients were 
mutation-negative, in contrast to patients with reverse curve HC where 80% was mutation-
positive.(30) This study extends these findings by showing that women ≥ 70 years old had a 
significantly lower genetic yield in comparison to men. Mutation-negative HC might culminate from a 
multifactorial process involving undefined genetic and environmental factors.(20)  
At baseline, female patients showed more signs of adverse remodeling than male patients 
(systolic and diastolic impairment, larger indexed left atria and larger LV). Whether female patients 
with HC are indeed at a higher risk of HF is currently unknown. Unlike previous studies(15, 16, 18, 
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19), we did not observe an increased risk of HF related mortality or hospital admission for HF in 
female patients during follow-up. The discrepancy with previous studies may be caused by the use of 
different end points. Studies which assessed LV contractility in similarly aged male and female 
patients with HC also reported conflicting results. Dimitrow et al. measured fractional shortening in 77 
males and 52 females with HC, and found no gender difference (45% vs 44%, p>0.05).(6) Kubo et al. 
described a higher fractional shortening in 88 female patients versus 173 male patients (43% vs 40%, 
p=0.01).(11)  
In the current study, there was no independent association between gender and all-cause 
mortality, cardiovascular mortality, HF related death, or SCD/aborted SCD. Important predictors of 
outcome were age at evaluation, abnormal systolic function, left atrial size adjusted for body surface 
area, and atrial fibrillation. Previous studies have also demonstrated a prognostic value for these 
variables in patients with HC.(31-33) The variables combined represent part of a distinct disease 
pathway termed ‘’stage III, adverse remodeling’’.(34) About 15-20% of the patients with HC follow 
this pathway and are at increased risk of death.(34) Previous studies that assessed gender and mortality 
in HC have reported conflicting results.(5, 15-17)  Similar to our results, Olivotto et al. found no 
association between gender and all-cause mortality, HC-related death or SCD among 969 patients with 
HC after 6.2 years follow-up.(15) However, they found an association between female gender and the 
combined end point of progression to NYHA classes III or IV or death from HF or stroke.(15) 
Terauchi et al. studied gender differences among 50 patients with HC caused by MYBPC3 mutations 
and reported more HF events in female patients, however no gender difference regarding survival.(19) 
Dimitrow et al. reported no survival difference between 111 male and 70 female patients with HC 
during 7 years follow-up.(5) In contrast to these studies, Wang et al. found female gender to be 
independently associated with all-cause mortality (HR 2.19, p=0.01), cardiovascular death (HR 2.19, 
p=0.01), and progression to HF  (HR 1.73, p=0.01) during 4 years follow-up of 621 patients with 
HC.(16) Of note, in that study patients with HF at baseline were excluded. Geske et al. demonstrated 
that female sex was an independent predictor of all-cause mortality (HR 1.13, p=0.01) during 11 years 
follow-up of 3673 patients with HC.(17) The discrepancy with previous studies was suggested to be 
caused by their larger, sicker cohort.(17) 
Overall, the findings in the current study illustrate that there is a significant delay in the 
clinical presentation of female patients with HC and that female patients present with more advanced 
disease than male patients. Similar observations were made for patients with coronary artery disease, 
which is partly attributable to sex-specific differences in the sensitivity of diagnostic procedures.(27) 
In the current study, adjusting echocardiographic parameters to body surface area revealed a worse 
phenotype than we suspected based on unadjusted parameters, suggesting a diagnostic bias. By 
applying gender- or body surface area-adjusted parameters, we may be able to recognize disease 
progression earlier, resulting in more intense follow-up and management and potentially a better 
outcome. Future studies are needed to investigate this further.(9)  
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This study has several limitations. First, this is a retrospective study which has inherent limitations. 
Second, the patients were referred to a tertiary center for cardiomyopathy, which may have caused a 
selection bias. Third, the prevalence of Dutch MYBPC3 founder mutations in the Netherlands is 
relatively high(35) which may affect extrapolation of the findings to other countries. And fourth, 
follow-up for the occurrence of nonfatal clinical events was available in only 69%, due to follow-up in 
other hospitals. 
In conclusion, female patients with HC present at a more advanced age with a different 
clinical, phenotypic, and genetic status. There is no independent association between female gender 
and all-cause, cardiovascular, heart failure related, or sudden cardiac death.  
 
Disclosures: None. 
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Supplementary table 1. Complex genotypes in patients with hypertrophic cardiomyopathy 
Case Complex type Gender Gene (s) Nucleotide change 
1 Homozygous female MYBPC3 c.1765C>G 
2 Homozygous female MYBPC3  c.1765C>G 
3 Homozygous female MYBPC3 c.1765C>G 
4 Homozygous female MYBPC3 c.1765C>G 
5 Homozygous female MYBPC3 c.1765C>G 
6 Homozygous male MYBPC3 c.1831G>A 
7 Homozygous male ALPK3 c.5294G>A 
8 Homozygous female ALPK3 c.3781C>T 
9 Digenic male MYBPC3 and MYL2 c.3065G>C and c.52T>C 
10 Digenic male MYBPC3 and MYL2 c.1000G>T and c.64G>A 
11 Digenic male MYH7 and MIB1 c.5135G>A and c.2530_2532delTCTinsC 
12 Digenic female MYL3 and TNNT2 c.452C>T and c.832C>T 
13 Compound heterozygous male MYBPC3  c.913_914delTT and c.1468G>A 
14 Compound heterozygous female MYBPC3  c.932C>A and c.442G>A 
15 Compound heterozygous male MYBPC3 c.2373insG and c.2827C>T 
16 Compound heterozygous male MYH7 c.3100-2A>C and c.5135G>A 
ALPK3, alpha kinase 3; MIB1, Mindbomb E3 ubiquitin protein ligase; MYBPC3, myosin binding protein C; 
MYL2, cardiac-regulatory myosin light chain; MYH7, ß-myosin heavy chain; MYL3, cardiac-essential myosin 
light chain. 
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ABSTRACT  
Background  
One of the first clinically detectable alterations in heart function in hypertrophic cardiomyopathy 
(HCM) is a decline in diastolic function. Diastolic dysfunction is caused by changes in intrinsic 
properties of cardiomyocytes and/or an increase in fibrosis. We investigated if clinical and cellular 
parameters of diastolic function are different between male and female HCM patients at the time of 
myectomy. 
Methods and Results  
Cardiac tissue from the interventricular septum of HCM patients (27 female; 44 male) was obtained 
during myectomy preceded by echocardiography. At myectomy, female patients were 7 years older 
than male patients, and showed more advanced diastolic dysfunction than men evident from 
significantly higher values for E/e’ ratio, LV filling pattern, TR velocity and left atrial diameter 
indexed for body surface. While most male patients (56%) showed mild (grade I) diastolic 
dysfunction, 50% of female patients showed grade III diastolic dysfunction. Passive tension in HCM 
cardiomyocytes was comparable to controls, and myofilament calcium-sensitivity was higher in HCM 
compared to controls, but no sex-differences were observed in myofilament function. In female HCM 
titin was more compliant and more fibrosis was present compared to males. Differences between 
female and male HCM patients remained significant after correction for age. 
Conclusion  
Female HCM patients are older at time of myectomy and show greater impairment of diastolic 
function. Furthermore, LV and LA remodeling is increased in women when corrected for body surface 
area. At cellular level HCM women showed increased compliant titin and a larger degree of interstitial 
fibrosis. 
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INTRODUCTION 
Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular (LV) 
hypertrophy.1 It is the most prevalent monogenetic inherited cardiac disease, with a prevalence of 200 
up to 500 per 100,000 individuals.2 In approximately 65% of patients with HCM, a causative mutation 
is identified which is inherited in an autosomal dominant fashion.3 Approximately 80% of identified 
mutations are located in two genes that encode the thick filament proteins, cardiac myosin binding 
protein C (cMyBP-C; gene MYBPC3) and β-myosin heavy chain (β-MyHC; gene MYH7).4 Despite 
increased knowledge of the HCM-causing mutations, the exact path from genetic defect to 
cardiomyopathy is still largely unknown. 
 LV hypertrophy in HCM patients is often asymmetric and mainly affects the interventricular 
septum (IVS), which causes LV outflow tract obstruction (LVOTO). HCM is defined by a wall 
thickness ≥ 15 mm, although a cut-off value of 13 mm applies to first-degree relatives.1 The 
hypertrophied myocardium is characterized by cardiomyocyte and myofilament disarray, reduced 
myofibrillar density, increased interstitial fibrosis and vascular abnormalities.5,6 While these structural 
changes are part of the more advanced (hypertrophied) stage of the disease, impaired relaxation is 
present at an early disease stage in mutation carriers without evident cardiac hypertrophy.7–9 
Interestingly, female HCM patients have been described to show less ventricular remodeling compared 
to male patients,10,11 while several studies reported more severe diastolic dysfunction in women than in 
men with HCM.12,13 Within the latest cohort studies, women represent a minority of HCM patients, 
with percentages ranging from 26% to 45%, suggesting lower disease penetrance in women.14,15 
Moreover, women are on average 9 years older than men at the time of HCM diagnosis.14,16 To better 
understand sex-differences in HCM pathology, we studied tissue properties of cardiac samples 
obtained during surgical myectomy from a clinically well-characterized group of female and male 
HCM patients carrying a thick filament (MYH7 or MYBPC3) mutation. A comparison was made 
between female and male HCM patients at the time of cardiac surgery. 
Our study shows that women are on average 7 years older than men at the time of surgery. 
Greater diastolic dysfunction was present in female compared to male HCM patients evident by 
diastolic grading. The sex-difference in diastolic function was not explained by intrinsic properties of 
the sarcomeres as similar increases in myofilament Ca2+-sensitivity and no changes in passive stiffness 
were observed in single cardiomyocytes isolated from female and male HCM hearts compared to non-
failing controls. A higher level of fibrosis in women compared to men may underlie the more severe 
impaired diastolic function in females, which was associated with an apparent compensatory shift 
towards more compliant titin isoform expression in female HCM hearts. Overall we see more severe 
changes in diastolic properties of the heart in female HCM patients compared to male HCM patients at 
the time of myectomy. Because the diagnostic criteria of LV wall thickness ≥15 mm does not take into 
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account body surface area, disease severity might be underestimated in female HCM patients and 
warrants future research.  
 
MATERIALS AND METHODS 
Myocardial Samples 
Our study included patients carrying mutations in MYH7 (n=17) and MYBPC3 (n=54), of which 38% 
were female (mean age 50±13 ranging from 6 to 72). Cardiac tissue from the IVS was obtained during 
myectomy surgery to relieve LVOTO. LV tissue from 37 non-failing donors without a history of 
cardiac abnormalities was used as control (51% female, mean age of 41±14 ranging from 14 to 65). 
All samples were immediately frozen and stored in liquid nitrogen. Not all samples were sufficiently 
large to perform all analysis. Clinical cut-off values are indicated by dotted lines in Figure 1. The 
average values of control cardiac samples are indicated by the dotted lines in Figures 2 to 5; data for 
male and female control samples are shown in Supplemental Figure 1. The study protocol was 
approved by the local Ethics Committees, and written consent was obtained. 
 
Echocardiographic measurements 
Echocardiographic studies were done with commercially available systems and analyzed according to 
the American Society of Echocardiography guidelines.17 Maximal wall thickness, left atrial diameter 
(LAD), LV end-diastolic diameter (LVEDD), and LVOTO gradient were measured. LVOTO was 
defined as a gradient ≥ 30 mmHg at rest or during provocation. Mitral valve inflow was recorded using 
pulsed wave Doppler from the apical four chamber view. Mitral E and A velocity (cm/s) and 
deceleration time (ms) were measured. Pulsed wave tissue Doppler imaging was used to measure 
septal e’ velocity (cm/s). Continuous wave Doppler in the parasternal and apical four chamber was 
used to measure tricuspid regurgitation (TR) velocity (m/s). 
 Diastolic dysfunction was graded as follows: grade I when E/A ratio ≤ 0.8 and E peak velocity 
≤ 50 cm/s; grade III when E/A ratio ≥ 2. In patients with E/A ratio ≤ 0.8 and E peak velocity > 50 cm/s 
or E/A ratio > 0.8 but < 2, the E/e’ ratio (>14), LADi (>24) and TR velocity (> 2.8 m/s) were used to 
further differentiate diastolic function. When ≥ 2 out of 3 variables  were abnormal, LA pressure was 
elevated and grade II diastolic dysfunction was present. When 1 out of 3 variables was abnormal, 
grade I diastolic dysfunction was present.18  
 
Isometric Force Measurements 
Force measurements were performed in mechanically isolated single membrane-permeabilized 
cardiomyocytes as described previously.19 In short, we measured passive tension at four sarcomere 
lengths (SL) ranging from 1.8 to 2.4 µm. All passive forces were normalized to cross-sectional area 
(CSA) (i.e. CSA = width x depth x π/4). To determine myofilament calcium-sensitivity (pCa50), active 
tension was measured at SL 2.2 µm, with different calcium concentrations.  
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Protein analyses  
Titin isoform gel electrophoresis was performed on patient samples as previously described.20 Samples 
were measured in triplicate, of which the mean was used. Phosphorylation of titin was assessed as 
previously described.21 Proteins were transferred to PVDF membrane (Roth) and these were blocked 
with 3% bovine serum albumin (BSA, Sigma). For assessment of titin phosphorylation, site-specific 
antibodies directed to Serine 4010 (N2Bunique sequence (N2Bus) domain; PKA and extracellular 
signal-regulated kinase 2 (ERK2) target), and Serine 11878 (PEVK domain; protein kinase C (PKC) 
and Ca2+/calmodulin dependent protein kinase II (CaMKIId) target) were used (Eurogentec Belgium), 
visualized with enhanced chemiluminescence detection kit (Amersham) and scanned with Amersham 
Imager 600. After stripping (RestoreTM Western Blot Stripping Buffer, Thermo Scientific), and 
blocking in 3% BSA membranes were incubated with an antibody directed to total titin (Eurogentech, 
Belgium), visualized with enhanced chemiluminescence detection kit (Amersham) and scanned with 
Amersham Imager 600. 
To determine cMyBP-C protein level, proteins were separated on 4-15% pre-cast Tris-HCl 
gels (BioRad) and stained with SYPRO Ruby. The level of cMyBP-C was expressed relative to α-
actinin. The same gels were stained with ProQ Diamond to determine phosphorylation of cMyBP-C.22 
The phosphorylation level of cMyBP-C was normalized to cMyBP-C expression and values given as a 
fraction of controls, which were set to 1. Phosphorylation of PKA sites in cardiac troponin I (cTnI) 
was analyzed using a specific antibody directed against serine 23 and 24 (Cell Signaling). The 
distribution of phosphorylated forms of cTnI was analyzed using Phos-tag acrylamide gels.23 
 Expression levels Ca2+-handling proteins phospholamban (PLN, Abcam) and sarcoplasmic 
reticulum Ca2+-ATPase 2 (SERCA2) were determined by Western blot analysis using specific 
antibodies and normalized to actin.  
 
Histomorphometrical analysis 
Histomorphological analysis was performed on 5 µm cryosections. Tissue was stained using Picro-
Sirius Red staining to determine the extent of interstitial and replacement fibrosis, expressed as 
collagen volume fraction (CVF %). Cardiomyocyte myofibril density (MFD) was determined in a 
subset of patients of all groups using Electron microscopy (EM) as described previously.24 The sum of 
myofibril area relative to cardiomyocyte area was expressed as a percentage.24,25   
 
Data Analysis 
Data in figures are presented as mean±standard error of the mean (SEM) per group. Data in tables is 
presented as mean±standard deviation (SD) per group. If data was normally distributed means were 
compared with a student’s T-test, a Mann-Whitney test was used when data was not normally 
distributed. To test sex-differences in abnormality of clinical data a Chi-square test was performed. 
Correlations were tested by means of linear regression. P<0.05 was considered significant, sex-
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differences are indicated by a hashtag (#) and differences in comparison to controls are indicated by an 
asterisk (*). As female HCM patients are on average older than male HCM patients additional analyses 
were performed in which we corrected for age at myectomy. For this we used a linear regression 
model with sex and age at myectomy as independent variables. Normality of residuals was checked. In 
case, residuals were not normally distributed a log-transformation was used for the dependent variable. 
The data and analytic methods are available to other researchers upon request for purposes of 
reproducing the results or replicating the procedure. 
 
RESULTS 
Female HCM patients are on average 7 years older at the time of myectomy 
Echocardiographic analysis was performed to study sex-differences in cardiac diastolic parameters 
(Table 1). Detailed characteristics and parameters per patient are provided in supplemental Table 1. 
Female HCM patients were on average 7 years older than their male counterparts at time of surgery 
(50±13 vs 43±13 years; p<0.05). IVS thickness was increased in all patients, meeting the wall 
thickness criteria of ≥ 15 mm, with a mean of 23±7 mm (Figure 1A). No difference was seen in 
absolute IVS thickness between women and men. LVEDD in our patient population was within 
normal range26 and showed no sex-difference (Table 1). LAD was increased compared to control 
values,26 but did not show a sex-difference.   
 
Greater impairment of in vivo diastolic function in female HCM patients at time of myectomy  
As diastolic impairment is one of the hallmarks of HCM, we looked for sex-differences in in vivo 
diastolic function assessed by echocardiography at the time of myectomy. Echocardiographic 
measurements of diastolic function included E/e’ ratio, E/A ratio and TR velocity (Table 1, Figure 
1).18,27  
E/e’ ratio is the ratio between early peak diastolic mitral valve flow (E in cm/s) and the 
movement of the mitral valve annulus during early diastole (e’ in cm/s). This ratio is a good indicator 
of LV filling pressure.28 An E/e’ ratio <8 implies normal filling pressure, while an E/e’ ratio >15 
indicates increased filling pressure.29 In 42 HCM patients E/e’ ratio was determined, of which 26 
showed an increased E/e’ ratio (92% of women and 48% of men; p<0.01). The average E/e’ ratio was 
also significantly higher in the female HCM group compared to males (Figure 1B; 23.8±7.8 vs 
14.8±3.4 respectively; p<0.0001). The normal range of LV filling pattern (E/A ratio) is between 0.8 
and 2, and only 33% of our female patients fit within this range compared to 67% of our male patients 
(Figure 1C; p=0.10). TR velocity showed higher values in female compared to male HCM patients 
(Figure 1D; 2.61±0.54 vs 2.15±0.54 respectively; p<0.05). Overall, LV filling pressure, LV filling 
pattern and TR velocity were more abnormal in HCM women than men (Figure 1). The differences in 
diastolic cardiac properties between female and male HCM patients remained even after correction for 
age (Table 1, P values corrected for age). 
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Table 1. Patient characteristics and echo parameters of diastolic function  
Table 1 shows the patient characteristics and echocardiographic parameters reflecting diastolic function grouped 
by sex as mean±SD. 1Linear regression on log(IVS). Residuals were normally distributed. Abbreviations: N 
(number of patients), IVS (inter ventricular septum); LVOTO (left ventricular outflow tract obstruction); 
LVEDD (left ventricular end-diastolic diameter); LAD (left atrial diameter); E (mitral E velocity); TR (tricuspid 
regurgitation) velocity. Detailed characteristics and parameters per patient are shown in supplemental Table 1, 2 
and 3 
 
Sex-differences in cardiac remodeling may be obscured by body size. IVS, LVEDD and LAD were 
therefore corrected for body surface area (BSA). After correction for BSA, indexed IVS thickness 
(IVSi) was significantly greater in HCM women compared to men with a difference of 2 mm/m2 
(Table 2). This might imply a more severe phenotype in our female HCM group. Correction of 
LVEDD for BSA did not reveal a sex-difference, while LA remodeling was affected more in female 
patients than in male patients evident from a significantly higher indexed LAD (LADi)(Table 2). 
Longstanding diastolic dysfunction leads to enlargement of the LA, with an LADi ≥ 24 considered to 
be abnormal.26 An LADi above this cut-off value was seen in 44% of our HCM patient cohort who 
were predominantly female (65%; p<0.01). The average LADi of male patients (22±3 mm/m2) falls 
within the normal range (15 to 24 mm/m2), while we observed a significantly larger average LADi in 
females (Figure 1E; 26±3 mm/m2; p<0.001). After correction for age, IVSi and LADi values were still 
significantly higher in female compared to male HCM patients (Table 2, P values corrected for age). 
 
Diastolic dysfunction can be graded into three groups: Abnormal (grade I), pseudo normal (grade II) 
and restrictive relaxation (grade III). We graded our patients and found a significant difference in 
distribution between female (n=15) and male (n=30) HCM patients (Figure 1F; p<0.0001). 50% of our 
female patients showed grade III diastolic dysfunction, while 56% of our male patients showed grade I 
diastolic dysfunction. Taken together, the echocardiographic data indicate a higher degree of diastolic 
dysfunction in HCM women at the time of myectomy. 
 
Sex Female (27) Male (44) N P value Distribution P value 
corrected for 
age 
Age at myectomy, years 50±13 (27) 43±13 (44) 71 <0.05 Normal  
IVS, mm  23±9 (26) 22±6 (40) 66 0.65 Not normal 0.331 
LVOTO, mmHg 66±31 (23) 58±32 (39) 62 0.34 Normal 0.39 
LVEDD, mm 43±5 (22) 43±6 (37) 59 0.81 Normal 0.77 
LAD, mm 48±7 (20) 45±7 (33) 53 0.26 Normal 0.10 
E, cm/s 95±35 (18) 74±21 (38) 56 <0.01 Normal 0.071 
E/A ratio 1.8±1.0 (15) 1.3±0.5 (33) 48 0.10 Normal <0.05 
E/e’ ratio 23.8±7.8 (13) 14.8±3.4 (29) 42 <0.0001 Normal <0.0001 
TR velocity, cm/s 2.61±0.54 (11) 2.15±0.54 (18) 29 <0.05 Normal <0.05 
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Table 2. LV and LA dimensions indexed for body surface area 
Indexed LV and LA dimension as mean±SD. 1Linear regression on IVSi. Residuals were normally distributed. 
Abbreviations: BSA, body surface area, IVSi (indexed interventricular septum thickness), LVEDDi (indexed left 
ventricular end-diastolic diameter), LADi (indexed left atrial diameter). Detailed characteristics and parameters 
per patient are shown in supplemental Table 1, 2 and 3. 
 
 
 
Figure 1. Influence of sex on echocardiographic parameters. A. Wall thickness of the interventricular septum 
was independent of sex (n=25(F)/44(M)). B. Female patients showed a higher E/e’ ratio compared to men 
(p<0.0001)(n=13(F)/29(M)). C. LV filling pattern determined by the E/A ratio was more abnormal in female 
HCM patients (p<0.05)(n=15(F)/33(M)). D. Tricuspid regurgitation (TR) velocity was higher in female than in 
male HCM patients (p<0.05)(n=11(F)/18(M)). 
TR
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Sex Female Male N P value Distribution P value 
corrected for 
Age 
BSA, m2 1.8±0.3 (19) 2.0±0.1 (34) 53 <0.001 Normal  
IVSi, mm/m2 13.3±5.3 (19) 10.5±1.8 (32) 51 <0.05 Not normal <0.011 
LVEDDi, mm/m2 23±3 (16) 21±3 (32) 48 0.12 Normal 0.10 
LADi, mm/m2 26±3 (17) 22±3 (28) 45 <0.001 Normal <0.01 
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Figure 1 (continued). Influence of sex on echocardiographic parameters. E. Indexed left atrial 
diameter was higher in female compared to male HCM patients (p<0.001)(n=17(F)/28(M)). F. 
Diastolic dysfunction graded per patient: Female patients show greater impairment compared to men 
(p<0.0001)(n=15(F)/30(M)). Significant sex-differences are depicted by #. HCM values are illustrated 
relative to published values in the general population (i.e. normal values, indicated by dotted lines and 
marked areas).1,18,29 
 
 
Cardiomyocyte stiffness is independent of sex  
Impaired relaxation may be caused by mutation-mediated changes in the intrinsic properties of 
cardiomyocytes, hypertrophy and/or an increase in fibrosis.8,30 At the cellular level, diastolic function 
can be influenced by passive tension of sarcomeres, which was assessed by single cardiomyocyte 
measurements. Data was compared to non-failing donor tissue to determine if the observed parameters 
deviate from control levels. Figure 2A demonstrates similar length-dependency of passive tension in 
female and male samples. Passive tension was not different between women (1.95±0.16 kN/m2) and 
men (1.91±0.10 kN/m2)(Figure 2B). Moreover, the HCM group did not significantly differ from 
control values (2.15±0.32 kN/m2). 
The number of myofibrils determine cellular passive tension and may be decreased as a result 
of hypertrophy.31 Therefore, passive tension was corrected for myofibril density (MFD). Figure 2C 
and D shows representative EM images of HCM tissue used to determine MFD. In line with our 
previous study,31 we found a significant decrease in MFD in HCM patients compared to controls 
(Figure 2E; 49±1% vs 65±2%; p<0.0001). No sex-difference in MFD was found in the HCM patient 
group. To test the hypothesis that the normal passive tension observed in HCM patients is caused by 
fewer but stiffer myofibrils, passive tension was corrected for MFD in a subset of patients (Figure 2F). 
Corrected passive tension was higher in HCM patients compared to controls, although not significantly 
(3.73±0.23 vs 2.88±0.42 respectively). Hence, passive tension of cardiomyocytes cannot explain the 
sex-difference in the degree of diastolic dysfunction. 
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Figure 2. Myofilament passive tension. A. Passive tension (Fpass) measured at different sarcomere 
lengths in female (n=9) and male (n=10) HCM samples. B. Passive tension was measured at a 
sarcomere length of 2.2 µm in a larger group of samples (15 female and 20 male HCM samples; 15 
controls). No sex-differences were observed in Fpass. C and D. Representative electron microscopy 
picture of a female and male HCM samples. E. Myofibril density was decreased in HCM patients 
(n=9(F)/15(M) in comparison to controls (n=9)(p<0.0001). F. Passive tension at a sarcomere length of 
2.2 µm corrected for myofibril density showed a trend towards an increase in HCM patients in 
comparison to controls (p=0.0623), but no sex-difference. Each data point reflects a mean of 
cardiomyocytes/EM pictures measured per patient. Significant differences between HCM and controls 
are depicted by *.  
  
D. 
5 µm 
Male 
Electron microscopy  
5 µm 
Female 
Electron microscopy  C. 
Sex-differences at the time of myectomy 
149 
 
Absence sex-difference in myofilament calcium-sensitivity 
Apart from high passive tension, high calcium-sensitivity may underlie impaired cellular relaxation.32 
From previous studies, it is known that calcium-sensitivity is increased in cardiomyocytes from HCM 
patients.33 Consistent with previous studies, an increase in myofilament calcium-sensitivity was 
observed in the HCM patient group compared to controls (Figure 3A and B; p<0.0001), but no 
influence of sex on calcium-sensitivity was found.  
 Disease-related changes in myofilament protein composition and phosphorylation may 
underlie altered myofilament function. Mutations in MYBPC3 were associated with reduced cMyBP-C 
expression (i.e. haploinsufficiency).34,35 Accordingly, in the present study we observed cMyBP-C 
haploinsufficiency in HCM patients carrying MYBPC3 mutations, which was independent of sex 
(females: 0.55±0.02 and males 0.55± 0.03 vs controls 0.81± 0.03; p<0.0001). Protein kinase A (PKA)-
mediated phosphorylation, via activation of the ß-adrenergic receptor pathway, is down-regulated in 
HCM.36 cMyBP-C and cTnI are sarcomeric proteins that are phosphorylated by PKA and thereby may 
influence myofilament function (i.e. reduction in myofilament calcium-sensitivity). In line with 
reduced PKA-mediated phosphorylation, phosphorylation levels of cMyBP-C were decreased in HCM 
patients (female 0.81± 0.07 and male 0.60± 0.07) compared to controls (1.00± 0.04; p<0.001). The 
sex-difference in overall cMyBP-C phosphorylation may be explained by site-specific phosphorylation 
differences between female and male as cMyBP-C is phosphorylated at multiple sites which are target 
for different kinases.37 The decrease was largest in male patients (Figure 3D). A decrease was also 
found in cTnI phosphorylation in HCM patients compared to controls (Figure 3D; F 0.35± 0.06 and M 
0.47± 0.09 vs controls 2.38± 0.49; p<0.0001). No sex-difference was found on cTnI phosphorylation. 
Accordingly, Phos-tag analyses of the different forms of cTnI phosphorylation (un-, mono-, and bis-
phosphorylated) showed a similar pattern in women and men (Figure 3F).  
 
Lower expression of Ca2+-handling proteins in myectomy samples from female compared to male HCM 
patients 
PLN and SERCA2 are key regulators of myocardial relaxation during diastole. PLN expression levels 
did not differ between HCM patients and controls (4.45±0.66). There was however a lower expression 
of PLN in female compared to male HCM patients (Figure 3F; 3.38±0.31 vs 4.44±0.33; p<0.05). 
SERCA2 expression was considerably lower in HCM patients (female 1.46±0.08 and male 1.79±0.12) 
compared to controls (Figure 3G; 3.34±0.24; p<0.0001). SERCA2 also showed a sex-difference with 
lower expression levels in female compared to male HCM patients (p<0.05). PLN/SERCA2 ratio was 
higher in HCM patients compared to controls (Figure 3G: female: 2.47±0.29 and male: 2.70±0.31 
versus controls: 1.32±0.18) but did not show a sex-difference.  
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Figure 3. Myofilament calcium-sensitivity. A. Calcium-force relationships at a sarcomere length of 
2.2 µm of female (n=11) and male (n=15) HCM samples are shifted to the left in comparison to 
controls (n=7). B. Myofilament calcium-sensitivity (pCa50) was significantly higher in HCM patients 
(p<0.0001; n=13(F)/18(M)) compared to controls (n=13), while no sex-difference was observed. Each 
data point reflects a mean of cardiomyocytes measured per patient. C. MyBP-C phosphorylation 
(p<0.001) was decreased in HCM patients (10 females/19 males) compared to controls (12). D and E. 
In comparison to controls (n=17), phosphorylation of cTnI was decreased in HCM patients (15 
females/18 males), with an even distribution in (un)phosphorylated cTnI forms between women and 
men. F. Phospholamban (PLN) expression was lower in female (n=16) than in male (n=30) HCM 
patients. G. SERCA2 expression was lower in HCM patients compared to controls (p<0.0001; n=11) 
with an even larger decrease in female than in male patients (p<0.05; 16 female /28 male). H. The 
PLN/SERCA2 ratio was higher in HCM patients compared to controls (p<0.05). Significant sex-
differences are depicted by #; Significant differences between HCM and controls are depicted by *. 
 
More compliant titin in female HCM patients 
Another important contributor to diastolic function is titin.38,39 Titin functions as a molecular spring 
thereby modulating passive stiffness of cardiomyocytes, and has been shown to regulate passive 
stiffness in an isoform-dependent manner.39 In cardiac muscle two major isoforms are identified: a 
short, more stiff isoform (N2B) and a long, more compliant isoform (N2BA). Both isoforms are co-
expressed within the human heart and can be displayed in a N2BA/N2B ratio to describe titin-based 
passive stiffness.  
A representative titin gel is depicted in Figure 4A. Sex had a profound effect on titin isoform 
composition in HCM patients, as women showed more compliant titin compared to men (Figure 4B; 
p<0.05). This sex-effect on titin composition was not seen in controls (0.58±0.06 (F) versus 0.70±0.09 
(M); mean value controls 0.63±0.20). The male HCM group (0.74±0.04) showed no difference 
compared to controls, but female HCM patients had more compliant titin isoform (1.00±0.10) 
compared to controls (p<0.01). The titin N2BA/N2B ratio significantly correlates with diastolic 
dysfunction (Figure 4C; p<0.01; R2 0.29).  
Phosphorylation of titin also influences passive stiffness of the cardiomyocytes. PKA-
mediated phosphorylation at serine 4010 decreases passive tension while PKC-mediated 
phosphorylation at serine 11878 increases passive tension.40,41 Representative blots of both 
phosphorylation sites are shown in Figure 4D. PKA phosphorylation did not show sex-differences 
(Figure 4E; female (n=10) 0.95±0.05 versus male (n=13) 0.96±0.07). In addition, no difference was 
observed in PKC phosphorylation of titin (Figure 4F; female (n=5) 1.07±0.19 versus male (n=6) 
1.21±0.31).  
Our data show that titin isoform changed in a sex-dependent manner with a shift towards a 
more compliant isoform in women, while no sex-differences in phosphorylation are present. The 
increase in compliant titin isoform appears to be related with the degree of diastolic dysfunction. 
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Figure 4. Increased compliant titin isoform in female HCM patients. A. Representative titin gel 
showing N2BA and N2B titin isoforms of HCM patients. B. N2BA/N2B ratio was increased in female 
(n=18) HCM patients in comparison to controls (p<0.01; n=15) and significantly higher than in male 
(n=20) HCM patients (p<0.05). C. Scatterplot showing a significant correlation (linear regression) 
between N2BA/N2B ratio and the grade of diastolic dysfunction (p<0.01; R2: 0.29) D. Representative 
titin phosphorylation blots of PKA and PKC sites on titin. E and F. Phosphorylation of both the PKA 
(serine 4010) and PKC (serine 11878) site did not show sex-differences. Each data point reflects a 
mean titin ratio measured per HCM patient and control. Significant sex-differences are depicted by #; 
Significant differences between HCM and controls are depicted by *. 
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More fibrosis in female HCM patients 
Stiffness of the cardiomyocyte is dependent on the cellular components mentioned above. However, 
changes in the extracellular matrix can influence cardiac stiffness as well. Both replacement-, and 
interstitial fibrosis are known to increase in HCM patients during remodeling, and negatively influence 
cardiac compliance.42,43 Figure 5A shows representative images of Picro-Sirius red stainings, from 
which CVF was determined. As expected our controls showed little fibrosis (1.21±0.23%), and no 
differences were found between women and men. CVF in HCM patients was significantly increased 
compared to control values (p<0.0001), with a significantly larger increase in female HCM patients 
compared to males (Figure 5B; 6.42±0.95 versus 4.18±0.66%; p<0.05). 
Sex-differences in titin isoform composition and fibrosis in the HCM patient group remained after 
correction for age, while no significant sex-difference was present for the Ca2+-handling proteins 
SERCA2 and PLN after age correction (Table 3). 
  
 
Table 3: Protein analyses: differences between males and females before and after correction for age. 
 
 
 
 
Figure 5. Higher amounts of fibrosis in HCM women. A. Representative Picro-Sirius red staining on a female 
(11.9%) and male (4.4%) HCM sample. The deep red staining depicts fibrosis. B. Fibrosis was higher in female 
compared to male HCM patients (p<0.05). Furthermore, the HCM group in total showed more fibrosis compared 
to controls (p<0.0001). Each data point reflects a mean collagen volume fraction measured per HCM patient. 
Significant sex-differences are depicted by #; Significant differences between HCM and controls are depicted by 
*. 
Protein N (female/male) P value Distribution P value corrected for age 
PLN/actin 
SERCA2/actin 
16/30 
16/28 
<0.05 
<0.05 
Not normal 
Normal 
0.090 
0.054 
Titin N2BA/N2B 18/20 <0.05 Normal <0.05 
Fibrosis 11/13 <0.05 Not  normal <0.05 
A. Picro Sirius red staining 
F 11.9% M 5.5%  
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DISCUSSION 
Here, we investigated if changes in diastolic characteristics of the heart in HCM patients at the time of 
cardiac surgery are sex-dependent.  Main findings of the study are that women with HCM have greater 
diastolic dysfunction than men at the time of surgery, apparent from the increased LV filling pressures, 
altered filling pattern, greater TR velocities and more pronounced LA remodeling. Factors contributing 
to impaired relaxation in HCM are increased calcium-sensitivity and fibrosis, with fibrosis being 
higher in women. Furthermore, the compliant titin isoform is increased in female HCM patients, 
suggesting a sex-difference in the compensatory response to the progression of diastolic dysfunction.  
  In this study, female HCM patients that underwent myectomy were on average 7 years older at 
time of surgery than men. Olivotto et al. found an age difference of 9 years at time of diagnosis and 
initial evaluation, with more advanced symptoms in female HCM patients.14 A number of other studies 
have confirmed these findings.15,44,45 Women are underrepresented in the patient population in the 
present (38%) and multiple previous HCM studies (~40%).10,14–16,43–48 We found greater diastolic 
dysfunction in our female HCM patients, which is in line with a previous study.12 The preload-
independent measure for diastolic function (E/e’ ratio) was in the pathological range in 92% of our 
female HCM patient group compared to 48% of the male group. Increases in LAD reflect the chronic 
burden of increased diastolic pressures on the LA.46 In most of our HCM population LAD was 
increased, confirming previous studies.49,50 We did not find a sex-difference in the absolute values of 
LAD, but after indexing LAD for BSA, LADi was significantly higher in women than in men. LADi 
values in our female HCM group range from moderately to severely abnormal, while in our male 
group values range from normal to mildly abnormal.26 LV wall thickness of ≥15 mm is currently the 
diagnostic criteria for HCM, without adjustment for BSA or sex.1 In line with earlier published data, 
absolute IVS thickness is independent of sex.47,48 However, when we indexed IVS thickness for BSA, 
female patients show a greater IVSi compared to male patients. The increases of LADi and IVSi in our 
female patients could simply be due to the more advanced age. However, there was no correlation 
between age and IVSi and only a weak positive correlation between age and LADi (p<0.01;R2=0.20). 
There were only two parameters that significantly correlated with age: LV filling pressure (E/e’) 
increases with age, while phospholamban expression decreases with age in both males and females 
(Supplemental Figure 2). In addition, after correction for age in vivo echocardiographic parameters of 
diastolic dysfunction and cardiac remodeling (IVS, and LADi) remained significantly different 
between female and male HCM patients (Tables 1 and 2). Overall, our data show a more severe stage 
of cardiac dysfunction and remodeling in females than in males at the time of myectomy.  
On a cellular level, titin is an important contributor to cardiomyocyte stiffness and thereby 
diastolic function. Specifically the ratio between the stiffer N2B isoform and the more compliant 
N2BA isoform.51,52 Our group of non-failing control samples had a titin isoform ratio of 0.63±0.20 
which is comparable to previously published data.53–55 We showed for the first time a higher 
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N2BA/N2B ratio in female compared to male HCM patients. However, titin phosphorylation by PKA 
and PKC did not show sex-differences. As no sex-difference in passive tension was observed, other 
post-translational modifications of titin (e.g. induced by oxidative stress)56 may counterbalance the 
higher level of compliant titin isoform in women. A correlation, independent of sex, was found 
between diastolic dysfunction and titin composition, which implies that the switch to longer titin 
isoforms is an attempt to compensate for the impaired relaxation. Despite the titin isoform change, 
women still show more severe diastolic dysfunction. A rat study showed that under metabolic stress 
female rats show an increase of the compliant titin isoform.38 Furthermore, ovariectomized rats show 
an even greater increase, suggesting an influence of female hormones on titin isoform switch during 
stress. Estrogen does not seem to have a direct effect on titin isoform expression but could, during 
stress, act as a modulator enabling isoform switch.38 The increase in titin compliance could also be a 
reaction to the increase in interstitial fibrosis seen in HCM patients, a correlation, however, was not 
found. Previous clinical studies in HCM patients showed more fibrosis in men,10,57 except for Chen et 
al.12 who showed no sex-difference. These studies have measured fibrosis through late gadolinium 
enhancement. Measuring interstitial fibrosis with the latter technology is not possible and might 
explain the contrast to our results.  
Although more compliant titin isoform was observed in female compared to male HCM, we 
did not observe a sex-difference in cardiomyocyte passive tension. Moreover, HCM values did not 
differ from control values. In line with our results, Hoskins et al. did not find a difference in passive 
tension between HCM cardiomyocytes and controls.58 Correction for MFD also did not reveal a 
significant sex-difference in passive tension. The increase in myofilament calcium-sensitivity in HCM 
cardiomyocytes could partly explain the diastolic dysfunction, although our data suggests that sex is 
not an influencing factor regarding calcium-sensitivity. The lower expression of PLN and SERCA2 in 
female compared to male HCM patients may underlie the sex-difference in diastolic dysfunction, 
although the PLN/SERCA2 ratio did not differ between female and male patients. 
   
Limitations and clinical implications 
Our study focused on patients who underwent myectomy, while many HCM patients receive alcohol 
septal ablation (ASA) to relieve LVOTO. As age and disease severity may differ between ASA and 
myectomy patients, the gender difference observed in the present study may not apply to the ASA 
group. Most HCM patient samples included in our study came from the Erasmus Medical Center. In a 
20-year period (1996-2016), 23% of patients received ASA at the Erasmus Medical Center. There was 
no age difference between the ASA and myectomy group (52±16 vs 52±15 years), and in both groups 
60% was male. Previous single and multicenter studies which compared outcome in ASA and 
myectomy patients showed that the age at the time of intervention was slightly higher in the ASA than 
in the myectomy group, but no differences were present in baseline functional/anatomical 
characteristics of the heart (similar maximal wall thickness, LVOT gradient, systolic and diastolic 
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dysfunction).59–61 Thus, currently there are no indications that disease severity is different between 
ASA and myectomy patients. 
The number of MYBPC3 mutations in our study is high compared to the previously reported average 
MYBPC3 mutation frequency (~20%).62 In the Netherlands, HCM is dominated by 3 MYBPC3 founder 
mutations,63 which is why the percentage of MYBPC3 compared to MYH7 is relatively high. This may 
limit translation of our observations to the general HCM population, because of differences in disease 
onset and progression between mutation groups. However, no difference was found in disease 
penetrance between MYBPC3 founder mutations and other MYBPC3 mutations.63 A recent meta-
analysis by Sedaghat-Hamedani and colleagues reported an average mutation frequency of 20% in 
MYBPC3 and 14% in MYH7.62 The meta-analysis showed a lower mean age of onset in MYH7 (35 
years) compared to MYBPC3 (39 years), and a higher risk of ventricular tachycardia in MYH7 
compared to MYBPC3, while no differences were observed in mean IVS thickness and LVOTO. The 
age of onset showed large heterogeneity in all mutation groups which is characteristic for HCM. 
Nannenberg and colleagues showed increased mortality risk in specific age categories (ranging from 
10-19 years to 50-59 years) in HCM families with MYBPC3 mutations.64 These studies show that 
disease onset and progression are highly variable in all mutation groups. In our patient group, no 
difference was observed in age of onset, LVOTO and IVS thickness between MYH7 and MYBPC3 
mutation groups, indicating that the clinical indications for myectomy were similar in both groups. 
Moreover, both mutation groups had a similar percentage of women, respectively 41% in the MYH7 
mutation group (7 out of 17) and 37%  in the MYBPC3 mutation group (20 out of 54). The average age 
distribution was also comparable in both mutation groups (mean age: MYH7 group: 49 years in 
females, 44 years in males; MYBPC3 group: 48 years in females, 44 years in males). 
To conclude, our clinical data shows that women are older at time of operation and have more 
advanced diastolic dysfunction, even upon correction for age. We found increased titin compliance, 
lower PLN and SERCA2 expression and more interstitial fibrosis in female compared to male HCM 
patients. Data from our HCM patient group suggests that disease severity may be underestimated in 
women with a similar IVS, but higher IVSi compared to men. 
 
Acknowledgments 
We would like to give special thanks to Dirk de Jong who has been a great help by digitalizing all of 
our EM pictures. We thank Peter van de Ven for statistical analyses. We acknowledge the support 
from the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart 
Foundation, CVON2011-11 ARENA. 
 
Disclosures: none.  
 
  
Sex-differences at the time of myectomy 
157 
 
REFERENCES 
1.  Authors/Task Force members, Elliott PM, 
Anastasakis A, Borger MA, Borggrefe M, Cecchi F, 
Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt 
H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri 
S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns 
C, Watkins H. 2014 ESC Guidelines on diagnosis and 
management of hypertrophic cardiomyopathy: the Task 
Force for the Diagnosis and Management of Hypertrophic 
Cardiomyopathy of the European Society of Cardiology 
(ESC). Eur Heart J. 2014;35:2733–2779. 
  
2.  Baudhuin LM, Kotzer KE, Kluge ML, 
Maleszewski JJ. What Is the True Prevalence of 
Hypertrophic Cardiomyopathy? J Am Coll Cardiol. 
2015;66:1845–1846. 
  
3.  Marian AJ. Hypertrophic cardiomyopathy: from 
genetics to treatment. Eur J Clin Invest. 2010;40:360–369. 
  
4.  Richard P, Charron P, Carrier L, Ledeuil C, 
Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, 
Burban M, Gueffet J-P, Millaire A, Desnos M, Schwartz K, 
Hainque B, Komajda M. Hypertrophic Cardiomyopathy 
Distribution of Disease Genes, Spectrum of Mutations, and 
Implications for a Molecular Diagnosis Strategy. 
Circulation. 2003;107:2227–2232. 
  
5.  Brouwer WP, van Dijk SJ, Stienen GJM, van 
Rossum AC, van der Velden J, Germans T. The 
development of familial hypertrophic cardiomyopathy: from 
mutation to bedside. Eur J Clin Invest. 2011;41:568–578. 
  
6.  Güçlü A, Happé C, Eren S, Korkmaz IH, Niessen 
HWM, Klein P, van Slegtenhorst M, Schinkel AF, Michels 
M, van Rossum AC, Germans T, van der Velden J. Left 
ventricular outflow tract gradient is associated with 
reduced capillary density in hypertrophic cardiomyopathy 
irrespective of genotype. Eur J Clin Invest. 2015;45:1252–
1259. 
  
7.  Michels M, Soliman OII, Kofflard MJ, 
Hoedemaekers YM, Dooijes D, Majoor-Krakauer D, ten 
Cate FJ. Diastolic Abnormalities as the First Feature of 
Hypertrophic Cardiomyopathy in Dutch Myosin-Binding 
Protein C Founder Mutations. JACC Cardiovasc Imaging. 
2009;2:58–64. 
  
8.  Germans T, Rüssel IK, Götte MJ, Spreeuwenberg 
MD, Doevendans PA, Pinto YM, Geest RJ van der, Velden 
J van der, Wilde AA, Rossum AC van. How do 
hypertrophic cardiomyopathy mutations affect myocardial 
function in carriers with normal wall thickness? 
Assessment with cardiovascular magnetic resonance. J 
Cardiovasc Magn Reson. 2010;12:13. 
  
9.  Ho CY, Carlsen C, Thune JJ, Havndrup O, 
Bundgaard H, Farrohi F, Rivero J, Cirino AL, Andersen PS, 
Christiansen M, Maron BJ, Orav EJ, K?ber L. 
Echocardiographic Strain Imaging to Assess Early and 
Late Consequences of Sarcomere Mutations in 
Hypertrophic Cardiomyopathy. Circ Cardiovasc Genet. 
2009;2:314–321. 
  
10.  Schulz-Menger J, Abdel-Aty H, Rudolph A, Elgeti 
T, Messroghli D, Utz W, Boyé P, Bohl S, Busjahn A, Hamm 
B, Dietz R. Gender-specific differences in left ventricular 
remodelling and fibrosis in hypertrophic cardiomyopathy: 
Insights from cardiovascular magnetic resonance. Eur J 
Heart Fail. 2008;10:850–854. 
  
11.  Leinwand LA. Sex is a potent modifier of the 
cardiovascular system. J Clin Invest. 2003;112:302–307. 
  
12.  Chen Y-Z, Qiao S-B, Hu F-H, Yuan J-S, Yang 
W-X, Cui J-G, Zhang Y, Zhang C-L. Left ventricular 
remodeling and fibrosis: Sex differences and relationship 
with diastolic function in hypertrophic cardiomyopathy. Eur 
J Radiol. 2015;84:1487–1492. 
  
13.  Borlaug BA, Redfield MM, Melenovsky V, Kane 
GC, Karon BL, Jacobsen SJ, Rodeheffer RJ. Longitudinal 
changes in left ventricular stiffness: a community-based 
study. Circ Heart Fail. 2013;6:944–952. 
  
14.  Olivotto I, Maron MS, Adabag AS, Casey SA, 
Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ. 
Gender-related differences in the clinical presentation and 
outcome of hypertrophic cardiomyopathy. J Am Coll 
Cardiol. 2005;46:480–487. 
  
15.  Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato 
K, Yamasaki N, Matsumura Y, Yabe T, Doi YL. Gender-
specific differences in the clinical features of hypertrophic 
cardiomyopathy in a community-based Japanese 
population: results from Kochi RYOMA study. J Cardiol. 
2010;56:314–319. 
  
Chapter 9 
158 
 
16.  Bos JM, Theis JL, Tajik AJ, Gersh BJ, Ommen 
SR, Ackerman MJ. Relationship between sex, shape, and 
substrate in hypertrophic cardiomyopathy. Am Heart J. 
2008;155:1128–1134. 
  
17.  Nagueh SF, Bierig SM, Budoff MJ, Desai M, 
Dilsizian V, Eidem B, Goldstein SA, Hung J, Maron MS, 
Ommen SR, Woo A. American Society of 
Echocardiography Clinical Recommendations for 
Multimodality Cardiovascular Imaging of Patients with 
Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr. 
2011;24:473–498. 
  
18.  Nagueh SF, Smiseth OA, Appleton CP. 
Recommendations for the Evaluation of Left Ventricular 
Diastolic Function by Echocardiography: An Update from 
the American Society of Echocardiography and the 
European Association of Cardiovascular Imaging. J Am 
Soc Echocardiogr. 2016:277–314. 
  
19.  Velden J van der, Klein LJ, Bijl M van der, 
Huybregts M a. JM, Stooker W, Witkop J, Eijsman L, 
Visser CA, Visser FC, Stienen GJM. Isometric tension 
development and its calcium sensitivity in skinned 
myocyte-sized preparations from different regions of the 
human heart. Cardiovasc Res. 1999;42:706–719. 
  
20.  Warren CM, Krzesinski PR, Greaser ML. Vertical 
agarose gel electrophoresis and electroblotting of high-
molecular-weight proteins. Electrophoresis. 2003;24:1695–
1702. 
  
21.  Kötter S, Kazmierowska M, Andresen C, 
Bottermann K, Grandoch M, Gorressen S, Heinen A, Moll 
JM, Scheller J, Gödecke A, Fischer JW, Schmitt JP, 
Krüger M. Titin-Based Cardiac Myocyte Stiffening 
Contributes to Early Adaptive Ventricular Remodeling After 
Myocardial Infarction. Circ Res. 2016;119:1017–1029. 
 
22.  Zaremba R, Merkus D, Hamdani N, Lamers JMJ, 
Paulus WJ, Dos Remedios C, Duncker DJ, Stienen GJM, 
van der Velden J. Quantitative analysis of myofilament 
protein phosphorylation in small cardiac biopsies. 
Proteomics Clin Appl. 2007;1:1285–1290. 
  
23.  Kinoshita E, Kinoshita-Kikuta E, Takiyama K, 
Koike T. Phosphate-binding Tag, a New Tool to Visualize 
Phosphorylated Proteins. Mol Cell Proteomics. 
2006;5:749–757. 
  
24.  Heerebeek L van, Borbély A, Niessen HWM, 
Bronzwaer JGF, Velden J van der, Stienen GJM, Linke 
WA, Laarman GJ, Paulus WJ. Myocardial Structure and 
Function Differ in Systolic and Diastolic Heart Failure. 
Circulation. 2006;113:1966–1973. 
  
25.  Hamdani N, Paulus WJ, van Heerebeek L, 
Borbély A, Boontje NM, Zuidwijk MJ, Bronzwaer JGF, 
Simonides WS, Niessen HWM, Stienen GJM, van der 
Velden J. Distinct myocardial effects of beta-blocker 
therapy in heart failure with normal and reduced left 
ventricular ejection fraction. Eur Heart J. 2009;30:1863–
1872. 
  
26.  Lang RM, Bierig M, Devereux RB, Flachskampf 
FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward 
J, Shanewise J, Solomon S, Spencer KT, Sutton MSJ, 
Stewart W. Recommendations for chamber quantification. 
Eur Heart J - Cardiovasc Imaging. 2006;7:79–108. 
  
27.  Nagueh SF, Lakkis NM, Middleton KJ, Spencer 
WH, Zoghbi WA, Quiñones MA. Doppler Estimation of Left 
Ventricular Filling Pressures in Patients With Hypertrophic 
Cardiomyopathy. Circulation. 1999;99:254–261. 
  
28.  Arques S, Roux E, Luccioni R. Current clinical 
applications of spectral tissue Doppler echocardiography 
(E/E’ ratio) as a noninvasive surrogate for left ventricular 
diastolic pressures in the diagnosis of heart failure with 
preserved left ventricular systolic function. Cardiovasc 
Ultrasound. 2007;5:16. 
  
29.  Ommen SR, Nishimura RA, Appleton CP, Miller 
FA, Oh JK, Redfield MM, Tajik AJ. Clinical Utility of 
Doppler Echocardiography and Tissue Doppler Imaging in 
the Estimation of Left Ventricular Filling Pressures. 
Circulation. 2000;102:1788–1794. 
  
30.  Zile MR, Brutsaert DL. New Concepts in Diastolic 
Dysfunction and Diastolic Heart Failure: Part II Causal 
Mechanisms and Treatment. Circulation. 2002;105:1503–
1508. 
  
31.  Witjas-Paalberends ER, Piroddi N, Stam K, Dijk 
SJ van, Oliviera VS, Ferrara C, Scellini B, Hazebroek M, 
Cate FJ ten, Slegtenhorst M van, Remedios C dos, 
Niessen HWM, Tesi C, Stienen GJM, Heymans S, Michels 
M, Poggesi C, Velden J van der. Mutations in MYH7 
reduce the force generating capacity of sarcomeres in 
human familial hypertrophic cardiomyopathy. Cardiovasc 
Res. 2013;99:432–441. 
Sex-differences at the time of myectomy 
159 
 
 32.  Sequeira V, Najafi A, McConnell M, Fowler ED, 
Bollen IAE, Wüst RCI, dos Remedios C, Helmes M, White 
E, Stienen GJM, Tardiff J, Kuster DWD, van der Velden J. 
Synergistic role of ADP and Ca2+ in diastolic myocardial 
stiffness. J Physiol. 2015;593:3899–3916. 
 
33.  Sequeira V, Wijnker PJM, Nijenkamp LLAM, 
Kuster DWD, Najafi A, Witjas-Paalberends ER, Regan JA, 
Boontje N, Cate FJ ten, Germans T, Carrier L, 
Sadayappan S, Slegtenhorst MA van, Zaremba R, Foster 
DB, Murphy AM, Poggesi C, Remedios C dos, Stienen 
GJM, Ho CY, Michels M, Velden J van der. Perturbed 
Length-Dependent Activation in Human Hypertrophic 
Cardiomyopathy With Missense Sarcomeric Gene 
Mutations. Circ Res. 2013;112:1491–1505. 
 
34.  Dijk SJ van, Paalberends ER, Najafi A, Michels 
M, Sadayappan S, Carrier L, Boontje NM, Kuster DWD, 
Slegtenhorst M van, Dooijes D, Remedios C dos, Cate FJ 
ten, Stienen GJM, Velden J van der. Contractile 
Dysfunction Irrespective of the Mutant Protein in Human 
Hypertrophic Cardiomyopathy With Normal Systolic 
FunctionClinical Perspective. Circ Heart Fail. 2012;5:36–
46. 
 
35.  Marston S, Copeland O, Jacques A, Livesey K, 
Tsang V, McKenna WJ, Jalilzadeh S, Carballo S, 
Redwood C, Watkins H. Evidence From Human Myectomy 
Samples That MYBPC3 Mutations Cause Hypertrophic 
Cardiomyopathy Through Haploinsufficiency. Circ Res. 
2009;105:219–222. 
 
36.  van Dijk SJ, Holewijn RA, Tebeest A, dos 
Remedios C, Stienen GJM, van der Velden J. A piece of 
the human heart: variance of protein phosphorylation in left 
ventricular samples from end-stage primary 
cardiomyopathy patients. J Muscle Res Cell Motil. 
2009;30:299–302. 
 
37.  Sadayappan S, de Tombe PP. Cardiac myosin 
binding protein-C as a central target of cardiac sarcomere 
signaling: a special mini review series. Pflugers Arch. 
2014;466:195–200. 
 
38.  Bupha-Intr T, Oo YW, Wattanapermpool J. 
Increased myocardial stiffness with maintenance of length-
dependent calcium activation by female sex hormones in 
diabetic rats. Am J Physiol Heart Circ Physiol. 
2011;300:H1661-1668. 
 
 
39.  Opitz CA, Leake MC, Makarenko I, Benes V, 
Linke WA. Developmentally regulated switching of titin size 
alters myofibrillar stiffness in the perinatal heart. Circ Res. 
2004;94:967–975. 
  
40.  Kötter S, Gout L, Von Frieling-Salewsky M, Müller 
AE, Helling S, Marcus K, Dos Remedios C, Linke WA, 
Krüger M. Differential changes in titin domain 
phosphorylation increase myofilament stiffness in failing 
human hearts. Cardiovasc Res. 2013;99:648–656. 
  
41.  Hidalgo C, Hudson B, Bogomolovas J, Zhu Y, 
Anderson B, Greaser M, Labeit S, Granzier H. PKC 
phosphorylation of titin’s PEVK element: a novel and 
conserved pathway for modulating myocardial stiffness. 
Circ Res. 2009;105:631–638, 17 p following 638. 
  
42.  Noureldin RA, Liu S, Nacif MS, Judge DP, 
Halushka MK, Abraham TP, Ho C, Bluemke DA. The 
diagnosis of hypertrophic cardiomyopathy by 
cardiovascular magnetic resonance. J Cardiovasc Magn 
Reson. 2012;14:17. 
  
43.  Kitamura M, Shimizu M, Ino H, Okeie K, 
Yamaguchi M, Fujino N, Mabuchi H, Nakanishi I. Collagen 
remodeling and cardiac dysfunction in patients with 
hypertrophic cardiomyopathy: The significance of type III 
and VI collagens. Clin Cardiol. 2001;24:325–329. 
  
44.  Dimitrow PP, Czarnecka D, Jaszcz KK, Dubiel JS. 
Sex differences in age at onset of symptoms in patients 
with hypertrophic cardiomyopathy. J Cardiovasc Risk. 
1997;4:33–35. 
  
45.  Terauchi Y, Kubo T, Baba Y, Hirota T, Tanioka K, 
Yamasaki N, Furuno T, Kitaoka H. Gender differences in 
the clinical features of hypertrophic cardiomyopathy 
caused by cardiac myosin-binding protein C gene 
mutations. J Cardiol. 2015;65:423–428. 
  
46.  Yang H, Woo A, Monakier D, Jamorski M, 
Fedwick K, Wigle ED, Rakowski H. Enlarged left atrial 
volume in hypertrophic cardiomyopathy: a marker for 
disease severity. J Am Soc Echocardiogr Off Publ Am Soc 
Echocardiogr. 2005;18:1074–1082. 
  
47.  Dimitrow PP, Czarnecka D, Kawecka-Jaszcz K, 
Dubiel JS. The influence of age on gender-specific 
differences in the left ventricular cavity size and 
contractility in patients with hypertrophic cardiomyopathy. 
Int J Cardiol. 2003;88:11–16. 
Chapter 9 
160 
 
 48.  Charron P, Dubourg O, Desnos M, Bennaceur M, 
Carrier L, Camproux AC, Isnard R, Hagege A, Langlard 
JM, Bonne G, Richard P, Hainque B, Bouhour JB, 
Schwartz K, Komajda M. Clinical features and prognostic 
implications of familial hypertrophic cardiomyopathy 
related to the cardiac myosin-binding protein C gene. 
Circulation. 1998;97:2230–2236. 
 
49.  Badran HM, Soltan G, Hassan H, Nazmy A, 
Faheem N, Saadan H, Yacoub MH. Changes in left atrial 
deformation in hypertrophic cardiomyopathy: Evaluation by 
vector velocity imaging. Glob Cardiol Sci Pract. 
2013;2012:67–80. 
 
50.  Paraskevaidis IA, Panou F, Papadopoulos C, 
Farmakis D, Parissis J, Ikonomidis I, Rigopoulos A, 
Iliodromitis EK, Kremastinos DT. Evaluation of left atrial 
longitudinal function in patients with hypertrophic 
cardiomyopathy: a tissue Doppler imaging and two-
dimensional strain study. Heart. 2009;95:483–489. 
 
51.  Linke WA, Popov VI, Pollack GH. Passive and 
active tension in single cardiac myofibrils. Biophys J. 
1994;67:782–792. 
 
52.  Cazorla O, Freiburg A, Helmes M, Centner T, 
McNabb M, Wu Y, Trombitás K, Labeit S, Granzier H. 
Differential expression of cardiac titin isoforms and 
modulation of cellular stiffness. Circ Res. 2000;86:59–67. 
 
53.  Neagoe C, Kulke M, del Monte F, Gwathmey JK, 
de Tombe PP, Hajjar RJ, Linke WA. Titin isoform switch in 
ischemic human heart disease. Circulation. 
2002;106:1333–1341. 
 
54.  Williams L, Howell N, Pagano D, Andreka P, 
Vertesaljai M, Pecor T, Frenneaux M, Granzier H. Titin 
isoform expression in aortic stenosis. Clin Sci Lond Engl 
1979. 2009;117:237–242. 
 
55.  Nagueh SF, Shah G, Wu Y, Torre-Amione G, 
King NMP, Lahmers S, Witt CC, Becker K, Labeit S, 
Granzier HL. Altered titin expression, myocardial stiffness, 
and left ventricular function in patients with dilated 
cardiomyopathy. Circulation. 2004;110:155–162. 
 
56.  Beckendorf L, Linke WA. Emerging importance 
of oxidative stress in regulating striated muscle elasticity. J 
Muscle Res Cell Motil. 2015;36:25–36. 
 
 
57.  Conte MR, Bongioanni S, Chiribiri A, Leuzzi S, 
Lardone E, Di Donna P, Pizzuti A, Luceri S, Cesarani F, 
Mabritto B, Zoccai GB, Bonamini R, Gaita F. Late 
gadolinium enhancement on cardiac magnetic resonance 
and phenotypic expression in hypertrophic 
cardiomyopathy. Am Heart J. 2011;161:1073–1077. 
  
58.  Hoskins AC, Jacques A, Bardswell SC, McKenna 
WJ, Tsang V, dos Remedios CG, Ehler E, Adams K, 
Jalilzadeh S, Avkiran M, Watkins H, Redwood C, Marston 
SB, Kentish JC. Normal passive viscoelasticity but 
abnormal myofibrillar force generation in human 
hypertrophic cardiomyopathy. J Mol Cell Cardiol. 
2010;49:737–745. 
  
59.  Valeti US, Nishimura RA, Holmes DR, Araoz PA, 
Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, 
Rihal CS, Schaff HV, Maron BJ. Comparison of surgical 
septal myectomy and alcohol septal ablation with cardiac 
magnetic resonance imaging in patients with hypertrophic 
obstructive cardiomyopathy. J Am Coll Cardiol. 
2007;49:350–357. 
  
60.  ten Cate FJ, Soliman OII, Michels M, Theuns 
DAMJ, de Jong PL, Geleijnse ML, Serruys PW. Long-term 
outcome of alcohol septal ablation in patients with 
obstructive hypertrophic cardiomyopathy: a word of 
caution. Circ Heart Fail. 2010;3:362–369. 
  
61.  Vriesendorp PA, Liebregts M, Steggerda RC, 
Schinkel AFL, Willems R, Ten Cate FJ, van Cleemput J, 
Ten Berg JM, Michels M. Long-term outcomes after 
medical and invasive treatment in patients with 
hypertrophic cardiomyopathy. JACC Heart Fail. 
2014;2:630–636. 
  
62.  Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, 
Lai A, Amr A, Haas J, Proctor T, Ehlermann P, Jensen K, 
Katus HA, Meder B. Clinical outcomes associated with 
sarcomere mutations in hypertrophic cardiomyopathy: a 
meta-analysis on 7675 individuals. Clin Res Cardiol Off J 
Ger Card Soc. 2017; 
 
63.  Christiaans I, Nannenberg EA, Dooijes D, 
Jongbloed RJE, Michels M, Postema PG, Majoor-Krakauer 
D, van den Wijngaard A, Mannens MMAM, van Tintelen 
JP, van Langen IM, Wilde AAM. Founder mutations in 
hypertrophic cardiomyopathy patients in the Netherlands. 
Neth Heart J. 2010;18:248–254. 
  
Sex-differences at the time of myectomy 
161 
 
64.  Nannenberg EA, Michels M, Christiaans I, 
Majoor-Krakauer D, Hoedemaekers YM, van Tintelen JP, 
Lombardi MP, ten Cate FJ, Schinkel AFL, Tijssen JGP, 
van Langen IM, Wilde AAM, Sijbrands EJG. Mortality Risk 
of Untreated Myosin-Binding Protein C–Related 
Hypertrophic CardiomyopathyInsight Into the Natural 
History. J Am Coll Cardiol. 2011;58:2406–2414.  
 
 
 
 
  
Chapter 9 
162 
 
CLINICAL PERSPECTIVE  
What is new? This study shows sex-differences in HCM patients at the time of myectomy with respect 
to diastolic (dys)function and parameters influencing passive stiffness on a cellular level. Female 
HCM patients showed a higher degree of diastolic dysfunction (measured by echocardiography) at the 
time of myectomy. At a cellular level female HCM patients showed a higher amount of fibrosis and 
more compliant titin compared to male HCM patients. One of the diagnostic criteria for HCM is a 
septal thickness of >15 mm, which was independent of sex.  However, when corrected for body mass 
index, we found a higher indexed IVS thickness in female compared to male HCM patients.  
What are the clinical implications? The higher indexed IVS thickness in women implies a more 
progressed state of HCM in women than in men at time of surgery. The degree of diastolic dysfunction 
and sex-related cellular differences may be explained by the progression of the disease. Future 
research  is needed to investigate if sex-specific diagnostic protocols (indexed for body mass) are 
warranted.  
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SUMMARY 
Genetic testing and family screening  
A pathogenic mutation is identified in 50-60% of patients with HCM.(1) Information on the prognostic 
value of genotype is currently limited.(2) Therefore, in chapter 1 we studied the clinical phenotype 
and outcome of 234 genotype-positive (G+) and 278 genotype-negative (G-) patients with HCM. At 
first evaluation, G+ probands were younger than G- probands, had more non-sustained ventricular 
tachycardia, more often a history of syncope and more extreme hypertrophy. In contrast, G- probands 
were more symptomatic and had higher left ventricular outflow tract gradients. Most likely, other 
genetic variants and lifestyle factors (hypertension) are involved in the pathophysiological process of 
G- HCM.(3-5) In comparison to probands, relatives with HCM who were identified via family 
screening were younger and had a more benign phenotype. It seems that family screening leads to the 
detection of disease in an earlier stage.(6) During 12±9 years follow-up of HCM probands, G+ status 
was an independent risk factor of all-cause mortality, cardiovascular mortality, heart failure related 
mortality, and sudden cardiac death (SCD). These findings are consistent with prior studies that 
demonstrate a predictive value of G+ status for adverse outcome.(7-10) In order to develop genotype-
specific risk-assessment and targeted therapies, fundamental research on the pathophysiological 
consequences of sarcomere mutations is crucial.(11, 12)  
 
Myosin-binding protein C (MYBPC3) founder mutations have been identified in populations in 
Iceland, Italy, Finland, Japan, France, and the Netherlands(13) and have arisen from common 
ancestors many generations ago.(14, 15). In the Netherlands, 35% of HCM cases are caused by 3 
MYBPC3 founder mutations: c.2373dupG (p.Trp792Valfs*41), c.2827C>T (p.Arg943*), and 
c.2864_2865delCT (p.Pro955fs*95).(13, 14, 16) They cause C-terminally truncated protein leading to 
haploinsufficiency(17-19), and are associated with a reduced force generating capacity of 
cardiomyocytes, cardiomyocyte hypertrophy and reduced myofibril density.(17, 20) In chapter 2, we 
analyzed 271 individuals with Dutch MYBPC3 founder mutations (134 probands and 128 relatives), 
and compared the clinical findings and outcome with that of 132 nonfounder G+ probands with HCM 
and 277 G- probands with HCM. There was no difference between MYBPC3 founder mutation HCM 
and nonfounder mutation G+ HCM, contradicting the existing notion that MYBPC3 founder HCM is 
more benign than HCM caused by other mutations.(15, 16, 21, 22) In this study we also compared 
patients with HCM who presented with signs or symptoms of disease and relatives who presented in 
the context of family screening. Relatives with HCM had significantly better clinical outcome, most 
likely reflecting earlier disease stages. This illustrates that the way of presentation has important 
prognostic value. Again, our study demonstrated the extreme phenotypic variability in individuals with 
the same mutation. In fact, a small proportion of the individuals with MYBPC3 founder mutations had 
non-compaction or dilated cardiomyopathy instead of HCM. This was partly explained by multiple 
sarcomere mutations. Indeed, the phenotypic variability which we observe in genetically homogeneous 
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groups is most likely explained by additional sarcomere or nonsarcomere mutations, and otherwise by 
nongenetic factors.(23) Further collaborative bench-to-bedside investigation is needed to unravel this 
genotype-phenotype ‘’black box’ (figure 1). 
 
 
 
Figure 1. The genotype-phenotype ‘’black box’’. 
 
 
When HCM is diagnosed in a patient, cardiologists need to inform the patient about the genetic aspect 
of the disease and organize appropriate cardiac evaluation of their relatives.(24) Guidelines have 
encouraged family screening by electrocardiography and echocardiography since 2003, with 
evaluations starting at the age of 10 years and repeating evaluations until advanced age.(25-28) Recent 
European guidelines recommend to include genetic testing (GT) in the screening strategy(25); a cost-
effective approach (29, 30) which allows the reassurance and discharge of genotype-negative relatives 
and the identification of G+ relatives at risk for the development of HCM.(24) In chapter 3, we 
evaluated the results of this contemporary screening strategy by analyzing GT results and clinical 
findings in 777 relatives descending from 209 patients with HCM. GT was performed in the majority 
of patients (93%) and relatives (80%) leading to the reassurance and discharge of 356 (46%) genotype-
negative relatives. First cardiac evaluation in 264 G+ relatives and 157 relatives without GT revealed 
HCM in 37% and 17% respectively. During follow-up, cardiac mortality among relatives with HCM 
was lower than is generally observed in patients with HCM (0.3%/y vs 1-2%/y) reflecting early 
disease stages and possibly, the effect of lifestyle modifications, periodic SCD risk evaluation and 
close clinical follow-up. In the 165 G+ relatives without HCM only one SCD occurred which was 
attributable to a long-QT mutation, illustrating a benign prognosis. During 7 years of 
echocardiographic follow-up in 178 relatives without HCM (65% G+), 29 (16%) developed subtle 
HCM (24 G+). Interestingly, the development of HCM was not observed during adolescence, which is 
thought to be a notorious phase for the development of HCM due to hormonal changes.(31) 
Conversion was rather observed before the age of 12 years and between the ages of 20 and 30 years. 
Therefore, we propose cardiac evaluations to be initiated earlier i.e. at the age of 8 years, repeating 
them every 2-4 years in children and once every 5 years in adults, which may be continued until  
advanced age. From the results in this study we conclude that GT facilitates HCM family screening by 
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reducing the number of clinical screening visits to the outpatient clinic. However, the feasibility of this 
screening strategy depends on on the genetic yield in the probands and on the uptake of GT in the 
families, both of which were relatively high in this study. The high genetic yield may partly be 
explained by the high prevalence of MYBPC3 founder mutations in the Netherlands(14, 32), and partly 
by a referral bias since relatives from G+ families are informed about the confirmed heritability of 
HCM and the HCM burden in G+ families is likely to be higher.(33) The high uptake of GT can be 
explained by the fact that GT is covered by our national basic health care insurance and because 
cardiac evaluation and genetic counselling and testing is offered simultaneously at our cardio-genetic 
outpatient clinic. Other countries have different financial and organizational approaches regarding GT 
in the HCM population. We must be aware of the potential psychosocial, emotional, and financial 
consequences of GT, especially since the prognostic value of genotype for disease-onset and risk is 
currently still limited.(2) In children, we generally do not perform GT before the age of 18 years. 
 
Imaging in hypertrophic cardiomyopathy 
Due to the age-related penetrance of sarcomere mutations, lifelong follow-up is advised in G+ 
relatives who do not express the clinical HCM phenotype (‘’HCM mutation carriers’’).(25, 26) 
Currently, we are unable to predict the development of HCM in HCM mutation carriers. Prior cross-
sectional investigations have identified pre-phenotypic markers, such as diastolic dysfunction(34-36), 
altered myocardial energetics(37), electrocardiography abnormalities(38), myocardial crypts(39-41), 
and mitral leaflet elongation(39, 42-44). However, longitudinal follow-up studies of HCM mutation 
carriers are scarce.(45) Since the development of HCM in HCM mutation carriers is generally very 
slow and occurs infrequently, it takes a considerable amount of time before enough data is collected. 
In the following two chapters we studied several functional and morphological features in HCM 
mutation carriers and performed longitudinal follow-up in order to assess its predictive value for the 
development of HCM. In chapter 4, we used two-dimensional echocardiography to measure anterior 
mitral valve leaflet (AMVL) length in 133 HCM mutation carriers and 135 healthy controls. AMVL 
length did not differ between the groups. In the 13/80 mutation carriers who developed HCM, AMVL 
length had no predictive value in contrast to pathological Q waves, E/e’ ratio and maximal wall 
thickness. These findings contradict the concept that AMVL elongation is a primary phenotypic 
feature of HCM.(39, 42-44) The etiology of AMVL elongation in patients with HCM is still 
unclear.(46) In chapter 5, we used speckle tracking echocardiography to assess the global longitudinal 
strain (GLS) in 120 HCM mutation carriers and 110 healthy controls. In patients with HCM, previous 
studies consistently demonstrate a reduced GLS indicating subclinical systolic dysfunction.(47-51) 
GLS was statistically higher in HCM mutation carriers than in controls, however many of the 
measurements overlap. In the 13/80 mutation carriers who developed HCM during follow-up, GLS 
had no predictive value. And so, GLS is not a useful parameter to discriminate HCM mutation carriers 
from normal individuals nor a useful predictor for the development of HCM. Why GLS is increased in 
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HCM mutation carriers is currently unclear. It might be a result of mutation-induced cardiomyocyte 
hypercontractility or a compensatory mechanism for regional hypocontractility.(52, 53) Indeed, 
whether sarcomere mutations cause hyper- or hypocontractility of the cardiomyocyte is subject to 
ongoing investigations.(54) Fundamental research has an important role in identifying primary triggers 
for the development of HCM.  
 
The usefulness of three-dimensional echocardiography (3DE) has been demonstrated in the evaluation 
of LV volumes and mass and visualization of heart valves.(55-58) In chapter 6, we investigated the 
usefulness of 3DE for the assessment of LV hypertrophy and papillary muscle (PM) morphology. We 
obtained 3DE images in 24 patients with HCM and 31 healthy controls, and identified a spiral pattern 
of LV hypertrophy in the patients with HCM. Also, we found that both PMs were significantly larger 
in patients with HCM than in controls, and enlargement of the posteromedial PM was associated with 
LV outflow obstruction. Since the location and morphology of the PM is important for determining the 
mechanism causing LV outflow obstruction and thus for determining the appropriate technique to 
relieve outflow obstruction(59), 3DE might in the future be of clinical value. Additional research is 
however needed to study the feasibility and reproducibility of 3DE imaging in the evaluation of PM 
morphology. 
 
Clinical aspects of hypertrophic cardiomyopathy 
Atrial fibrillation (AF) is the most common arrhythmia in patients with HCM and an independent 
predictor of morbidity and mortality, mainly heart failure or stroke-related.(60, 61) Due to the high 
incidence of stroke, lifelong therapy with oral anticoagulants is recommended in all patients with 
HCM and AF, even when sinus rhythm is restored and irrespective of the CHA2DS2-VASc score.(25, 
26) AF can be difficult to detect, due to the often episodic and paroxysmal nature. Guidelines 
recommend 24-48 hour ambulatory electrocardiographic monitoring every 6-12 months, depending on 
the size of the left atrium.(25) Patients with a cardiac implantable electronic device (CIED) often have 
continuous monitoring of atrial activity, allowing for the detection of subclinical AF. In chapter 7 we 
studied the incidence and impact of device-detected AF in 114 patients with HCM and a CIED. During 
2.8 years follow-up, the annual incidence of device-detected AF was 7%, which is high in comparison 
to the previously reported incidence of AF in patients with HCM (2-3%).(62) This might be related to 
the fact that patients with a CIED have more advanced disease. Also, the device may have detected 
more AF episodes in comparison to traditional intermittent monitoring strategies. Since some of the 
patients included in the study had devices without atrial sensing capabilities, an underestimation of the 
incidence might have occurred. The incidence of thromboembolism was relatively low (1.3%), 
possibly because oral anticoagulants were initiated, and the majority of AF cases were consequently 
treated with antiarrhythmic medication or electrocardioversion. The findings in this study demonstrate 
the added value of CIEDs in the detection of AF and the implications for management. It might be a 
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stimulus for physicians to consider devices which allow atrial sensing, such as a single-chamber 
system with a floating bipole in the atrium.(63)  
 
Gender differences have been observed in many cardiovascular diseases, such as ischemic heart 
disease, heart failure, hypertension, and aortic valve stenosis.(64) In HCM, gender has been proposed 
to impact the age of onset and the phenotype.(4, 65-75) In addition, some studies found an 
independent association between female sex and all-cause mortality(76, 77), while other studies did 
not.(67, 78, 79). In chapter 8 we analyzed the clinical presentation, phenotype, genotype, and 
outcomes of 1007 patients (620 male, 387 female) who were evaluated between 1977 and 2017. We 
found that at presentation female patients were older, more frequently had a history of hypertension, 
and presented more frequently with symptoms. In addition, female patients more frequently had an 
impaired systolic and diastolic function and more frequently exhibited LVOT obstruction. During 6.8 
years follow-up, female patients had increased all-cause mortality, cardiovascular mortality, and HF 
related mortality. Multivariable cox regression analysis demonstrated that the worse survival in 
women was attributable to the worse baseline status. We did not find an independent association 
between female sex and mortality. Why female patients present at a more advanced age in a worse 
condition is currently unclear. Sociocultural processes (lack of attention to early clinical signs in 
women or diagnostic bias) or differences in sexual hormones and gene expression possibly account for 
the delay.(64, 65, 78, 80, 81) Interestingly, we found that adjusting echocardiographic indices to body 
surface area (more specifically, maximal wall thickness, left atrial size, and left ventricular end-
diastolic dimension) changed the clinical picture of females versus males dramatically, so that it 
illustrated a worse phenotype in females than we would suspect based on unadjusted indices. 
Currently, indices are not adjusted to body surface area which may have caused undertreatment of 
women by underestimation of disease severity. Additional gender studies are needed to elaborate on 
these findings. Future studies are needed to investigate further the cause of delayed diagnosis in 
women in order to try to advance diagnosis in women and thus improve outcome.  
 
Finally, in chapter 9 we go from bedside-to-bench by studying sex-differences in the 
echocardiographic (E/e’ ratio, E/A ratio, tricuspid regurgitation, left atrial size) and cellular (passive 
tension, myofilament Ca2+ sensitivity, expression of Ca2+ handling proteins, titin isoform expression, 
interstitial fibrosis) parameters of diastolic function in patients with HCM. Cardiac tissue was obtained 
during surgical myectomy in 71 patients (38% female) preceded by echocardiography. Females were 
significantly older at the time of myectomy, and diastolic function was more severely affected than in 
males. The cellular analyses revealed more interstitial fibrosis in females, but no sex-difference  
regarding passive tension or myofilament Ca2+ sensitivity. Compliant titin isoform was increased in 
women, possibly reflecting a compensatory mechanism. Overall, the data showed a more severe stage 
of cardiac remodeling in females than in males at the time of myectomy. In addition, the current study 
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supports previous literature which states that women with HCM have a delayed clinical 
presentation.(65, 78) Factors causing this delay are unclear and warrant additional investigations. 
Again, since wall thickness was significantly higher in women than in men after correction for body 
surface area but appeared to be similar to men before correction to body surface area, we postulate that 
maybe disease severity is underestimated in women due to the fact that currently HCM diagnosis is 
based on absolute cutoff values of wall thickness without adjusting to gender or body surface area.  
 
FUTURE PERSPECTIVES 
Ultimate goals in the HCM scientific field are to prevent the development of HCM, improve quality of 
life and decrease symptoms associated with HCM, and to prevent life-threatening events (sudden 
cardiac death, stroke, heart failure). In order to realize this, we need to define all causes of HCM, 
unravel the pathophysiological pathways which lead from mutation to disease, and improve the risk 
stratification for sudden cardiac death and heart failure.  
 
Advances in genetic testing 
Currently, a pathogenic mutation is identified in about 50-60% of patients with HCM.(1) Whole-
exome and whole-genome sequencing may uncover novel disease-causing genes. These new 
technologies demand major efforts regarding the handling of data and variant interpretation.(82) This 
includes the time-consuming manual analysis of large amounts of variants in order to select those most 
likely to have clinical relevance.(82) Subsequently, variants are classified into one of 5 classes 
(pathogenic, likely pathogenic, etcetera), a process which involves several steps including a literature 
review, co-segregation analysis, the use of predictive tools and in-vitro studies.(83) Genotype-negative 
HCM (in particular, the nonfamilial HCM subtype(84)) has a better prognosis and different clinical 
features (chapter 1). In order to fully understand the pathophysiology of genotype-negative HCM, 
future studies investigating disease modifiers such as (epi)genetic variations and environmental 
triggers are needed.(11) Also, the extreme phenotypic variability observed among individuals carrying 
the same pathogenic mutation (chapter 2) underlines the complexity of the HCM pathophysiology. 
Further collaborative bench-to-bedside investigation is needed to unravel this genotype-phenotype 
‘’black box’. (11, 12, 85)  
 
Improved phenotyping 
Advanced imaging studies using speckle-tracking and three-dimensional echocardiography, cardiac 
magnetic resonance, and positron emission tomography(86), may reveal structural or functional 
disease manifestations of sarcomere mutations. Genotype-positive, phenotype-negative family 
members are ideal for gaining insight into the early manifestations of HCM (chapters 4 and 5). Future 
longitudinal follow-up studies are needed to further improve risk stratification. Since in HCM most 
follow-up studies are limited by little outcome-related events, large multicenter collaborations such as 
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the HCMR study(87) and the SHARE registry (https://theshareregistry.org/) are needed to identify 
novel risk markers, such as late gadolinium enhancement, T1 mapping (extracellular volume), 
genetics, and biomarkers (markers of fibrosis).  
 
Gender differences 
Women with HCM present later in life with more advanced disease in comparison to men. Adjusting 
echocardiographic parameters to body surface area revealed a worse phenotype in women than was 
suspected based on unadjusted parameters (chapters 8 and 9). Whether diagnostic bias or other 
sociocultural processes are accountable or if hormones and gene expression cause this delay is still 
unknown.(64) Therefore, future gender studies are needed to investigate further the cause of delayed 
diagnosis in women and assess whether using gender- or body surface area-adjusted parameters would 
improve the treatment and outcome of women with HCM. 
 
Future therapeutic strategies 
Unraveling the pathophysiology of HCM is necessary for the design of novel drugs which can prevent 
the onset and progression of HCM. For example, studies in human cardiac muscle revealed that the 
myocardial energetics were impaired, suggesting there is a therapeutic potential for myocardial energy 
modulators.(88) The ENERGY trial will investigate whether energy deficiency could be a therapeutic 
target to prevent the onset of HCM (http://www.amsterdamresearch.org/web/instituut-
1/nieuws/tonenop/400k-grant-for-research-into-hypertrophic-cardiomyopathy.htm). Other examples of 
potential therapies include gene correction(89), myosin inhibitors(90), late sodium current 
inhibitors(91), and calcium and sodium channel blockers(92).(12) Large multicenter collaborations 
with long-term follow-up, such as the LIBERTY-HCM trial(93) and the EXPLORER-HCM trial 
(https://clinicaltrials.gov/ct2/show/NCT03470545) are needed for randomized controlled trials to have 
enough power to demonstrate alterations in disease progression or survival. 
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Hypertrofische cardiomyopathie (HCM) is de meest voorkomende erfelijke hartziekte met een 
prevalentie van 1:500 tot 1:200.(1, 2) De definitie van HCM is een hartspierverdikking dat niet 
veroorzaakt wordt door hoge bloeddruk of aortaklepvernauwing.(3) HCM wordt veroorzaakt door 
mutaties in genen die coderen voor eiwitten met een functie in het sarcomeer; de kleinste zich 
herhalende structuur in spiervezels die zorgen voor het samentrekken van de spier.(3)  
 
Genetisch onderzoek en familiescreening in hypertrofische cardiomyopathie 
In ongeveer 50-60% van de patienten met HCM die genetisch onderzoek ondergaan wordt een 
pathogene mutatie ontdekt.(4) Een mutatie is pathogeen als zeker is dat het de ziekte veroorzaakt na 
raadpleging van de literatuur en databases.(5) De prognostische waarde van genotype (i.e. het wel of 
niet hebben van een pathogene mutatie) is momenteel beperkt.(6) In hoofdstuk 1 analyseerden wij de 
klinische kenmerken en lange termijn uitkomsten van 234 genotype-positieve (G+) en 278 genotype-
negatieve (G-) patienten met HCM. Ten tijde van de eerste cardiale evaluatie waren G+ patienten 
jonger dan G- patienten en vertoonden zij meer kenmerken die geassocieerd zijn met een verhoogd 
risico op plotse hartdood. Zo hadden zij meer non-sustained ventriculaire tachycardieen, waren zij 
vaker gecollabeerd in het verleden en waren er meer gevallen van extreme hypertrofie. G- patienten 
waren symptomatischer en hadden hogere drukgradienten over de uitstroombaan van het linker 
ventrikel. Waarschijnlijk spelen nog onontdekte genetische varianten en leefstijl factoren (hypertensie) 
een rol in de pathofysiologie van G- HCM.(7-9) Familieleden met HCM die zich presenteerden via 
familieonderzoek waren jonger en hadden een betere prognose dan patienten met HCM die zich 
presenteerden met signalen of symptomen van HCM. Waarschijnlijk is de HCM in de familieleden in 
een vroeger ziektestadium ontdekt.(10) Gedurende 12±9 jaar follow-up was G+ status een 
onafhankelijke risicofactor voor algehele mortaliteit, cardiovasculaire mortaliteit, hartfalen-
gerelateerde mortaliteit en plotse hartdood. Deze bevindingen zijn overeenkomstig met voorgaande 
onderzoeken.(11-14) Fundamenteel onderzoek naar de pathofysiologische gevolgen van sarcomeer 
mutaties is cruciaal voor de ontwikkeling van genotype-specifieke risicostratificatie en gerichte 
therapieen.(15, 16)  
 
Myosin-binding protein C (MYBPC3) founder mutaties zijn geidentificeerd in IJsland, Italie, Finland, 
Japan, Frankrijk en Nederland.(17) Het zijn mutaties die meerdere generaties oud zijn en een 
gezamenlijke voorouder hebben.(18, 19) In Nederland wordt maar liefst 35% van de HCM gevallen 
veroorzaakt door 1 van de 3 MYBPC3 founder mutaties: c.2373dupG (p.Trp792Valfs*41), c.2827C>T 
(p.Arg943*), en c.2864_2865delCT (p.Pro955fs*95).(17, 18, 20) De mutaties leiden tot inkorting van 
de C-terminus van het MYBPC3 eiwit en haploinsufficientie.(21-23) Hartspierweefselonderzoek van 
patienten met HCM laat een associatie zien tussen MYBPC3 founder mutaties en een verminderde 
kracht genererende capaciteit van de cardiomyocyt, cardiomyocyt hypertrofie en een verlaagde 
myofibril dichtheid.(21, 24) In hoofdstuk 2 vergeleken wij de klinische kenmerken en lange termijn 
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uitkomsten tussen 271 individuen met een MYBPC3 founder mutatie (134 patienten, 128 
familieleden), 132 nonfounder G+ patienten met HCM en 277 G- patienten met HCM. Het fenotype en 
de prognose van MYBPC3 founder HCM was vergelijkbaar met dat van nonfounder G+ HCM; een 
bevinding die in strijd is met de heersende gedachte dat MYBPC3 founder HCM een goedaardiger 
beloop kent.(19, 20, 25, 26) Familieleden die via familiescreening waren gediagnosticeerd met HCM 
hadden een betere prognose dan patienten die zich hadden gepresenteerd wegens signalen of 
symptomen van HCM, meest waarschijnlijk doordat familieleden zich in een vroeger ziektestadium 
bevinden. Tot slot laat deze MYBPC3 founder mutatie populatie een extreme fenotypische 
heterogeniteit zien. Sommige individuen waren gediagnosticeerd met non-compactie of dilaterende 
cardiomyopathie. Additionele sarcomeermutaties of andere nongenetische factoren zullen een rol 
spelen.(27) Toekomstig translationeel onderzoek is nodig om deze genotype-fenotype ‘’black box’’ te 
ontrafelen (figuur 1). 
 
Figuur 1. De genotype-fenotype ‘’black box’’. 
 
 
Wanneer HCM wordt gediagnosticeerd bij een patient dient de behandelend cardioloog de patient te 
informeren over het genetische aspect van de ziekte en familieonderzoek aan te bieden aan zijn of haar 
familieleden.(28) Sinds het jaar 2003 adviseert de HCM richtlijn om familieonderzoek te organiseren 
door gebruik te maken van electro- en echocardiografie.(3, 29-31) Hierbij wordt aangeraden om de 
evaluaties aan te bieden vanaf de leeftijd van 10 jaar en deze te herhalen tot vergevorderde leeftijd. De 
recente Europese HCM richtlijn raadt aan om genetisch onderzoek (GO) toe te voegen aan de 
screening strategie(3); een kost-effectieve benadering.(32, 33) Deze strategie maakt het mogelijk om 
G- familieleden gerust te stellen en te ontslaan uit de screening. Daarnaast bewerktstelligt het de 
identificatie van G+ familieleden die een verhoogd risico lopen om HCM te ontwikkelen.(28) In 
hoofdstuk 3 hebben wij deze hedendaagse screening strategie geevalueerd door de resultaten van het 
GO en de klinische bevindingen te analyseren in 777 familieleden die van 209 patienten met HCM 
afstammen. De meerderheid van de patienten (93%) en familieleden (80%) hebben GO ondergaan. Al 
met al heeft deze benadering geleid to de geruststelling van 356 (46%) familieleden. De cardiale 
evaluatie in 264 G+ familieleden en 157 familieleden zonder GO onthulde HCM in 37% en 17% 
respectievelijk. De cardiale mortaliteit tijdens follow-up van familieleden met HCM was lager dan de 
cardiale mortaliteit dat over het algemeen beschreven is bij patienten met HCM (0.3%/jaar t.o.v. 1-
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2%/jaar). Dit reflecteert het vroegere ziektestadium waarin familieleden zich bevinden en mogelijk het 
effect van leefstijladviezen en intense follow-up met periodieke risicostratificatie voor plotse hart 
dood. De prognose van de 165 G+ familieleden zonder HCM was benigne. Één G+ familielid zonder 
HCM overleed plotseling waarbij GO een mutatie aantoonde dat geassocieerd is met het lang-QT 
syndroom. Gedurende 7 jaar echocardiografische follow-up van 178 familieleden zonder HCM (65% 
G+) ontwikkelden 29 (16%) een milde vorm van HCM (24 G+). Opmerkelijk genoeg ontwikkelde 
HCM zich niet tijdens de adolescentie, een periode dat berucht zou zijn voor de ontwikkeling van 
HCM door hormonale veranderingen.(34) HCM ontwikkelde zich met name voor de leeftijd van 12 
jaar en tussen de leeftijd van 20 en 30 jaar. Daarom stellen wij voor om cardiale evaluaties vroeger te 
initiëren (vanaf 8 jaar) om ze vervolgens iedere 2-4 jaar te herhalen in kinderen en adolescenten en 
iedere 5 jaar in volwassenen en dit te continueren tot vergevorderde leeftijd. Gezien de resultaten van 
de huidige studie concluderen wij dat GO het HCM familieonderzoek faciliteert doordat het het aantal 
polikliniekbezoeken bedoeld voor cardiale screening aanzienlijk reduceert. De haalbaarheid van deze 
strategie hangt af van het aantal mensen dat GO wilt ondergaan en de opbrengst van het GO in de 
patienten. In onze patientenpopulatie was de genetische opbrengst relatief hoog, hetgeen verklaard kan 
worden door de hoge prevalentie van MYBPC3 founder mutaties in Nederland.(18, 35) Tevens kan er 
een vertekening door verwijzing zijn opgetreden doordat familieleden van G+ families zijn 
geinformeerd over de erfelijkheid van HCM; de ziektelast in G+ families is waarschijnlijk ook 
hoger.(36) Daarnaast waren in onze patientenpopulatie relatief veel mensen bereid om GO te 
ondergaan, waarschijnlijk doordat in Nederland de kosten worden vergoed door de zorgverzekering en 
doordat genetische counselling, GO en cardiale evaluatie simultaan worden aangeboden. Andere 
landen hebben diverse financiele en organisatorische benaderingen omtrent GO in de HCM populatie. 
We moeten ons bewust zijn van de potentiële psychosociale, emotionele en financiele consequenties 
van GO, met name omdat de prognostische waarde van genotype beperkt is.(6) We bieden over het 
algemeen geen GO aan aan individuen jonger dan 18 jaar. 
 
Beeldvorming van hypertrofische cardiomyopathie 
Wegens leeftijdsgerelateerde penetrantie van sarcomeer mutaties wordt levenslange follow-up 
geadviseerd aan G+ familieleden zonder HCM (‘’mutatiedragers’’).(3, 30) Momenteel kunnen wij niet 
voorspellen welke mutatiedrager HCM gaat ontwikkelen. Eerdere studies hebben pre-fenotypische 
kenmerken geïdentificeerd zoals diastolische disfunctie(37-39), aantasting van de energiehuishouding 
van het myocard(40), electrocardiografische afwijkingen(41), myocard crypten(42-44) en mitralisklep 
verlenging(42, 45-47). Longitudinale follow-up studies van mutatiedragers zijn schaars.(48) Doordat 
HCM zich langzaam en infrequent ontwikkelt kan het lang duren voordat genoeg data is verzameld. In 
hoofdstuk 4 hebben wij door middel van twee-dimensionale echocardiografie de lengte van het 
voorste mitralis klepblad (VMK) in 133 mutatiedragers en 135 gezonde controles gemeten; er was 
geen verschil. In de 13/80 mutatiedragers die HCM ontwikkelden tijdens follow-up had VMK lengte 
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geen voorspellende waarde, in tegenstelling tot pathologische Q golven, E/e’ ratio en maximale 
wanddikte. Deze bevindingen zijn tegenstrijdig met voorgaande studies die rapporteren dat de VMK 
verlenging een primaire uiting is van HCM.(42, 45-47) De etiologie van VMK verlenging in patienten 
met HCM is nog onduidelijk.(49) In hoofdstuk 5 gebruikten we speckle-tracking echocardiografie om 
de globale longitudinale strain (GLS) in 120 mutatiedragers en 110 gezonde controles te meten. 
Eerdere studies hebben consequent aangetoond dat de GLS verminderd is in patienten met HCM en 
een normale linker ventrikel ejectiefractie, hetgeen subklinische systolische disfunctie aanduidt.(50-
54) In onze studiepopulatie was de GLS statistisch significant hoger in de mutatiedragers, echter de 
individuele metingen vertoonden veel overlap. GLS had geen voorspellende waarde voor de 
ontwikkeling van HCM in de 13/80 mutatiedragers die HCM hebben ontwikkeld tijdens follow-up. 
GLS is dus geen geschikte parameter om mutatiedragers te onderscheiden van gezonde mensen noch 
een bruikbare voorspeller voor de ontwikkeling van HCM. Waarom de GLS hoger is in mutatiedragers 
is onduidelijk. Hypercontractiliteit zou geinduceerd kunnen zijn door de mutatie.(55) Anderzijds zou 
het een compensatiemechanisme kunnen zijn voor regionale hypocontractiliteit.(56) Of sarcomeer 
mutaties hyper- of hypocontractiliteit veroorzaken wordt aanhoudend onderzocht.(57) Fundamenteel 
onderzoek heeft een belangrijke rol in de identificatie van primaire triggers voor de ontwikkeling van 
HCM. 
 
De bruikbaarheid van drie-dimensionale echocardiografie (3DE) is aangetoond voor de evaluatie van 
linker ventrikel volume en massa en voor de visualisatie van hartkleppen.(58-61) In hoofdstuk 6 
onderzochten wij de bruikbaarheid van 3DE voor het beoordelen van linker ventrikel hypertrofie en 
papillairspier morfologie. Door middel van 3DE analyse in 24 patienten met HCM en 31 gezonde 
controles identificeerden wij een spiraalvormig patroon van de linker ventrikel hypertrofie in de 
patienten. Voorts waren de papillairspieren significant groter in de patienten dan in de controles. 
Vergroting van de posteromediale papillairspier was geassocieerd met linker ventrikel uitstroombaan 
obstructie. 3DE heeft potentieel klinische waarde in deze patientenpopulatie omdat het beoordelen van 
de locatie en morfologie van de papillairspier belangrijk is om het mechanisme van linker ventrikel 
uitstroombaan obstructie te beoordelen. Dit bepaalt namelijk onder andere welke techniek gewenst is 
om de obstructie te verhelpen.(62) Toekomstig onderzoek is verreist om de haalbaarheid en 
reproducibiliteit van 3DE bij patienten met HCM te evalueren. 
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Klinische aspecten van hypertrofische cardiomyopathie 
Atriumfibrilleren (AF) is de meest voorkomende ritmestoornis onder patienten met HCM en een 
onafhankelijke risicofactor voor morbiditeit en mortaliteit, voornamelijk gerelateerd aan hartfalen en 
thrombo embolische complicaties.(63, 64) Vanwege de hoge incidentie van AF in de HCM populatie 
wordt levenslange therapie met orale antistolling geadviseerd aan alle patienten met HCM en AF, zelfs 
bij hersteld sinusritme en onafhankelijk van de CHA2DS2-VASc score.(3, 30) Het is vaak moeilijk om 
AF te detecteren vanwege het episodisch en paroxysmaal optreden. Richtlijnen adviseren 24-48 uur 
Holtermonitoring iedere 6-12 maanden, afhankelijk van de grootte van het linker atrium.(3) Patienten 
met een cardiaal inwendig elektronisch apparaat (CIEA) hebben vaak een continue bewaking van de 
atriale activiteit waardoor AF opgespoord kan worden. In hoofdstuk 7 bestudeerden wij de incidentie 
en impact van CIEA-gedecteerde AF. Gedurende 2.8 jaar follow-up was de jaarlijkse incidentie van 
CIEA-gedecteerde AF 7%. Dit is hoog in vergelijking met eerder gerapporteerde incidenties van AF in 
patienten met HCM (2-3%).(65) Het zou gerelateerd kunnen zijn aan het feit dat HCM patienten met 
een CIEA zich vaak in een verder gevorderd ziektestadium bevinden. Daarnaast zal de CIEA meer AF 
episoden detecteren in vergelijking met traditionele intermitterende monitoring strategieen. Er heeft 
mogelijk een onderschatting van de echte incidentie plaats gevonden, omdat sommige apparaten niet 
het vermogen hadden om atriaal te sensen. De incidentie van thrombo embolische complicaties was 
relatief laag (1.3%), mogelijk ten gevolge van tijdige behandeling met orale anticoagulantia of doordat 
de meerderheid van de AF gevallen behandeld werden met anti-aritmische medicatie of 
electrocardioversie. De bevindingen in deze studie tonen de toegevoegde waarde van CIEAs aan voor 
de detectie van AF en de gevolgen dat het opsporen van AF heeft voor de behandeling. Het zou een 
stimulus kunnen zijn voor cardiologen om CIEDs met atriale sensing te overwegen indien er een 
indicatie is voor CIEA implantatie, zoals bijvoorbeeld een enkelkamer apparaat met een zwevende 
electrode in het atrium.(66) 
 
Geslachtsverschillen zijn geobserveerd in meerdere cardiovasculaire aandoeningen zoals ischemisch 
hartlijden, hartfalen, hypertensie en aortaklepstenose.(67) In patienten met HCM is meermaals 
gerapporteerd dat geslacht de leeftijd van presentatie en het fenotype beinvloedt.(8, 68-78) Sommige 
studies beschrijven een onafhankelijke associatie tussen vrouwelijke geslacht en algehele 
mortaliteit(79, 80), in tegenstelling tot andere studies.(70, 81, 82) In hoofdstuk 8 analyseerden wij de 
klinische presentatie, het fenotype, genotype en de uitkomsten van 1007 patienten met HCM (620 
man, 387 vrouw) die klinisch beoordeeld zijn tussen 1977 en 2017. Ten tijde van de eerste evaluatie 
waren vrouwen ouder, symptomatischer en hadden zij vaker hypertensie. Ook hadden vrouwen vaker 
obstructie van de linker ventrikel uitstroombaan en was de systolische en diastolische linker ventrikel 
functie vaker aangetast. Multivariate cox regressie analyse gedurende 6.8 jaar follow-up liet geen 
onafhankelijke relatie zien tussen geslacht en algehele mortaliteit, cardiovasculaire mortaliteit, 
hartfalen-gerelateerde mortaliteit of plotse hartdood. Waarom vrouwen met HCM zich later 
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presenteren in een verdergevorderd ziektestadium is onduidelijk. Socioculturele processen (het 
negeren van vroege symptomen, diagnostische onnauwkeurigheid) of geslachtshormonen danwel 
verschillen in genexpressie zouden eraan ten grondslag kunnen liggen.(67, 68, 81, 83, 84) In de 
huidige studie observeerden we een verschuiving van het klinisch beeld als wij echocardiografische 
parameters corrigeren voor lichaamsoppervlakte. Waar de maximale wanddikte, linker atrium grootte 
en linker ventrikel eind-diastolische dimensie een relatief milder fenotype in de vrouwen ten opzichte 
van de mannen suggereerden bleek na correctie voor lichaamsoppervlakte het fenotype juist ernstiger. 
Het is dus mogelijk dat wij de ernst van het ziektebeeld in vrouwen onderschatten door 
ongecorrigeerde echocardiografische parameters te gebruiken. Toekomstige studies zullen moeten 
aantonen of corrigeren voor lichaamsoppervlakte danwel geslacht de diagnostiek en behandeling van 
HCM verbetert.  
 
In hoofdstuk 9 bestudeerden wij geslachtsverschillen in de echocardiografische (E/e’ ratio, E/A ratio, 
tricuspidalisklepregurgitatie, linker atrium grootte) en cellulaire (passieve spanning, myofilament Ca2+ 
gevoeligheid, expressie van eiwitten die met Ca2+ werken, expressie van titine isoform, interstitiele 
fibrose) parameters van diastolische functie in patienten met HCM. Hartspierweefsel werd verkregen 
via chirurgische myectomie in 71 patienten met HCM (38% vrouw) voorafgegaan door 
echocardiografie. Vrouwen waren significant ouder ten tijde van de myectomie en de diastolische 
functie was vaker aangetast in de vrouwen. Voorts was er meer sprake van interstitiele fibrose in de 
vrouwen. Er waren geen verschillen aangaande passieve spanning of Ca2+ gevoeligheid. Buigzaam 
titine isoform was verhoogd in de vrouwen hetgeen mogelijk een compensatie mechanisme reflecteert. 
Over het algemeen toont de data ernstiger cardiale remodeling in vrouwen dan in mannen ten tijde van 
de myectomie. Daarnaast ondersteunt de data voorgaande studies die rapporteren dat vrouwen een 
verlate klinische presentatie hebben.(68, 81) De factoren die dit veroorzaken zijn vooralsnog 
onduidelijk en behoeven aanvullend onderzoek. Eveneens wordt in de vrouwen een relatief hogere 
maximale wanddikte gezien na correctie voor lichaamsoppervlakte. Dit suggereert wederom dat het 
ziektestadium van HCM mogelijk wordt onderschat in vrouwen indien ongecorrigeerde parameters 
worden gebruikt. 
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TOEKOMSTPERSPECTIEVEN 
Het uiteindelijke doel van wetenschappelijk onderzoek op het gebied van HCM is om de klinische 
expressie van HCM te voorkomen, de kwaliteit van leven van patienten met HCM te verbeteren, 
symptomen te verminderen en om levensbedreigende complicaties van HCM te voorkomen (plotse 
hart dood, thrombo embolische complicaties, hartfalen). Om dit te realiseren willen we alle oorzaken 
van HCM achterhalen, de pathofysiologische processen ontrafelen en de risicostratificatie voor plotse 
hartdood en hartfalen verbeteren. 
 
Vooruitgang in de genetische diagnostiek 
Momenteel wordt in ongeveer 50-60% van de patienten met HCM die genetisch onderzoek ondergaan 
een pathogene mutatie ontdekt.(4) Met behulp van exoom- en genoomsequencing worden mogelijk 
nieuwe mutaties ontdekt die HCM veroorzaken. Deze nieuwe technologieen vereisen intensieve 
inspanningen om de data te analyseren en varianten te interpreteren.(85) Grote hoeveelheden varianten 
moeten handmatig geanalyseerd worden om degenen te selecteren die klinische relevantie hebben.(85) 
Vervolgens worden de varianten ingedeeld in 5 groepen (pathogeen, waarschijnlijk pathogeen, 
etcetera). Dit proces vereist het nakijken van de literatuur, co-segregatie onderzoek, predictie software 
en in-vitro studies.(5) Genotype-negatieve HCM (met name niet-familiaire HCM(86)) heeft een betere 
prognose en andere klinische kenmerken (hoofdstuk 1). Om de pathofysiologie van genotype-
negatieve HCM te begrijpen zijn toekomstige studies nodig die modificerende factoren zoals 
(epi)genetische variaties en omgevingsfactoren onderzoeken.(15) De extreem fenotypische 
heterogeniteit in personen met dezelfde pathogene mutatie (hoofdstuk 2) benadrukt tevens de 
complexiteit van de HCM pathofysiologie. Translationeel onderzoek is cruciaal om de genotype-
fenotype ‘’black box’’ verder te ontrafelen.(15, 16, 87) 
 
Verbetering van de fenotypering 
Geavanceerde beeldvorming zoals speckle-tracking en drie-dimensionale echocardiografie, 
magnetisch resonantie imaging en positron emissie tomografie(88) kan potentieel structurele en 
functionele manifestaties van sarcomeer mutaties aantonen. Om inzicht te krijgen in de vroege 
manifestaties van HCM vormen genotype-positief, fenotype-negatieve familieleden een ideale 
testpopulatie (hoofdstukken 4 en 5). Lange termijn follow-up studies zijn belangrijk om de 
risicostratificatie te verbeteren. In de HCM populatie worden follow-up studies vaak gelimiteerd door 
het beperkt aantal levensbedreigende complicaties. Daarom zijn grote internationale samenwerkingen 
zoals de HCMR studie(89) en de SHARE registratie (https://theshareregistry.org/) essentieel voor de 
identificatie van nieuwe risicofactoren zoals late aankleuring met gadolinium, T1 mapping 
(extracellulair volume), genetica en biomarkers (markers van fibrose). 
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Geslachtsverschillen 
In vergelijking met mannen presenteren vrouwen met HCM zich later in het leven in een 
verdergevorderd ziektestadium. Het corrigeren van echocardiografische parameters voor 
lichaamsoppervlakte liet een ernstiger fenotype zien in vrouwen dan beoordeeld werd op basis van 
ongecorrigeerde parameters (hoofdstukken 8 en 9). Het is onduidelijk of diagnostische 
onnauwkeurigheid, andere socioculturele processen, hormonen of genexpressie verantwoordelijk zijn 
voor de vertraagde klinische presentatie onder vrouwen.(67) Aanvullende studies zijn nodig om de 
oorzaak te achterhalen en om te analyseren of het corrigeren voor geslacht of lichaamsoppervlakte de 
diagnostiek en behandeling van vrouwen met HCM verbetert. 
 
Toekomstige therapeutische strategieen 
Om nieuwe medicijnen te creëren die de ontwikkeling of progressie van HCM kunnen voorkomen, is 
het noodzakelijk om de pathofysiologie van HCM te begrijpen. Hartspierweefselonderzoek liet 
bijvoorbeeld zien dat de energiehuishouding van het myocard is aangetast, hetgeen mogelijk een 
doelwit kan zijn om de ontwikkeling van HCM te voorkomen.(90) De ENERGY trial zal dit verder 
onderzoeken. (http://www.amsterdamresearch.org/web/instituut-1/nieuws/tonenop/400k-grant-for-
research-into-hypertrophic-cardiomyopathy.htm). Andere voorbeelden van potentiële nieuwe 
therapieen zijn gencorrectie(91), myosineremmers(92), late natrium-instroom remmers(93), en calcium 
en natrium kanaal blokkers(94). Teneinde voldoende power te hebben om een verandering aan te tonen 
in de progressie of overleving van de ziekte zijn grote internationale samenwerkingen met lange 
termijn follow-up nodig. Voorbeelden hiervan zijn de LIBERTY-HCM trial(95) en de EXPLORER-
HCM trial (https://clinicaltrials.gov/ct2/show/NCT03470545). 
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